
<html lang="en"     class="pb-page"  data-request-id="535322bf-f2d7-458e-aa79-6d0b3e828f9c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-2;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c02005;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer" /></meta><meta name="dc.Creator" content="Yonggang  Meng" /></meta><meta name="dc.Creator" content="Bin  Yu" /></meta><meta name="dc.Creator" content="He  Huang" /></meta><meta name="dc.Creator" content="Youmei  Peng" /></meta><meta name="dc.Creator" content="Ertong  Li" /></meta><meta name="dc.Creator" content="Yongfang  Yao" /></meta><meta name="dc.Creator" content="Chuanjun  Song" /></meta><meta name="dc.Creator" content="Wenquan  Yu" /></meta><meta name="dc.Creator" content="Kaikai  Zhu" /></meta><meta name="dc.Creator" content="Kai  Wang" /></meta><meta name="dc.Creator" content="Dongxu  Yi" /></meta><meta name="dc.Creator" content="Jinfa  Du" /></meta><meta name="dc.Creator" content="Junbiao  Chang" /></meta><meta name="dc.Description" content="Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for..." /></meta><meta name="Description" content="Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 18, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02005" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02005" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02005" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02005" /></link>
        
    
    

<title>Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02005" /></meta><meta property="og:title" content="Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0009.jpeg" /></meta><meta property="og:description" content="Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). However, AZ5104, a primary toxic metabolite of osimertinib, has caused unwanted toxicities. To address this unmet medical need, we initiated an iterative program focusing on structural optimizations of osimertinib and preclinical characterization, leading to the discovery of a highly potent, selective, and orally efficacious deuterated EGFR-targeting clinical candidate, dosimertinib. Preclinical studies revealed that dosimertinib demonstrated robust in vivo antitumor efficacy and favorable PK profiles, but with lower toxicity than osimertinib. These preclinical data support further clinical development of dosimertinib for the treatment of NSCLC. Dosimertinib has received official approval in China to initiate the phase I clinical trial (registration numbers: CXHL2000060 and CXHL2000061)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02005"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02005">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02005&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02005&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02005&amp;href=/doi/10.1021/acs.jmedchem.0c02005" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 2</span><span class="cit-fg-pageRange">, 925-937</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/2" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01563" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c02235" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yonggang Meng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yonggang Meng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Chemistry, Zhengzhou University, Zhengzhou 450001, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yonggang++Meng">Yonggang Meng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bin Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Yu">Bin Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">He Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">He Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Chemistry, Zhengzhou University, Zhengzhou 450001, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=He++Huang">He Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Youmei Peng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Youmei Peng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Henan Key Laboratory for Pharmacology of Liver Diseases, Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Youmei++Peng">Youmei Peng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ertong Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ertong Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Chemistry, Zhengzhou University, Zhengzhou 450001, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ertong++Li">Ertong Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yongfang Yao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongfang Yao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongfang++Yao">Yongfang Yao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chuanjun Song</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chuanjun Song</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Chemistry, Zhengzhou University, Zhengzhou 450001, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chuanjun++Song">Chuanjun Song</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7733-578X" title="Orcid link">http://orcid.org/0000-0001-7733-578X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenquan Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenquan Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Chemistry, Zhengzhou University, Zhengzhou 450001, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenquan++Yu">Wenquan Yu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3711-0006" title="Orcid link">http://orcid.org/0000-0002-3711-0006</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kaikai Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kaikai Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Henan Metab Biopharma Co., Ltd., Zhengzhou Airport Economy Zone, Taiwan Science Park, Zhengzhou 450006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kaikai++Zhu">Kaikai Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kai Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kai Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Henan Metab Biopharma Co., Ltd., Zhengzhou Airport Economy Zone, Taiwan Science Park, Zhengzhou 450006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kai++Wang">Kai Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dongxu Yi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dongxu Yi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Henan Metab Biopharma Co., Ltd., Zhengzhou Airport Economy Zone, Taiwan Science Park, Zhengzhou 450006, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dongxu++Yi">Dongxu Yi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jinfa Du</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jinfa Du</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Henan Genuine Biotech Co., Ltd. 10 Fuxing Road, Xincheng District, Pingdingshan, Henan 467036, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#2541504f4c4b4344655f5656524e4f0b4b4051"><span class="__cf_email__" data-cfemail="a6c2d3cccfc8c0c7e6dcd5d5d1cdcc88c8c3d2">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jinfa++Du">Jinfa Du</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Junbiao Chang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junbiao Chang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">College of Chemistry, Zhengzhou University, Zhengzhou 450001, China</div><div class="loa-info-affiliations-info">Henan Key Laboratory of Organic Functional Molecule and Drug Innovation, School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#dab9b2bbb4bdb0afb4b8b3bbb59aa0a0aff4bfbeaff4b9b4"><span class="__cf_email__" data-cfemail="8cefe4ede2ebe6f9e2eee5ede3ccf6f6f9a2e9e8f9a2efe2">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junbiao++Chang">Junbiao Chang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6236-1256" title="Orcid link">http://orcid.org/0000-0001-6236-1256</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02005&amp;href=/doi/10.1021%2Facs.jmedchem.0c02005" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 2</span><span class="cit-pageRange">, 925–937</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 18, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 November 2020</li><li><span class="item_label"><b>Published</b> online</span>18 January 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 January 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D925%26pageCount%3D13%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYonggang%2BMeng%252C%2BBin%2BYu%252C%2BHe%2BHuang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D2%26contentID%3Dacs.jmedchem.0c02005%26title%3DDiscovery%2Bof%2BDosimertinib%252C%2Ba%2BHighly%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BEfficacious%2BDeuterated%2BEGFR%2BTargeting%2BClinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small-Cell%2BLung%2BCancer%26numPages%3D13%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D937%26publicationDate%3DJanuary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02005"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3474</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02005" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yonggang&quot;,&quot;last_name&quot;:&quot;Meng&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;He&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Youmei&quot;,&quot;last_name&quot;:&quot;Peng&quot;},{&quot;first_name&quot;:&quot;Ertong&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yongfang&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Chuanjun&quot;,&quot;last_name&quot;:&quot;Song&quot;},{&quot;first_name&quot;:&quot;Wenquan&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Kaikai&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Kai&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Dongxu&quot;,&quot;last_name&quot;:&quot;Yi&quot;},{&quot;first_name&quot;:&quot;Jinfa&quot;,&quot;last_name&quot;:&quot;Du&quot;},{&quot;first_name&quot;:&quot;Junbiao&quot;,&quot;last_name&quot;:&quot;Chang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;18&quot;,&quot;issue&quot;:&quot;2&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;925-937&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02005&quot;},&quot;abstract&quot;:&quot;Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). However, AZ5104, a primary toxic metabolite of osimertinib, has caused unwanted toxicities. To address this unmet medical need, we initiated an iterative program focusing on structural optimizations of osimertinib and preclinical characterization, leading to the discovery of a highly potent, selective, and orally efficacious deuterated EGFR-targeting clinical candidate, dosimertinib. Preclinical studies revealed that dosimertinib demonstrated robust in vivo antitumor efficacy and favorable PK profiles, but with lower toxicity than osimertinib. These preclinical data support further clinical development of dosimertinib for the treatment of NSCLC. Dosimertinib has received official approval in China to initiate the phase I clinical trial (registratio&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02005&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02005" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02005&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02005" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02005&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02005" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02005&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02005&amp;href=/doi/10.1021/acs.jmedchem.0c02005" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02005" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02005" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26pmid%3D33459024%26genre%3Darticle%26aulast%3DMeng%26date%3D2021%26atitle%3DDiscovery%2Bof%2BDosimertinib%252C%2Ba%2BHighly%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BEfficacious%2BDeuterated%2BEGFR%2BTargeting%2BClinical%2BCandidate%2Bfor%2Bthe%2BTreatment%2Bof%2BNon-Small-Cell%2BLung%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/2" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/jmcmar.2021.64.issue-2/20210128/jmcmar.2021.64.issue-2.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Osimertinib is a highly potent and selective third-generation epidermal growth factor receptor (EGFR) inhibitor, which provides excellent clinical benefits and is now a standard-of-care therapy for advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). However, AZ5104, a primary toxic metabolite of osimertinib, has caused unwanted toxicities. To address this unmet medical need, we initiated an iterative program focusing on structural optimizations of osimertinib and preclinical characterization, leading to the discovery of a highly potent, selective, and orally efficacious deuterated EGFR-targeting clinical candidate, dosimertinib. Preclinical studies revealed that dosimertinib demonstrated robust <i>in vivo</i> antitumor efficacy and favorable PK profiles, but with lower toxicity than osimertinib. These preclinical data support further clinical development of dosimertinib for the treatment of NSCLC. Dosimertinib has received official approval in China to initiate the phase I clinical trial (registration numbers: CXHL2000060 and CXHL2000061).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that has indispensable roles in various biological processes such as cell proliferation, survival, migration, differentiation, <i>etc</i>.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Thus, EGFR has been widely recognized as a highly valuable therapeutic target and predictive biomarker for new drug discovery against non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> To date, numerous EGFR inhibitors have been reported, some of which are currently being used in the clinic.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> Very recently, EGFR degraders have also been reported, offering novel therapeutic options for NSCLC.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11">(8−11)</a> The U.S. Food and Drug Administration (FDA)-approved first-generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> and erlotinib<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) provide significant clinical benefits in patients bearing activating mutations including L858R and del19, resulting in marked tumor shrinkage. Acquired drug resistance, particularly the T790M mutation within the ATP binding pocket in EGFR mutant NSCLC, limits the clinical efficacy of EGFR inhibitors after long-term treatment, thus posing a new challenge in cancer therapy.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> It has been reported that about 60% of the EGFR mutant NSCLC patients harbor the EGFR T790M mutation that renders the first-generation EGFR TKIs less effective in these patients. The covalent second-generation EGFR inhibitors afatinib<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> and dacomitinib<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) effectively inhibit T790M drug-resistant EGFR but also demonstrate insufficient clinical efficacy due to severe dose-limiting side effects by inhibiting wild-type (WT) EGFR.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Third-generation EGFR TKIs such as rociletinib<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and osimertinib<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) potently and selectively inhibit both activating mutations and the T790M drug-resistance mutation of EGFR while sparing WT EGFR.<a onclick="showRef(event, 'ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29 ref30 ref31">(26−31)</a> Particularly, osimertinib (also known as Tagrisso and AZD9291) approved by the FDA in 2015 displays excellent clinical outcomes and reduced on-target toxicity and now is a standard-of-care therapy for previously untreated advanced EGFR mutation-positive (EGFRm<sup>+</sup>) NSCLC.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Preclinical studies suggest that osimertinib is primarily metabolized by cytochrome P450 (CYP450) to produce two main active metabolites: AZ5104 and AZ7550.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> AZ7550 shows a very similar potency to osimertinib, while AZ5104 has better potency against WT EGFR and its mutant forms (del19 deletion and T790M), but exhibits a reduced selectivity over WT EGFR. The improved potency against WT EGFR and reduced selectivity of AZ5104 may contribute to the adverse effects observed in patients receiving osimertinib treatment.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Therefore, improving the metabolic profiles of osimertinib could be a feasible strategy to reduce the toxicity and achieve better clinical benefits. It is well documented that incorporation of deuterium into the drug molecules could alter their physical properties and oxidative metabolism and increase the concentration, finally achieving substantial benefits on the safety and disposition of the drugs.<a onclick="showRef(event, 'ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39">(36−39)</a> On Dec 3, 2020, Bristol-Myers Squibb announced that deuterated deucravacitinib (BMS-986165), a selective tyrosine kinase 2 (TYK2) inhibitor, demonstrated superiority to placebo and apremilast in patients with moderate to severe plaque psoriasis (<a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> Identifier: NCT03624127). In order to improve the metabolic profiles, we performed further structural modifications of osimertinib,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> leading to the discovery of deuterium-containing dosimertinib that exhibited robust antitumor activity and lower toxicity against NSCLC compared to osimertinib. Dosimertinib was officially approved on April 29, 2020 by the Center for Drug Evaluation, National Medical Products Administration (NMPA) of China to initiate the phase I clinical trial for the treatment of NSCLC (registration numbers: CXHL2000060 and CXHL2000061).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative EGFR inhibitors in the clinic, the key metabolites AZ5104 and AZ7550 of osimertinib, and dosimertinib reported in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthetic routes of compounds <b>2a</b>–<b>2h</b> are shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. The key intermediate <b>1</b> was prepared following the previously reported procedures.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Compound <b>1</b> reacted with methacryloyl chloride smoothly in the presence of NaOH to give compound <b>2a</b>. Compound <b>2c</b> was efficiently synthesized from <b>1</b> and 1-trifluoromethyl acrylic acid in the presence of T3P and TEA. Compound <b>1</b> reacted with the corresponding carboxylic acid in the presence of HBTU and DIPEA in DMF to form compounds <b>2b</b>, <b>2d</b>–<b>2f</b>, and <b>3</b>, respectively. Compound <b>3</b> then reacted with poly(oxymethylene-d2) ((CD<sub>2</sub>O)<sub><i>n</i></sub>) directly in the presence of KOH and LiOH in THF/H<sub>2</sub>O (4:1) to generate compound <b>2g</b> in an overall yield of 58% from compound <b>1</b>. Similarly, the deuterated indermediate <b>4</b> was also synthesized from 1-CD<sub>3</sub>-indole according to the methods reported in the literature.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Compound <b>4</b> reacted with diethylphosphonoacetic acid in the presence of HATU and DIPEA in THF to form compound <b>5</b>, which then reacted with (CD<sub>2</sub>O)<sub><i>n</i></sub> to afford compound <b>2h</b>. Treatment of <b>2h</b> with methanesulfonic acid in acetone/H<sub>2</sub>O (10:1) gave dosimertinib in 90% yield.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">()</a><a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">()</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2a</b>–<b>2g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) isobutyryl chloride, NaOH, THF/H<sub>2</sub>O (4:1); (b) crotonic acid, HBTU, DIPEA, DMF, rt; (c) 2-trifluoromethyl acrylic acid, T3P, TEA, DCM, rt; (d) 2-fluoroacrylic acid, HBTU, DIPEA, DMF, rt; (e) 2-chloroacrylic acid, HBTU, DIPEA, DMF, rt; (f) 2-broroacrylic acid, HBTU, DIPEA, DMF, rt; (g) diethylphosphonoacetic acid, HATU, DIPEA, DMF, rt; (h) (CD<sub>2</sub>O)<sub><i>n</i></sub>, LiOH, KOH, THF/H<sub>2</sub>O (4/1), rt.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Dosimertinib<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diethylphosphonoacetic acid, HATU, DIPEA, THF, rt; (b) (CD<sub>2</sub>O)<i><sub>n</sub></i>, LiOH, KOH, THF/H<sub>2</sub>O (4/1), rt; (c) MeSO<sub>3</sub>H, acetone/H<sub>2</sub>O (10:1), 50 °C.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02872" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02872" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Structure–Activity Relationship</h3><div class="NLM_p">All the synthesized compounds were evaluated at different concentrations to examine their inhibitory activity against WT EGFR and L858R/T790M EGFR using the ELISA method (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Osimertinib was used as the positive control. Initially, we introduced the methyl group into the double bond of the acrylamide moiety in osimertinib, giving compounds <b>2a</b> and <b>2b</b>, respectively. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, both compounds exhibited significantly decreased inhibitory activity against WT EGFR and L858R/T790M mutated EGFR compared with osimertinib. The results indicated that introduction of an additional methyl group into the double bond was not tolerated. Replacement of the methyl group in <b>2a</b> with the trifluoromethyl group afforded compound <b>2c</b>, which also had poor inhibitory activity against both forms of EGFR with inhibitory rates less than 50% at 1.0 μM. Further replacement of the methyl group in <b>2a</b> with other halogen atoms such as F, Cl, and Br generated compounds <b>2d</b>, <b>2e</b>, and <b>2f</b>, respectively. Relative to <b>2a</b>, <b>2b</b>, and <b>2c</b>, compounds <b>2d</b>, <b>2e</b>, and <b>2f</b> displayed significantly improved inhibitory activity against WT EGFR and L858R/T790M EGFR but were still less potent than osimertinib. It is well documented that the isotopic substitution can alter physical properties of the drug and increase the concentration of the active drug by slowing down or blocking the oxidative metabolism, without significantly altering the pharmacological properties of the drug.<a onclick="showRef(event, 'ref36 ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38 ref39">(36−39)</a> The terminal CH<sub>2</sub> of the acrylamide moiety in osimertinib is a key site for covalent binding to the cysteine of EGFR. To investigate the deuterium kinetic isotope effect on the activity, we synthesized the deuterated compound <b>2g</b>, which bears two deuterium atoms on the double bond of the acrylamide moiety in osimertinib. Compound <b>2g</b> was less potent than osimertinib against both WT EGFR and L858R/T790M EGFR. As demonstrated by AZ5104, the <i>N</i>-methyl group in the indole ring of osimertinib was one of the main metabolic sites; isotopic replacement of the hydrogen atoms in the <i>N</i>-methyl group with deuterium may alter the physical profiles and thus affect the bioactivity. To our delight, compound <b>2h</b> showed excellent potency against L858R/T790M EGFR (IC<sub>50</sub> = 1.7 nM), comparable to that of osimertinib (IC<sub>50</sub> = 1.8 ± 0.3 nM). Collectively, <b>2h</b> is a highly potent candidate compound against L858R/T790M EGFR and warrants further investigation for the treatment of NSCLC.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. <i>In Vitro</i> Enzymatic Inhibitory Activity against WT EGFR and L858R/T790M EGFR of Osimertinib Analogs<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">enzymatic inhibitory activity (%, μM)</th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">WT EGFR</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">L858R/T790M EGFR</th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">enzymatic inhibitory activity (IC<sub>50</sub>, nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">1.0</th><th class="colsep0 rowsep0" align="center" char=".">0.1</th><th class="colsep0 rowsep0" align="center" char=".">0.01</th><th class="colsep0 rowsep0" align="center" char=".">1.0</th><th class="colsep0 rowsep0" align="center" char=".">0.1</th><th class="colsep0 rowsep0" align="center" char=".">0.01</th><th class="colsep0 rowsep0" align="center" char="±">WT EGFR</th><th class="colsep0 rowsep0" align="center" char="±">L858R/T790M EGFR</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="char" char=".">88.0</td><td class="colsep0 rowsep0" align="char" char=".">84.4</td><td class="colsep0 rowsep0" align="char" char=".">16.3</td><td class="colsep0 rowsep0" align="char" char=".">84.2</td><td class="colsep0 rowsep0" align="char" char=".">84.4</td><td class="colsep0 rowsep0" align="char" char=".">19.2</td><td class="colsep0 rowsep0" align="char" char="±">152.3 ± 60.0</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char=".">29.9</td><td class="colsep0 rowsep0" align="char" char=".">16.2</td><td class="colsep0 rowsep0" align="center" char=".">ND<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">50.8</td><td class="colsep0 rowsep0" align="char" char=".">13.4</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char=".">15.4</td><td class="colsep0 rowsep0" align="char" char=".">5.5</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">38.3</td><td class="colsep0 rowsep0" align="char" char=".">0.0</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char=".">27.5</td><td class="colsep0 rowsep0" align="char" char=".">8.8</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">42.9</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char=".">53.7</td><td class="colsep0 rowsep0" align="char" char=".">17.5</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">75.6</td><td class="colsep0 rowsep0" align="char" char=".">42.0</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char=".">50.1</td><td class="colsep0 rowsep0" align="char" char=".">9.7</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="char" char=".">70.6</td><td class="colsep0 rowsep0" align="char" char=".">42.4</td><td class="colsep0 rowsep0" align="center" char=".">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char=".">77.6</td><td class="colsep0 rowsep0" align="char" char=".">86.7</td><td class="colsep0 rowsep0" align="char" char=".">24.1</td><td class="colsep0 rowsep0" align="char" char=".">100.0</td><td class="colsep0 rowsep0" align="char" char=".">90.8</td><td class="colsep0 rowsep0" align="char" char=".">15.8</td><td class="colsep0 rowsep0" align="center" char="±">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="char" char=".">78.0</td><td class="colsep0 rowsep0" align="char" char=".">53.8</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td><td class="colsep0 rowsep0" align="char" char=".">79.6</td><td class="colsep0 rowsep0" align="char" char=".">71.0</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="center" char="±">ND</td><td class="colsep0 rowsep0" align="center" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2h</b></td><td class="colsep0 rowsep0" align="char" char=".">88.7</td><td class="colsep0 rowsep0" align="char" char=".">76.7</td><td class="colsep0 rowsep0" align="char" char=".">10.8</td><td class="colsep0 rowsep0" align="char" char=".">100.0</td><td class="colsep0 rowsep0" align="char" char=".">95.9</td><td class="colsep0 rowsep0" align="char" char=".">18.9</td><td class="colsep0 rowsep0" align="char" char="±">113.8 ± 21.6</td><td class="colsep0 rowsep0" align="char" char="±">1.7 ± 0.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data are averages of two independent determinations.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">ND means not determined.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Cellular Antiproliferative Activity</h3><div class="NLM_p">We next examined the antiproliferative activity of compounds <b>2a</b>–<b>2h</b> against H1975 cells expressing L858R/T790M EGFR and A431 cells harboring WT EGFR using the sulforhodamine B (SRB) colorimetric assay. Osimertinib was used as the positive control. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, the cellular antiproliferative activity of compounds <b>2a</b>–<b>2h</b> against the tested cell lines was closely associated with the biochemical activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). These compounds showed stronger inhibitory activity against H1975 cells over A431 cells. Particularly, compound <b>2h</b> exhibited superior potency against H1975 cells with an IC<sub>50</sub> value of 28.4 nM, much more potent than osimertinib (IC<sub>50</sub> = 47.3 nM). However, for A431 cells, compound <b>2h</b> was less potent than osimertinib with IC<sub>50</sub> values of 243.9 and 138.7 nM, respectively. The data demonstrate that, compared with osimertinib, compound <b>2h</b> exhibited superior potency against H1975 cells and higher cellular selectivity over A431 cells. In view of the superior potency of <b>2h</b> against H1975 cells, we further evaluated the antiproliferative activity of osimertinib and <b>2h</b> against L858/T790M EGFR- and del19/T790M EGFR-dependent BaF3 cells by the CellTiter-Glo luminescent cell viability assay. As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, compound <b>2h</b> also demonstrated excellent cellular potency against these two cell lines with IC<sub>50</sub> values of 18.0 ± 5.0 and 3.5 ± 0.5 nM, respectively, comparable to those of osimertinib.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. <i>In Vitro</i> Antiproliferative Activity against A431 and H1975 Cells<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">cellular antiproliferative activity (IC<sub>50</sub>, nM)</th><th class="rowsep1 colsep0" align="center">cellular selectivity</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">A431</th><th class="colsep0 rowsep0" align="center" char="±">H1975</th><th class="colsep0 rowsep0" align="center">A431:H1975</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="char" char="±">138.7 ± 18.2</td><td class="colsep0 rowsep0" align="char" char="±">47.3 ± 5.4</td><td class="colsep0 rowsep0" align="center">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2a</b></td><td class="colsep0 rowsep0" align="char" char="±">5339.0 ± 496.5</td><td class="colsep0 rowsep0" align="char" char="±">485.8 ± 35.7</td><td class="colsep0 rowsep0" align="center">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2b</b></td><td class="colsep0 rowsep0" align="char" char="±">5789.0 ± 425.8</td><td class="colsep0 rowsep0" align="char" char="±">496.0 ± 40.5</td><td class="colsep0 rowsep0" align="center">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2c</b></td><td class="colsep0 rowsep0" align="char" char="±">11 230.0 ± 690.3</td><td class="colsep0 rowsep0" align="char" char="±">546.4 ± 61.1</td><td class="colsep0 rowsep0" align="center">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2d</b></td><td class="colsep0 rowsep0" align="char" char="±">2504.0 ± 364.1</td><td class="colsep0 rowsep0" align="char" char="±">207.6 ± 21.2</td><td class="colsep0 rowsep0" align="center">12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2e</b></td><td class="colsep0 rowsep0" align="char" char="±">1554.0 ± 292.8</td><td class="colsep0 rowsep0" align="char" char="±">241.3 ± 28.9</td><td class="colsep0 rowsep0" align="center">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2f</b></td><td class="colsep0 rowsep0" align="char" char="±">1061.0 ± 90.4</td><td class="colsep0 rowsep0" align="char" char="±">146.8 ± 20.6</td><td class="colsep0 rowsep0" align="center">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2g</b></td><td class="colsep0 rowsep0" align="char" char="±">568.6 ± 63.8</td><td class="colsep0 rowsep0" align="char" char="±">60.8 ± 7.4</td><td class="colsep0 rowsep0" align="center">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2h</b></td><td class="colsep0 rowsep0" align="char" char="±">243.9 ± 42.7</td><td class="colsep0 rowsep0" align="char" char="±">28.4 ± 2.6</td><td class="colsep0 rowsep0" align="center">9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The antiproliferative activity of the compounds were evaluated  using the sulforhodamine B (SRB) colorimetric assay. Data are averages of at least three independent determinations and reported as the means ± SEM (standard error of mean).</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. <i>In Vitro</i> Antiproliferative Activity of Osimertinib and <b>2h</b> against EGFR-L858/T790M BaF3 and EGFR-del19/T790M BaF3 Cells<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">cellular antiproliferative activity (IC<sub>50</sub>, nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">EGFR-L858/T790M BaF3</th><th class="colsep0 rowsep0" align="center" char="±">EGFR-del19/T790M BaF3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="char" char="±">21.5 ± 2.5</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2h</b></td><td class="colsep0 rowsep0" align="char" char="±">18.0 ± 5.0</td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The antiproliferative activity of the compounds were tested by the CellTiter-Glo luminescent cell viability assay. Data are averages of two independent determinations and reported as the means ± SEM (standard error of mean).</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Inhibitory Effects of Osimertinib and <b>2h</b> on EGFR and Downstream Signaling Transduction</h3><div class="NLM_p">Compound <b>2h</b> was further examined for its effects on the phosphorylation of EGFR and the downstream signaling transduction in H1975 and A431 cells by the Western blot analysis (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Osimertinib was used as the positive control. In H1975 cells, compound <b>2h</b> potently inhibited L858R/T790M EGFR and downstream ERK phosphorylation even at 10 nM. More importantly, compound <b>2h</b> showed much more potent inhibitory activity than osimertinib in inhibiting EGFR signaling pathway (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). A similar phenomenon was also observed in A431 cells (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). Compound <b>2h</b> moderately inhibited both WT EGFR and ERK phosphorylation at 100 nM. The data clearly showed that compound <b>2h</b> exhibited better potency than osimertinib in inhibiting the phosphorylation of EGFR and downstream signaling transduction (p-ERK) at the cellular level.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibitory effects of osimertinib and <b>2h</b> on EGFR and downstream signaling transduction in H1975 cells (A) and A431 cells (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Target Duration of Action of Compound <b>2h</b><i>in Vitro</i></h3><div class="NLM_p">The washout experiment was performed to examine the duration of L858R/T790M EGFR inhibition <i>in vitro</i>, compound <b>2h</b> was washed out after incubation for 2 h in H1975 cells. Then the L858R/T790M EGFR and ERK phosphorylation were detected at different time points by the Western blot. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A, inhibition of L858R/T790M EGFR activation continued up to 24 h, and inhibition of ERK activation caused by <b>2h</b> also lasted for over 12 h. In contrast, the target duration of osimertinib was similar to that of <b>2h</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). The inhibition of ERK activation caused by osimertinib only lasted for <12 h.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Target duration <i>in vitro</i>. H1975 cells were treated with <b>2h</b> (A) or osimertinib (B) for 2 h, then washed with PBS three times. Target inhibition at different time points was detected by Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> Antitumor Efficacy Studies</h3><div class="NLM_p">In view of the cellular potency of compound <b>2h</b>, we also assessed the <i>in vivo</i> antitumor activity of dosimertinib (mesylate of <b>2h</b>) in two mouse xenograft models bearing H1975 (L858R/T790M EGFR) cells and BaF3 (Δ19del/T790M EGFR) cells, respectively. In the H1975 mouse xenograft model, the tumor-bearing mice were dosed daily by oral gavage with dosimertinib at 0.75, 1.5, or 3 mg/kg or osimertinib as the positive control (1.5 mg/kg) for 24 days. In a BaF3 mouse xenograft model, the tumor-bearing mice were dosed daily by oral gavage with dosimertinib at 1.25, 2.5, or 5 mg/kg or osimertinib as the positive control (2.5 mg/kg) for 18 days. As depicted in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and C, dosimertinib exhibited robust antitumor activity in H1975 and BaF3 bearing xenograft models, comparable to that of osimertinib at the same dose. In H1975 groups, dosimertinib at the dose of 1.5 or 3 mg/kg significantly reduced tumor size with tumor growth inhibition (TGI) of 72.94% and 97.62%, respectively. The antitumor activity of dosimertinib at 1.5 mg/kg was comparable to that of osimertinib at a dose of 1.5 mg/kg. In particular, dosimertinib at a dose of 2.5 and 5 mg/kg strongly suppressed tumor growth with a TGI of 76.3% and 104.1%, respectively, in BaF3 bearing xenograft models. For both xenograft models, dosimertinib at 3.0 and 5.0 mg/kg exhibited almost complete suppression of the tumor growth. The body weight was also measured twice a week, and the data showed that over the course of the studies, the body weight of the mice in both groups treated with osimertinib (1.5 and 2.5 mg/kg, respectively) was lower that of the vehicle group and the group receiving dosimertinib (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B and D). We also found that treatment of dosimertinib did not cause significant body weight loss even at high dosages of 3.0 and 5.0 mg/kg, respectively. These results indicated that dosimertinib exhibited comparable antitumor activity with osimertinib but with lower toxicity.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> antitumor effects of dosimertinib or osimertinib on H1975 (A) and BaF3 (C) tumor xenografts for 18–24 days. The body weight was measured twice a week in H1975 (B) and BaF3 (D) tumor xenograft mice. All values represent mean ± SEM. **<i>p</i> < 0.01 and ***<i>p</i> < 0.001 compared to the vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Stability and Metabolic Profiling in Liver Microsomes</h3><div class="NLM_p">To assess the metabolic stability of dosimertinib and osimertinib, we determined their degree of degradation using the liver microsomes of five different species (mouse, rat, dog, monkey, and human). The <i>in vitro t</i><sub>1/2</sub> and intrinsic clearance of dosimertinib and osimertinib were both determined, and the metabolic rates of dosimertinib and osimertinib were both low in humans, moderate in rats and monkeys, and high in mice and dogs. There was no significant difference of <i>t</i><sub>1/2</sub> and CL<sub>int</sub> in both groups, indicating similar metabolic stability in liver microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Metabolic profiling of dosimertinib was also evaluated in liver microsomes of these five different species. Four primary metabolites were detected, including three demethylated metabolites (M3, M6, and AZ5104-D2) and one oxidative metabolite (M11; <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The relative abundance of metabolites generated in human liver microsomes was 1.85%, 15.58%, 1.47%, and < 0.1% for M3, M6, M11, and AZ5104-D2, respectively. The results suggested that dosimertinib and osimertinib exhibited similar metabolic profiles.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> It has been reported that AZ5104 is a primary toxic metabolite of osimertinib.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Therefore, the levels of AZ5104 and AZ5104-D2 were further determined in this study (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). After incubation for 60 min, low levels of AZ5104-D2 (<1.0 nM) were determined in liver microsomes of five species treated with dosimertinib. In contrast, a high concentration of AZ5104 in liver microsomes was observed in the osimertinib group. Particularly, the concentration of AZ5104 in live microsomes of SD rats was up to 54.7 nM. The results indicated that the deuterium replacement altered the metabolic pathways and thus significantly reduced the generation of AZ5104-D2 in five species, which may be responsible for the observed low toxicity in both xenograft models (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Metabolic Stability in Mouse, Rat, Dog, Monkey, and Human Liver Microsomes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">dosimertinib</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">osimertinib</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int</sub> (mL/min/mg)</th><th class="colsep0 rowsep0" align="center" char=".">AZ5104-D2 (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char=".">CL<sub>int</sub> (mL/min/mg)</th><th class="colsep0 rowsep0" align="center" char=".">AZ5104 (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CD-1 mouse</td><td class="colsep0 rowsep0" align="char" char=".">23.7</td><td class="colsep0 rowsep0" align="char" char=".">58.6</td><td class="colsep0 rowsep0" align="char" char="."><1.0</td><td class="colsep0 rowsep0" align="char" char=".">22.3</td><td class="colsep0 rowsep0" align="char" char=".">62.1</td><td class="colsep0 rowsep0" align="char" char=".">9.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SD rat</td><td class="colsep0 rowsep0" align="char" char=".">34.6</td><td class="colsep0 rowsep0" align="char" char=".">40.0</td><td class="colsep0 rowsep0" align="char" char="."><1.0</td><td class="colsep0 rowsep0" align="char" char=".">36.8</td><td class="colsep0 rowsep0" align="char" char=".">37.6</td><td class="colsep0 rowsep0" align="char" char=".">54.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">beagle dog</td><td class="colsep0 rowsep0" align="char" char=".">22.6</td><td class="colsep0 rowsep0" align="char" char=".">61.3</td><td class="colsep0 rowsep0" align="char" char="."><1.0</td><td class="colsep0 rowsep0" align="char" char=".">26.1</td><td class="colsep0 rowsep0" align="char" char=".">53.2</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus macaque</td><td class="colsep0 rowsep0" align="char" char=".">25.6</td><td class="colsep0 rowsep0" align="char" char=".">54.2</td><td class="colsep0 rowsep0" align="char" char="."><1.0</td><td class="colsep0 rowsep0" align="char" char=".">33.2</td><td class="colsep0 rowsep0" align="char" char=".">41.7</td><td class="colsep0 rowsep0" align="char" char=".">13.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">144.1</td><td class="colsep0 rowsep0" align="char" char=".">9.6</td><td class="colsep0 rowsep0" align="char" char="."><1.0</td><td class="colsep0 rowsep0" align="char" char=".">171.4</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td></tr></tbody></table></div></div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolic profiling of dosimertinib in liver microsomes of five different species (mouse, rat, dog, monkey, and human).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Pharmacokinetics of Dosimertinib and Its Toxic Metabolite in Rats</h3><div class="NLM_p">The mean <i>C</i><sub>max</sub> and AUC<sub>0–<i>t</i></sub> values were proportionate to a dose in the range of 2–12 mg/kg. There were no significant differences in <i>t</i><sub>1/2</sub> among the three dose groups, implying linear pharmacokinetics of dosimertinib in rats (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The absolute oral bioavailability of dosimertinib was 29.6%–43.0%, measured by comparing the respective AUC after oral and intravenous administration, suggesting moderate oral absorption of dosimertinib in rats (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). After multiple dosings of 6 mg/kg/day of dosimertinib, the mean <i>C</i><sub>max</sub> was 132 ± 44 and 180 ± 51 nM, and the mean AUC<sub>0–<i>t</i></sub> was 1320 ± 733 and 1570 ± 891 nM·h on day 1 and day 7, respectively. There were no significant changes for <i>C</i><sub>max</sub> and AUC<sub>0–<i>t</i></sub> between day 1 and day 7, indicating no significant accumulation of dosimertinib in the plasma and low cumulative toxicity. In addition, dosimertinib and osimertinib also exhibited comparable clearance rates with a CL of 19.5 and 18.8 L/h/kg, respectively, after oral dosing of 6 mg/kg/day.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Mean Pharmacokinetic Parameters of Dosimertinib and Osimertinib and Their Toxic Metabolites after i.g. or i.v. Administration to Rats (<i>n</i> = 6)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center">parent compound</th><th class="rowsep1 colsep0" colspan="5" align="center">dosimertinib</th><th class="rowsep1 colsep0" colspan="2" align="center">osimertinib</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">detected compound</th><th class="colsep0 rowsep0" colspan="4" align="center">dosimertinib</th><th class="colsep0 rowsep0" align="center">AZ5104-D2</th><th class="colsep0 rowsep0" align="center">osimertinib</th><th class="colsep0 rowsep0" align="center">AZ5104</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">administration route</td><td class="colsep0 rowsep0" align="center">i.v.</td><td class="colsep0 rowsep0" align="center">i.g.</td><td class="colsep0 rowsep0" align="center">i.g.</td><td class="colsep0 rowsep0" align="center">i.g.</td><td class="colsep0 rowsep0" align="center">i.g.</td><td class="colsep0 rowsep0" align="center">i.g.</td><td class="colsep0 rowsep0" align="center">i.g.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>0</sub> or <i>C</i><sub>max</sub> (nM)</td><td class="colsep0 rowsep0" align="center">277 ± 105</td><td class="colsep0 rowsep0" align="center">46.7 ± 10.7</td><td class="colsep0 rowsep0" align="center">113 ± 19.8</td><td class="colsep0 rowsep0" align="center">283 ± 137</td><td class="colsep0 rowsep0" align="center">0.395 ± 0.26</td><td class="colsep0 rowsep0" align="center">145 ± 70.9</td><td class="colsep0 rowsep0" align="center">6.40 ± 4.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">4.17 ± 2.56</td><td class="colsep0 rowsep0" align="center">4.67 ± 1.63</td><td class="colsep0 rowsep0" align="center">5.00 ± 1.67</td><td class="colsep0 rowsep0" align="center">6.80 ± 1.10</td><td class="colsep0 rowsep0" align="center">5.33 ± 1.03</td><td class="colsep0 rowsep0" align="center">6.33 ± 1.51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="center">5.40 ± 1.84</td><td class="colsep0 rowsep0" align="center">3.76 ± 1.08</td><td class="colsep0 rowsep0" align="center">3.27 ± 0.43</td><td class="colsep0 rowsep0" align="center">4.04 ± 1.50</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">3.78 ± 1.50</td><td class="colsep0 rowsep0" align="center">5.68 ± 2.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–<i>t</i></sub> (nM·h)</td><td class="colsep0 rowsep0" align="center">1070 ± 565</td><td class="colsep0 rowsep0" align="center">459 ± 191</td><td class="colsep0 rowsep0" align="center">1020 ± 313</td><td class="colsep0 rowsep0" align="center">2830 ± 1780</td><td class="colsep0 rowsep0" align="center">2.64 ± 2.15</td><td class="colsep0 rowsep0" align="center">1530 ± 985</td><td class="colsep0 rowsep0" align="center">67.3 ± 34.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL/F (L/h/kg)</td><td class="colsep0 rowsep0" align="center">22.3 ± 11.1</td><td class="colsep0 rowsep0" align="center">32.2 ± 13.6</td><td class="colsep0 rowsep0" align="center">19.5 ± 5.1</td><td class="colsep0 rowsep0" align="center">14.9 ± 6.4</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">18.8 ± 13.2</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bioavailability (%)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">41.2</td><td class="colsep0 rowsep0" align="center">29.6</td><td class="colsep0 rowsep0" align="center">43.0</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">AUC<sub>0–<i>t</i></sub> = area under the plasma concentration–time curve from time zero to 24 h; <i>t</i><sub>1/2</sub> = elimination half-life; <i>T</i><sub>max</sub> = time to reach <i>C</i><sub>max</sub>; CL/F = apparent clearance; <i>C</i><sub>0</sub> = plasma concentration at initial time; <i>C</i><sub>max</sub> = maximum plasma concentration; ND = not detected; NA, not applicable. Data were expressed as mean ± SD.</p></div></div></div><div class="NLM_p last">In this study, the compared pharmacokinetics was also evaluated by analysis of the parent compound and toxic metabolites of dosimertinib and osimertinib. After oral dosing of 6 mg/kg of dosimertinib, the mean <i>C</i><sub>max</sub> and AUC<sub>0–<i>t</i></sub> of AZ5104-D2 were 0.395 ± 0.26 nM and 2.64 ± 2.15 nM·h, respectively, with an AUC ratio of 0.259% relative to dosimertinib. However, after oral dosing of 6 mg/kg of osimertinib, the mean <i>C</i><sub>max</sub> and AUC<sub>0–<i>t</i></sub> of AZ5104 were 6.40 ± 4.06 nM and 67.3 ± 34.3 nM·h, respectively, with an AUC ratio of 4.19% relative to osimertinib (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). The results indicated that dosimertinib produced a similar level of parent compound and lower level of toxic metabolite compared to osimertinib, which was in line with the results of metabolic profiles in liver microsomes. The data also revealed that dosimertinib exhibited lower toxicity compared to osimertinib.</div></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> CYP Reaction Phenotyping</h3><div class="NLM_p">To determine which CYP450 isoforms are involved in dosimertinib metabolism, reaction phenotyping studies were performed. Three metabolites (M3, M6, and M11) were determined in both human liver microsomes (HLMs) and recombinant CYP450 isoforms (rCYPs) reaction systems without selective inhibitors. In HLMs, selective inhibitors ketoconazole (CYP3A), montelukast (CYP2C8), and sulphaphenazole (CYP2C9) substantially inhibited the formation of M3 by 122.1%, 24.0%, and 27.1%, respectively. M6 formation was inhibited in the presence of ketoconazole (CYP3A) and montelukast (CYP2C8) by 67.5% and 45.2%, while M11 was inhibited in the presence of ketoconazole (CYP3A) and sulphaphenazole (CYP2C9) by 88.5% and 23.7%, respectively. Moreover, the rCYP results exhibited rapid metabolism of dosimertinib to generate M3 and M11 in the presence of rCYP3A4 (98.9% and 88.5%) and to generate M6 in the presence of rCYP3A4 (57.5%) and rCYP2C8 (38.8%; <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Hence, CYP3A4 was the predominant isoform involved in the metabolism of dosimertinib with a minor contribution from CYP2C8.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Reaction phenotyping of dosimertinib. (A) Inhibition in the formation of M1, M6, and M11 in HLMs in the presence of selective P450 inhibitors, respectively. (B) Relative contribution of various recombinant P450 isoforms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Evaluation of CYP450 Inhibition</h3><div class="NLM_p">To evaluate the inhibition potential of dosimertinib against CYP450 isoforms, incubation with CYP450 probe substrates was carried out in human liver microsomes. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>, the strongest inhibition of dosimertinib in human liver microsomes was observed against CYP3A4 (IC<sub>50</sub> = 17.3 μM for midazolam and IC<sub>50</sub> = 27.1 μM for testosterone). Dosimertinib showed weak inhibition against CYP1A2, CYP2C8, and CYP2C19 (IC<sub>50</sub> = 39.8, 29.3, and 43 μM, respectively). For CYP2B6, CYP2C9, and CYP2D6, their corresponding IC<sub>50</sub> values were >50 μM. These results showed that dosimertinib was found to be a relatively weak inhibitor against the P450s tested.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibition of P450 Activity by Dosimertinib in Human Liver Microsomes</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">CYP450 isoforms</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP1A2</td><td class="colsep0 rowsep0" align="center">39.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2B6</td><td class="colsep0 rowsep0" align="center">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2C8</td><td class="colsep0 rowsep0" align="center">29.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2C9</td><td class="colsep0 rowsep0" align="center">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2C19</td><td class="colsep0 rowsep0" align="center">43.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP2D6</td><td class="colsep0 rowsep0" align="center">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP3A4 (midazolam)</td><td class="colsep0 rowsep0" align="center">27.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP3A4 (testosterone)</td><td class="colsep0 rowsep0" align="center">17.3</td></tr></tbody></table></div></div></div><div id="sec3_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Evaluation of CYP450 Induction</h3><div class="NLM_p">The effect of dosimertinib on CYP mRNA expression and activity was assessed in three donors.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Positive control inducers omeprazole, phenobarbital, and rifampicin significantly increase CYPs mRNA expression and activity, indicating that the induction assays for these CYP isoforms were performed appropriately (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Dosimertinib at 0.1 and 1.0 μM did not result in significant induction of CYP1A2, CYP2B6, or CYP3A4 mRNA expression and activity in any donor, suggesting that dosimertinib had no impact on CYP450 induction <i>in vitro</i>. In summary, dosimertinib had a weak inhibitory activity against CYP450 isoforms and no impact on CYP450 induction <i>in vitro</i>. The clinical relevance of the weak CYP450 inhibition will depend on the concentration of dosimertinib in patients. On the basis of the results of our study, it is expected that administration of the proposed doses of dosimertinib would not cause remarkable CYP450-mediated drug–drug interactions in patients.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Dose-Response of P450 mRNA Expression and Activity after Treatment with Dosimertinib in Three Individual Hepatocyte Donors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">P450 activity<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">P450 mRNA expression<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">donor</th><th class="colsep0 rowsep0" align="center">concentration (μM)</th><th class="colsep0 rowsep0" align="center" char=".">CYP1A2</th><th class="colsep0 rowsep0" align="center" char=".">CYP2B6</th><th class="colsep0 rowsep0" align="center" char=".">CYP3A4</th><th class="colsep0 rowsep0" align="center" char=".">CYP1A2</th><th class="colsep0 rowsep0" align="center" char=".">CYP2B6</th><th class="colsep0 rowsep0" align="center" char=".">CYP3A4</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">1</td><td class="colsep0 rowsep0" align="left">positive control<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">12.6</td><td class="colsep0 rowsep0" align="char" char=".">7.54</td><td class="colsep0 rowsep0" align="char" char=".">8.74</td><td class="colsep0 rowsep0" align="char" char=".">153</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="char" char=".">37.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="char" char=".">1.45</td><td class="colsep0 rowsep0" align="char" char=".">1.23</td><td class="colsep0 rowsep0" align="char" char=".">1.26</td><td class="colsep0 rowsep0" align="char" char=".">1.96</td><td class="colsep0 rowsep0" align="char" char=".">1.01</td><td class="colsep0 rowsep0" align="char" char=".">2.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1.87</td><td class="colsep0 rowsep0" align="char" char=".">1.21</td><td class="colsep0 rowsep0" align="char" char=".">1.42</td><td class="colsep0 rowsep0" align="char" char=".">1.59</td><td class="colsep0 rowsep0" align="char" char=".">1.40</td><td class="colsep0 rowsep0" align="char" char=".">1.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">2</td><td class="colsep0 rowsep0" align="left">positive control<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">19.4</td><td class="colsep0 rowsep0" align="char" char=".">9.87</td><td class="colsep0 rowsep0" align="char" char=".">7.79</td><td class="colsep0 rowsep0" align="char" char=".">107</td><td class="colsep0 rowsep0" align="char" char=".">14.3</td><td class="colsep0 rowsep0" align="char" char=".">31.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="char" char=".">1.25</td><td class="colsep0 rowsep0" align="char" char=".">1.08</td><td class="colsep0 rowsep0" align="char" char=".">1.07</td><td class="colsep0 rowsep0" align="char" char=".">1.50</td><td class="colsep0 rowsep0" align="char" char=".">1.13</td><td class="colsep0 rowsep0" align="char" char=".">1.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1.75</td><td class="colsep0 rowsep0" align="char" char=".">0.97</td><td class="colsep0 rowsep0" align="char" char=".">1.21</td><td class="colsep0 rowsep0" align="char" char=".">2.04</td><td class="colsep0 rowsep0" align="char" char=".">1.23</td><td class="colsep0 rowsep0" align="char" char=".">3.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left">3</td><td class="colsep0 rowsep0" align="left">positive control<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">6.05</td><td class="colsep0 rowsep0" align="char" char=".">6.93</td><td class="colsep0 rowsep0" align="char" char=".">3.29</td><td class="colsep0 rowsep0" align="char" char=".">53.7</td><td class="colsep0 rowsep0" align="char" char=".">6.31</td><td class="colsep0 rowsep0" align="char" char=".">194</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="char" char=".">1.41</td><td class="colsep0 rowsep0" align="char" char=".">1.15</td><td class="colsep0 rowsep0" align="char" char=".">1.07</td><td class="colsep0 rowsep0" align="char" char=".">1.30</td><td class="colsep0 rowsep0" align="char" char=".">1.36</td><td class="colsep0 rowsep0" align="char" char=".">1.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1.38</td><td class="colsep0 rowsep0" align="char" char=".">0.89</td><td class="colsep0 rowsep0" align="char" char=".">0.79</td><td class="colsep0 rowsep0" align="char" char=".">1.23</td><td class="colsep0 rowsep0" align="char" char=".">1.99</td><td class="colsep0 rowsep0" align="char" char=".">3.00</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Fold change of P450 mRNA or P450 activity relative to the vehicle control.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">Omeprazole (50 μM), phenobarbital (1000 μM), and rifampicin (10 μM) were used as positive control inducers for CYP1A2, CYP2B6, and CYP3A4, respectively.</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25381" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25381" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Starting from the third-generation EGFR inhibitor osimertinib, further structural optimizations were performed, aiming to obtain new EGFR inhibitors with improved selectivity, antitumor efficacy, and lower toxicity. Delightfully, the deuterium-containing compound <b>2h</b> exhibited excellent potency in enzymatic and cellular levels. In particular, compound <b>2h</b> effectively inhibited growth of H1975 cells with an IC<sub>50</sub> value of 28.4 nM, showing about 9-fold cellular selectivity over A431 cells (IC<sub>50</sub> = 243.9 nM). A low nanomolar cellular potency was also observed toward EGFR-L858/T790M BaF3 and EGFR-del19/T790M BaF3 cells (IC<sub>50</sub> = 18.0 ± 5.0 and 3.5 ± 0.5 nM, respectively), comparable to that of osimertinib (IC<sub>50</sub> = 21.5 ± 2.5 and 4.0 ± 1.0 nM, respectively). In H1975 cells, compound <b>2h</b> potently inhibited EGFR L858R/T790M and downstream ERK phosphorylation. The washout experiment further confirmed the target duration.</div><div class="NLM_p last">Dosimertinib (mesylate of <b>2h</b>) demonstrated comparable antitumor efficacy with osimertinib in two xenograft models bearing H1975 and BaF3 cells (TGI = 72.94% and 76.3% at the dose of 1.5 and 2.5 mg/kg, respectively), but with lower toxicity even at a high dosage. In both xenograft models, dosimertinib exhibited almost complete and sustained tumor suppression at doses of 3.0 and 5.0 mg/kg, respectively. Dosimertinib exhibited similar metabolic stability with osimertinib in mouse, rat, dog, monkey, and human liver microsomes. Metabolic profiling of dosimertinib revealed that the concentration of the toxic metabolite AZ5104-D2 in five species was <1.0 nM, significantly lower than that of AZ5104, a well-characterized toxic metabolite of osimertinib. Pharmacokinetic studies showed that dosimertinib had favorable PK properties and formed lower levels of the toxic metabolite AZ5104-D2 compared to osimertinib. Like osimertinib, CYP3A4 was the predominant CYP isoform responsible for dosimertinib metabolism. Dosimertinib exhibited weak inhibition against all CYP450 isoforms and had minimal impact on CYP450 induction. The data further suggest that the deuterium replacement is a feasible strategy to alter metabolic properties. These preclinical data support further clinical development of dosimertinib for the treatment of NSCLC. Dosimertinib may have therapeutic potential in patients who cannot tolerate osimertinib due to the toxicity. Dosimertinib has recently received approval from the Center for Drug Evaluation, NMPA to initiate the phase I clinical trial (registration numbers: CXHL2000060 and CXHL2000061).</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54382" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54382" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Methods</h3><div class="NLM_p">All chemical reagents and solvents used in experiments were purchased from commercial suppliers and used without further purification. Silica gel (300–400 mesh) used for column chromatography and thin-layer chromatography (TLC) used to monitor progress of the reaction were purchased from Qingdao Haiyang Chemical Co., Ltd. <sup>1</sup>H and <sup>13</sup>C NMR spectra were performed on the Bruker spectrometer (AV-400) at 400 and 100 MHz, respectively. The high-resolution mass spectra (HRMS, Waters LCT Premier XE TOF) were measured at the Institute of Fine Chemistry of ECUST. Melting points were determined with the digital melting point apparatus (WRS-1B). The purity of all final compounds were analyzed by HPLC (Hewlett-Packard 1100), with the purity of all compounds being over 95%. The HPLC instrument was equipped with a photodiode array detector using an ODS-C18 (Agilent, 4.6 × 250 mm, 5 μm). The mobile phases A and B were acetonitrile and the solution of 0.1% aqueous formic acid, respectively.</div><div class="NLM_p">Compounds <b>1</b> and <b>4</b> were synthesized following the previously reported procedures.<a onclick="showRef(event, 'ref32 ref41'); return false;" href="javascript:void(0);" class="ref ref32 ref41">(32,41)</a> Therefore, no synthetic details are shown here.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)methacrylamide (<b>2a</b>)</h4><div class="NLM_p last">To a solution of compound <b>1</b> (500 mg, 1.12 mmol) and isobutyryl chloride (100 mg, 1.12 mmol) in a mixture of THF/water (4:1) was added NaOH (110 mg, 2.68 mmol) at room temperature. The reaction mixture was stirred until TLC indicated complete consumption of the starting material. The reaction was quenched by the addition of saturated NH<sub>4</sub>Cl solution and extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was removed by rotary evaporation. The residue was purified by silica gel chromatography (dichloromethane/methanol = 10:1, v/v) to give the product <b>2a</b> as a yellow solid (400 mg, 68%). mp 102–104 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.88 (s, 1H), 9.81 (s, 1H), 9.11 (s, 1H), 8.38 (d, <i>J</i> = 5.3 Hz, 1H), 8.08–8.05 (m, 1H), 7.74 (s, 1H), 7.40–7.38 (m, 1H), 7.30–7.23 (m, 2H), 7.21 (d, <i>J</i> = 5.3 Hz, 1H), 6.80 (s, 1H), 5.91 (s, 1H), 5.45 (t, <i>J</i> = 1.4 Hz, 1H), 3.99 (s, 3H), 3.88 (s, 3H), 2.96 (t, <i>J</i> = 6.3 Hz, 2H), 2.68 (s, 3H), 2.25 (t, <i>J</i> = 6.3 Hz, 2H), 2.18 (s, 6H), 2.14 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 165.8, 162.2, 159.7, 158.0, 144.2, 141.6, 138.3, 135.3, 134.2, 129.7, 127.9, 126.1, 121.8, 121.0, 120.3, 119.2, 113.7, 110.2, 109.4, 108.0, 104.6, 57.5, 56.2, 55.7, 45.6, 44.7, 33.1, 19.1. HRMS (ESI; <i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>36</sub>N<sub>7</sub>O<sub>2</sub>: 514.2925. Found: 514.2927. HPLC purity: 97.27%. Retention time = 2.21 min.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (E)-N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)but-2-enamide (<b>2b</b>)</h4><div class="NLM_p last">A mixture of compound <b>1</b> (450 mg, 1.01 mmol), crotonic acid (95 mg, 1.11 mmol), HBTU (420 mg, 1.11 mmol), and DIPEA (500 mg, 4.04 mmol) in DMF (8 mL) was stirred at room temperature for 3 h. It was then quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified through silica gel column chromatography (dichloromethane/methanol = 10:1, v/v) to give product <b>2b</b> as a yellow solid (410 mg, 80%). mp 116–117 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.93 (s, 1H), 9.82 (s, 1H), 9.10 (s, 1H), 8.38 (d, <i>J</i> = 5,3 Hz, 1H), 8.07 (dd, <i>J</i> = 5.7, 2.1 Hz, 1H), 7.71 (s, 1H), 7.40–7.38 (m, 1H), 7.30–7.25 (m, 2H), 7.20 (d, <i>J</i> = 5.4 Hz, 1H), 7.02–6.94 (m, 1H), 6.79 (s, 1H), 6.08 (dd, <i>J</i> = 15.1, 1.3 Hz, 1H), 4.00 (s, 3H), 3.87 (s, 3H), 2.88 (t, <i>J</i> = 5.5 Hz, 2H), 2.68 (s, 3H), 2.30–2.24 (m, 8H), 1.94 (dd, <i>J</i> = 6.9, 1.6 Hz, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.4, 162.2, 159.7, 158.0, 144.1, 138.5, 138.3, 135.4, 134.6, 129.9, 127.7, 127.4, 126.1, 121.8, 121.0, 120.4, 113.8, 110.1, 109.9, 108.0, 104.7, 57.5, 56.6, 56.2, 45.6, 43.8, 33.2, 18.1. HRMS (ESI; <i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>36</sub>N<sub>7</sub>O<sub>2</sub>: 514.2925. Found: 514.2926. HPLC purity: 97.93%. Retention time = 2.34 min.</div></div><div id="sec5_1_3b" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-2-(trifluoromethyl)acrylamide (<b>2c</b>)</h4><div class="NLM_p last">A mixture of compound <b>1</b> (450 mg, 1.01 mmol), 2-(trifluoromethyl)acrylic acid (170 mg, 1.21 mmol), T3P (420 mg, 1.32 mmol), and TEA (203 mg, 1.51 mmol) in DCM (8 mL) was stirred at room temperature for 1 h. It was then quenched with H<sub>2</sub>O (30 mL) and extracted with DCM (3 × 10 mL). The combined organic layer was washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified through silica gel column chromatography (dichloromethane/methanol = 10:1, v/v) to give product <b>2c</b> as a yellow solid (280 mg, 50%). mp 101–103 °C. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −65.86. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.44 (s, 1H), 9.77 (s, 1H), 9.04 (s, 1H), 8.39 (d, <i>J</i> = 5.3 Hz, 1H), 8.06–8.04 (m, 1H), 7.76 (s, 1H), 7.41–7.39 (m, 1H), 7.30–7.25 (m, 2H), 7.23 (d, <i>J</i> = 5.3 Hz, 1H), 6.81 (s, 1H), 6.45 (d, <i>J</i> = 1.4 Hz, 1H), 6.29 (d, <i>J</i> = 1.1 Hz, 1H), 3.96 (s, 3H), 3.89 (s, 3H), 2.95 (t, <i>J</i> = 6.0 Hz, 2H), 2.69 (s, 3H), 2.23 (t, <i>J</i> = 6.1 Hz, 2H), 2.17 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.2, 159.5, 159.1, 158.0, 144.7,138.3, 136.3 (q, <i>J</i> = 30.2 Hz), 135.0, 134.3, 129.1, 128.0, 125.9, 122.2 (q, <i>J</i> = 271 Hz), 121.8, 120.9, 120.1, 113.5, 110.2, 109.3, 108.1, 104.6, 57.3, 56.1, 55.8, 45.3, 44.6, 32.9, 29.7. HRMS (ESI; <i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>33</sub>F<sub>3</sub>N<sub>7</sub>O<sub>2</sub>: 568.2642. Found: 568.2645. HPLC purity: 100%. Retention time = 2.35 min.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-2-fluoroacrylamide (<b>2d</b>)</h4><div class="NLM_p last">A mixture of compound <b>1</b> (450 mg, 1.01 mmol), 2-fluoroacrylic acid (100 mg, 1.11 mmol), HBTU (420 mg, 1.11 mmol), and DIPEA (500 mg, 4.04 mmol) in DMF (8 mL) was stirred at room temperature for 3 h. It was then quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified through silica gel column chromatography (dichloromethane/methanol = 10:1, v/v) to give product <b>2d</b> as a yellow solid (350 mg, 68%). mp 123–124 °C. <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>): δ −118.9. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.50 (s, 1H), 9.71 (s, 1H), 8.92 (s, 1H), 8.39 (d, <i>J</i> = 5.3 Hz, 1H), 8.08 (dd, <i>J</i> = 5.9, 2.1 Hz, 1H), 7.75 (s, 1H), 7.40–7.38 (m, 1H), 7.30–7.24 (m, 2H), 7.21 (d, <i>J</i> = 5.3 Hz, 1H), 6.81 (s, 1H), 5.76 (dd, <i>J</i> = 46.6, 2.9 Hz, 1H), 5.20 (dd, <i>J</i> = 14.9, 2.9 Hz, 1H), 3.96 (s, 3H), 3.89 (s, 3H), 2.98 (t, <i>J</i> = 6.4 Hz, 2H), 2.68 (s, 3H), 2.26 (t, <i>J</i> = 6.4 Hz, 2H), 2.22 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.1, 159.6, 158.1, 158.0 (d, <i>J</i> = 271.9 Hz), 157.0, (d, <i>J</i> = 29.4 Hz), 145.1, 138.3, 135.1, 134.9, 128.5, 128.0, 126.0, 122.0, 121.1, 120.4, 113.8, 110.4, 110.2, 108.2, 104.7, 98.2 (d, <i>J</i> = 15.7 Hz), 57.3, 56.2, 55.7, 45.14, 45.13, 45.0, 33.2. HRMS (ESI; <i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>33</sub>FN<sub>7</sub>O<sub>2</sub>: 518.2674. Found: 518.2676. HPLC purity: 99.89%. Retention time = 2.41 min.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Chloro-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (<b>2e</b>)</h4><div class="NLM_p last">A mixture of compound <b>1</b> (450 mg, 1.01 mmol), 2-chloroacrylic acid (120 mg, 1.11 mmol), HBTU (420 mg, 1.11 mmol), and DIPEA (500 mg, 4.04 mmol) in DMF (8 mL) was stirred at room temperature for 3 h. It was then quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified through silica gel column chromatography (dichloromethane/methanol = 10:1, v/v) to give product <b>2e</b> as a yellow solid (400 mg, 78%). mp 114–116 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.35 (s, 1H), 9.78 (s, 1H), 8.95 (s, 1H), 8.39 (d, <i>J</i> = 5.3 Hz, 1H), 8.08–8.06 (m, 1H), 7.74 (s, 1H), 7.40–7.38 (m, 1H), 7.29–7.26 (m, 2H), 7.21 (d, <i>J</i> = 5.3 Hz, 1H), 6.82 (s, 1H), 6.64 (d, <i>J</i> = 1.2 Hz, 1H), 5.90 (d, <i>J</i> = 1.2 Hz, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 3.02 (t, <i>J</i> = 6.6 Hz, 2H), 2.69 (s, 3H), 2.33 (t, <i>J</i> = 6.6 Hz, 2H), 2.22 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.2, 159.6, 158.3, 158.0, 145.0, 138.3, 134.93, 134.85, 134.6, 128.3, 127.9, 126.0, 122.0, 121.6, 121.1, 120.4, 113.8, 110.2, 109.4, 108.2, 104.4, 57.6, 56.2, 55.5, 45.6, 44.8, 33.2. HRMS (ESI; <i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>33</sub>ClN<sub>7</sub>O<sub>2</sub>: 534.2379. Found: 534.2381. HPLC purity: 99.76%. Retention time = 2.33 min.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-Bromo-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide (<b>2f</b>)</h4><div class="NLM_p last">A mixture of compound <b>1</b> (450 mg, 1.01 mmol), 2-bromoacrylic acid (166 mg, 1.10 mmol), HBTU (420 mg, 1.11 mmol), and DIPEA (500 mg, 4.04 mmol) in DMF (8 mL) was stirred at room temperature for 3 h. It was then quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified through silica gel column chromatography (dichloromethane/methanol = 10:1, v/v) to give product <b>2f</b> as a yellow solid (370 mg, 64%). mp 128–130 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.37 (s, 1H), 9.78 (s, 1H), 8.98 (s, 1H), 8.39 (d, <i>J</i> = 5.3 Hz, 1H), 8.07 (dd, <i>J</i> = 6.0, 1.9 Hz, 1H), 7.75 (s, 1H), 7.41–7.39 (m, 1H), 7.31–7.24 (m, 2H), 7.22 (d, <i>J</i> = 5.3 Hz, 1H), 7.02 (d, <i>J</i> = 1.5 Hz, 1H), 6.82 (s, 1H), 6.14 (d, <i>J</i> = 1.5 Hz, 1H), 3.98 (s, 3H), 3.90 (s, 3H), 3.02 (t, <i>J</i> = 7.1 Hz, 2H), 2.70 (s, 3H), 2.34 (t, <i>J</i> = 7.1 Hz, 2H), 2.22 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 162.2, 159.6, 158.6, 158.1, 144.9, 138.3, 134.9, 128.5, 127.8, 126.1, 126.0, 125.5, 122.0, 121.1, 120.4, 113.8, 110.2, 109.1, 108.2, 104.4, 57.7, 56.2, 55.6, 45.8, 44.8, 33.3. HRMS (ESI; (<i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>33</sub>BrN<sub>7</sub>O<sub>2</sub>: 578.1874. Found: 578.1875. HPLC purity: 99.47%. Retention time = 2.37 min.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d<sub>2</sub> (<b>2g</b>)</h4><div class="NLM_p">A mixture of compound <b>1</b> (500 mg, 1.12 mmol), diethylphosphoacetic acid (235 mg, 1.22 mmol), HATU (495 mg, 1.31 mmol), and DIPEA (168 mg, 1.31 mmol) in THF (8 mL) was stirred at room temperature for 5 h. It was then quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The crude product <b>3</b> was carried on to the next step without further purification.</div><div class="NLM_p last">To a solution of crude <b>3</b> from the previous reaction (500 mg) in THF/water (4:1) was added (CD<sub>2</sub>O)<sub><i>n</i></sub> (25 mg, 0.25 mmol), LiOH (50 mg, 1.21 mmol), and KOH (140 mg, 2.41 mmol). After 15 h, the reaction was quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layer was washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified through silica gel column chromatography (dichloromethane/methanol = 10:1, v/v) to give product <b>2g</b> as a yellow solid (320 mg, 58% yield over 2 steps). mp 108–109 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.07 (s, 1H), 9.47 (s, 1H), 8.98 (s, 1H), 8.37 (d, <i>J</i> = 5.3 Hz, 1H), 8.08 (d, <i>J</i> = 6.9 Hz, 1H), 7.71 (s, 1H), 7.40–7.38 (m, 1H), 7.29–7.25 (m, 2H), 7.18 (d, <i>J</i> = 5.3 Hz, 1H), 6.77 (s, 1H), 6.38 (s, 1H), 3.97 (s, 3H), 3.88 (s, 3H), 2.92 (t, <i>J</i> = 5.5 Hz, 2H), 2.68 (s, 3H), 2.36 (t, <i>J</i> = 5.5 Hz, 2H), 2.30 (s, 6H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 163.2, 162.2, 159.6, 158.0, 144.6, 138.3, 135.0, 134.9, 132.6, 129.2, 127.7, 126.0, 121.9, 121.0, 120.4, 113.7, 110.6, 110.2, 108.0, 104.5, 57.2, 56.2, 45.3, 44.1, 33.2. HRMS (ESI; <i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>32</sub>D<sub>2</sub>N<sub>7</sub>O<sub>2</sub>: 502.2894. Found: 502.2895. HPLC purity: 99.69%. Retention time = 2.29 min.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d<sub>3</sub>)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d<sub>2</sub> (<b>2h</b>)</h4><div class="NLM_p">A mixture of compound <b>4</b> (500 mg, 1.11 mmol), diethylphosphoacetic acid (235 mg, 1.21 mmol), HATU (495 mg, 1.31 mmol), and DIPEA (168 mg, 1.31 mmol) in THF (8 mL) was stirred at room temperature for 5 h. It was then quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and then concentrated. The crude product <b>5</b> was carried on to the next step without further purification.</div><div class="NLM_p last">To a solution of crude <b>5</b> from the previous reaction (510 mg) in THF/water (4:1) was added (CD<sub>2</sub>O)<sub><i>n</i></sub> (25 mg, 0.25 mmol), LiOH (50 mg, 1.21 mmol), and KOH (140 mg, 2.41 mmol). After 15 h, the reaction was quenched with H<sub>2</sub>O (30 mL) and extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with H<sub>2</sub>O (10 mL) and brine (10 mL) successively, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated, and purified through silica gel column chromatography (dichloromethane/methanol = 10:1, v/v) to give product <b>2h</b> as a yellow solid (315 mg, 56% yield over 2 steps). mp 104–105 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.42 (d, <i>J</i> = 7.9 Hz, 1H), 8.30 (s, 1H), 8.26 (d, <i>J</i> = 5.3 Hz, 1H), 7.80 (s, 1H), 7.51 (d, <i>J</i> = 8.1 Hz, 1H), 7.48 (s, 1H), 7.24 (t, <i>J</i> = 7.3 Hz, 1H), 7.18–7.13 (m, 2H), 6.76 (s, 1H), 4.59 (s, 2H), 3.74 (s, 3H), 2.88 (t, <i>J</i> = 6.7 Hz, 2H), 2.63 (s, 3H), 2.35 (t, <i>J</i> = 6.7 Hz, 2H), 2.17 (s, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>): δ 162.1, 160.4, 157.0, 141.8, 137.6, 136.7, 133.4, 132.8, 125.6, 125.2, 122.3, 122.1, 120.9, 112.4, 110.3, 109.1, 106.8, 105.2, 57.4, 56.4, 54.0, 45.8, 41.6. HRMS (ESI; <i>m</i>/<i>z</i>; M + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>39</sub>D<sub>5</sub>FN<sub>7</sub>O<sub>2</sub>: 505.3082. Found: 505.3085. HPLC purity: 100%. Retention time = 2.32 min.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> N-(2-((2-(Dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(methyl-d<sub>3</sub>)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide-3,3-d<sub>2</sub>, methanesulfonate (1:1) (Dosimertinib)</h4><div class="NLM_p last">To a solution of <b>2h</b> (100 mg, 0.20 mmol) in acetone/water (10:1) was added methane sulfonic acid (19 mg, 0.20 mmol) as a solution in acetone; the resulting mixture was stirred for 3 h at 50 °C. The resulting solid was collected by filtration and dried at 80 °C under a vacuum overnight to give dosimertinib (108 mg, 90%). <sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O): δ 8.21 (s, 1H), 7.48 (s, 1H), 7.42 (d, <i>J</i> = 4.3 Hz, 1H), 7.28 (s, 1H), 6.94–6.86 (m, 2H), 6.78 (s, 2H), 6.45 (s, 1H), 6.19 (d, <i>J</i> = 3.6 Hz, 1H), 3.80 (s, 3H), 3.18 (s, 4H), 2.81 (s, 3H), 2.74 (s, 6H), 2.49 (s, 3H). <sup>13</sup>C NMR (150 MHz, D<sub>2</sub>O): δ 166.1, 162.2, 156.9, 137.4, 133.9, 130.2, 124.9, 124.8, 123.7, 122.0, 121.1, 120.5, 112.0, 110.0, 106.8, 104.1, 56.1, 54.6, 49.3, 42.6, 38.5. HRMS (ESI; <i>m</i>/<i>z</i>; M-MsOH + H)<sup>+</sup> calcd for C<sub>28</sub>H<sub>39</sub>D<sub>5</sub>FN<sub>7</sub>O<sub>2</sub>: 505.3082. Found: 505.3084. HPLC purity: 99.3%. Retention time = 2.26 min.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36"><a href="/doi/suppl/10.1021/acs.jmedchem.0c02005" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20460" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20460" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c02005?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02005</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental details, NMR spectra, and HPLC traces of representative compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_001.pdf">jm0c02005_si_001.pdf (1.42 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_002.csv">jm0c02005_si_002.csv (1.51 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02005" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinfa Du</span> - <span class="hlFld-Affiliation affiliation">Henan
Genuine Biotech Co., Ltd. 10 Fuxing Road, Xincheng District, Pingdingshan, Henan 467036, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f094859a999e9691b08a8383879b9ade9e9584"><span class="__cf_email__" data-cfemail="b0d4c5dad9ded6d1f0cac3c3c7dbda9eded5c4">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junbiao Chang</span> - <span class="hlFld-Affiliation affiliation">College
of Chemistry, Zhengzhou University, Zhengzhou 450001, China</span>; 
    <span class="hlFld-Affiliation affiliation">Henan
Key Laboratory of Organic Functional Molecule and Drug Innovation,
School of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang 453007, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6236-1256" title="Orcid link">http://orcid.org/0000-0001-6236-1256</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#43202b222d2429362d212a222c033939366d2627366d202d"><span class="__cf_email__" data-cfemail="d8bbb0b9b6bfb2adb6bab1b9b798a2a2adf6bdbcadf6bbb6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yonggang Meng</span> - <span class="hlFld-Affiliation affiliation">College
of Chemistry, Zhengzhou University, Zhengzhou 450001, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Yu</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">He Huang</span> - <span class="hlFld-Affiliation affiliation">College
of Chemistry, Zhengzhou University, Zhengzhou 450001, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youmei Peng</span> - <span class="hlFld-Affiliation affiliation">Henan
Key Laboratory for Pharmacology of Liver Diseases, Institute of Medical
and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ertong Li</span> - <span class="hlFld-Affiliation affiliation">College
of Chemistry, Zhengzhou University, Zhengzhou 450001, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongfang Yao</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chuanjun Song</span> - <span class="hlFld-Affiliation affiliation">College
of Chemistry, Zhengzhou University, Zhengzhou 450001, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7733-578X" title="Orcid link">http://orcid.org/0000-0001-7733-578X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenquan Yu</span> - <span class="hlFld-Affiliation affiliation">College
of Chemistry, Zhengzhou University, Zhengzhou 450001, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3711-0006" title="Orcid link">http://orcid.org/0000-0002-3711-0006</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kaikai Zhu</span> - <span class="hlFld-Affiliation affiliation">Henan Metab
Biopharma Co., Ltd., Zhengzhou Airport Economy Zone, Taiwan Science Park, Zhengzhou 450006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kai Wang</span> - <span class="hlFld-Affiliation affiliation">Henan Metab
Biopharma Co., Ltd., Zhengzhou Airport Economy Zone, Taiwan Science Park, Zhengzhou 450006, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dongxu Yi</span> - <span class="hlFld-Affiliation affiliation">Henan Metab
Biopharma Co., Ltd., Zhengzhou Airport Economy Zone, Taiwan Science Park, Zhengzhou 450006, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>These authors contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e3317-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66102" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66102" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by National Natural Science Foundation of China (No. U1804283). We sincerely thank Profs. Honglin Li (East China University of Science & Technology) and Hua Xie (Shanghai Institute of Materia Medica, CAS) for testing the enzymatic activity of the compounds.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AUC<sub>0–<i>t</i></sub></td><td class="NLM_def"><p class="first last">area under the plasma concentration–time curve from time zero to 24 h</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>0</sub></td><td class="NLM_def"><p class="first last">plasma concentration at initial time</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">apparent clearance</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">YP450</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">TYK2</td><td class="NLM_def"><p class="first last">tyrosine kinase 2</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">EGFRm<sup>+</sup></td><td class="NLM_def"><p class="first last">EGFR mutation–positive</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxide hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HBSS</td><td class="NLM_def"><p class="first last">Hank’s balanced salt solution</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">LM</td><td class="NLM_def"><p class="first last">liver microsomes</p></td></tr><tr><td class="NLM_term">MRM</td><td class="NLM_def"><p class="first last">multiple reaction monitoring</p></td></tr><tr><td class="NLM_term">NADPH</td><td class="NLM_def"><p class="first last">nicotinamide adenine dinucleotide phosphate</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">PTSA</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonamide</p></td></tr><tr><td class="NLM_term">rCYP</td><td class="NLM_def"><p class="first last">recombinant human cytochrome P450</p></td></tr><tr><td class="NLM_term">SRB</td><td class="NLM_def"><p class="first last">sulforhodamine B</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">propanephosphonic acid anhydride</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time to reach <i>C</i><sub>max</sub></p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0ljXkrYJlvyEfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rude
Voldborg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damstrup, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spang-Thomsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skovgaard Poulsen, H.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1023/A:1008209720526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1023%2FA%3A1008209720526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=9496384" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=1197-1206&author=B.+Rude%0AVoldborgauthor=L.+Damstrupauthor=M.+Spang-Thomsenauthor=H.+Skovgaard+Poulsen&title=Epidermal+growth+factor+receptor+%28EGFR%29+and+EGFR+mutations%2C+function+and+possible+role+in+clinical+trials&doi=10.1023%2FA%3A1008209720526"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008209720526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008209720526%26sid%3Dliteratum%253Aachs%26aulast%3DRude%2BVoldborg%26aufirst%3DB.%26aulast%3DDamstrup%26aufirst%3DL.%26aulast%3DSpang-Thomsen%26aufirst%3DM.%26aulast%3DSkovgaard%2BPoulsen%26aufirst%3DH.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520EGFR%2520mutations%252C%2520function%2520and%2520possible%2520role%2520in%2520clinical%2520trials%26jtitle%3DAnn.%2520Oncol.%26date%3D1997%26volume%3D8%26spage%3D1197%26epage%3D1206%26doi%3D10.1023%2FA%3A1008209720526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moasser, M. M.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor family: Biology driving targeted therapeutics</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1584</span>, <span class="refDoi"> DOI: 10.1007/s00018-008-7440-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1007%2Fs00018-008-7440-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=18259690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt12qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=1566-1584&author=M.+J.+Wieduwiltauthor=M.+M.+Moasser&title=The+epidermal+growth+factor+receptor+family%3A+Biology+driving+targeted+therapeutics&doi=10.1007%2Fs00018-008-7440-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The epidermal growth factor receptor family: Biology driving targeted therapeutics</span></div><div class="casAuthors">Wieduwilt, M. J.; Moasser, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1566-1584</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review of the biol. of ErbB receptors, including their structure, signaling, regulation, and roles in development and disease, and their increasing roles as targets for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSSPMwgxaFLVg90H21EOLACvtfcHk0liEYbpnOpfjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt12qu7o%253D&md5=d0e8b0634b2b401b1c94838fe389ca91</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00018-008-7440-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-008-7440-8%26sid%3Dliteratum%253Aachs%26aulast%3DWieduwilt%26aufirst%3DM.%2BJ.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520family%253A%2520Biology%2520driving%2520targeted%2520therapeutics%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2008%26volume%3D65%26spage%3D1566%26epage%3D1584%26doi%3D10.1007%2Fs00018-008-7440-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor pathway: a model for targeted therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5268</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1158%2F1078-0432.CCR-05-1554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=17000658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFShs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5268&author=M.+Scaltritiauthor=J.+Baselga&title=The+epidermal+growth+factor+receptor+pathway%3A+a+model+for+targeted+therapy&doi=10.1158%2F1078-0432.CCR-05-1554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Epidermal Growth Factor Receptor Pathway: a Model for Targeted Therapy</span></div><div class="casAuthors">Scaltriti, Maurizio; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5268-5272</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors.  The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic.  Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clin. targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXuFE-mrma7Vg90H21EOLACvtfcHk0liEYbpnOpfjPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFShs74%253D&md5=1dce384cc003760669ffd798bdcca768</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1554%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520pathway%253A%2520a%2520model%2520for%2520targeted%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5268%26doi%3D10.1158%2F1078-0432.CCR-05-1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2Fj.apsb.2019.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=31867165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BB3MbjtV2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1193-1203&author=P.+Heauthor=S.+Niuauthor=S.+Wangauthor=X.+Shiauthor=S.+Fengauthor=L.+Duauthor=X.+Zhangauthor=Z.+Maauthor=B.+Yuauthor=H.+Liu&title=Discovery+of+WS-157+as+a+highly+potent%2C+selective+and+orally+active+EGFR+inhibitor&doi=10.1016%2Fj.apsb.2019.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor</span></div><div class="casAuthors">He Pengxing; Niu Shenghui; Wang Shuai; Shi Xiaojing; Feng Siqi; Du Linna; Zhang Xuyang; Ma Zhilu; Yu Bin; Liu Hongmin; Yu Bin</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1193-1203</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors.  In the present study, we reported the discovery of WS-157 from our in-house diverse compound library, which was validated to be a potent and selective EGFR-TKI.  WS-157 showed excellent inhibitory activities against EGFR (IC50 = 0.81 nmol/L), EGFR([d746-750]) (IC50 = 1.2 nmol/L) and EGFR([L858R]) (IC50 = 1.1 nmol/L), but was less effective or even inactive against other nine kinases.  WS-157 also displayed excellent antiproliferative activities against a panel of human cancer cell lines, and exhibited the ability to reduce colony formation and wound healing the same as gefitinib.  We found that WS-157 upon oral administration showed better anti-tumor activity in A431 bearing xenograft mouse models compared to gefitinib.  In addition, WS-157 showed better intestinal absorption than gefitinib and had favorable pharmacokinetic properties and microsomal metabolic stability in different species.  These studies indicate that WS-157 has strong antitumor activity in vitro and in vivo, and could be used for the development of anti-lung cancer agent targeting EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlv_RDCglknUewzGPswiWOfW6udTcc2ebgAG2xtaTg9Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbjtV2rtg%253D%253D&md5=028496f2984bc9d3a62f4b1812b45fb5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520WS-157%2520as%2520a%2520highly%2520potent%252C%2520selective%2520and%2520orally%2520active%2520EGFR%2520inhibitor%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D1193%26epage%3D1203%26doi%3D10.1016%2Fj.apsb.2019.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+progress+of+small-molecule+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+C797S+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lj-7v5uLU7GFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520of%2520small-molecule%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520C797S%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6580</span>– <span class="NLM_lpage">6594</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6580-6594&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+perspectives+on+the+development+of+small-molecule+EGFR+inhibitors+against+T790M-mediated+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Song, Zhendong; Ge, Yang; Wang, Changyuan; Huang, Shanshan; Shu, Xiaohong; Liu, Kexin; Zhou, Youwen; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6580-6594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the development of drug-resistance mutations, particularly the "gatekeeper" threonine790-to-methionine790 (T790M) mutation in the ATP-binding pocket of the epidermal growth factor receptor (EGFR), the current generation of EGFR tyrosine kinase inhibitors lost their clin. efficacy.  Recently, a large no. of small-mol. inhibitors with striking inhibitory potency against EGFR mutants with the T790M change have been identified.  In particular, the inhibitors rociletinib and osimertinib, which can selectively target both sensitizing mutations and the T790M resistance while sparing the wild-type (WT) form of the receptor, have been designated as breakthrough therapies in the treatment of mutant non-small-cell lung cancer (NSCLC) by the U.S.  FDA in 2014.  We hope that this review on the small-mol. EGFR T790M inhibitors, along with their discovery strategies, will assist in the design of future T790M-contg. EGFR inhibitors with high levels of selectivity over WT EGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEcAydAIVpNbVg90H21EOLACvtfcHk0lhGMiy5GpDTjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D&md5=2112d52e116494f61b1c8bd3f8f383d9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520perspectives%2520on%2520the%2520development%2520of%2520small-molecule%2520EGFR%2520inhibitors%2520against%2520T790M-mediated%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6580%26epage%3D6594%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponthier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">14481</span>– <span class="NLM_lpage">14489</span>, <span class="refDoi"> DOI: 10.1002/anie.202003500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1002%2Fanie.202003500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=14481-14489&author=J.+Jangauthor=C.+Toauthor=D.+J.+H.+De+Clercqauthor=E.+Parkauthor=C.+M.+Ponthierauthor=B.+H.+Shinauthor=M.+Mushajiangauthor=R.+P.+Nowakauthor=E.+S.+Fischerauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Mutant-selective+allosteric+EGFR+degraders+are+effective+against+a+broad+range+of+drug-resistant+mutations&doi=10.1002%2Fanie.202003500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations</span></div><div class="casAuthors">Jang, Jaebong; To, Ciric; De Clercq, Dries J. H.; Park, Eunyoung; Ponthier, Charles M.; Shin, Bo Hee; Mushajiang, Mierzhati; Nowak, Radoslaw P.; Fischer, Eric S.; Eck, Michael J.; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">14481-14489</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting epidermal growth factor receptor (EGFR) through an allosteric mechanism provides a potential therapeutic strategy to overcome drug-resistant EGFR mutations that emerge within the ATP binding site.  Here, we develop an allosteric EGFR degrader, DDC-01-163, which can selectively inhibit the proliferation of L858R/T790M (L/T) mutant Ba/F3 cells while leaving wildtype EGFR Ba/F3 cells unaffected.  DDC-01-163 is also effective against osimertinib-resistant cells with L/T/C797S and L/T/L718Q EGFR mutations.  When combined with an ATP-site EGFR inhibitor, osimertinib, the anti-proliferative activity of DDC-01-163 against L858R/T790M EGFR-Ba/F3 cells is enhanced.  Collectively, DDC-01-163 is a promising allosteric EGFR degrader with selective activity against various clin. relevant EGFR mutants as a single agent and when combined with an ATP-site inhibitor.  Our data suggests that targeted protein degrdn. is a promising drug development approach for mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-uPhJ2k9kLVg90H21EOLACvtfcHk0lhGMiy5GpDTjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I&md5=4e24a6a1a746e446a052f27e404f8adf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202003500%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DPonthier%26aufirst%3DC.%2BM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DMutant-selective%2520allosteric%2520EGFR%2520degraders%2520are%2520effective%2520against%2520a%2520broad%2520range%2520of%2520drug-resistant%2520mutations%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D14481%26epage%3D14489%26doi%3D10.1002%2Fanie.202003500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1216-1232&author=M.+Chengauthor=X.+Yuauthor=K.+Luauthor=L.+Xieauthor=L.+Wangauthor=F.+Mengauthor=X.+Hanauthor=X.+Chenauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Discovery+of+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+bifunctional+small-molecule+degraders&doi=10.1021%2Facs.jmedchem.9b01566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders</span></div><div class="casAuthors">Cheng, Meng; Yu, Xufen; Lu, Kaylene; Xie, Ling; Wang, Li; Meng, Fanye; Han, Xiaoran; Chen, Xian; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1216-1232</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed and approved by Food and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be compromised by acquired drug resistance conferred by EGFR-mutant variants.  Here, we described the discovery of a novel E3 ligase von Hippel-Lindau-recruiting EGFR degrader, MS39 (compd. 6), and a first-in-class E3 ligase cereblon-recruiting EGFR degrader, MS154 (compd. 10), using the proteolysis targeting chimera technol.  These compds. potently induced the degrdn. of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines and effectively suppressed the growth of lung cancer cells compared with the corresponding neg. controls.  The global proteomic analyses revealed that the compds. were highly selective for EGFR.  Furthermore, both compds. were bioavailable in mouse pharmacokinetic studies, and compd. 6 is the first EGFR degrader suitable for in vivo efficacy studies.  Overall, we provide a set of well-characterized chem. tools to the research community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFLSjUGE-6rVg90H21EOLACvtfcHk0lhGMiy5GpDTjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D&md5=ec831897a4258f1968e254aa433426c3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01566%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bifunctional%2520small-molecule%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1216%26epage%3D1232%26doi%3D10.1021%2Facs.jmedchem.9b01566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112199</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2Fj.ejmech.2020.112199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=32171162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112199&author=X.+Zhangauthor=F.+Xuauthor=L.+Tongauthor=T.+Zhangauthor=H.+Xieauthor=X.+Luauthor=X.+Renauthor=K.+Ding&title=Design+and+synthesis+of+selective+degraders+of+EGFRL858R%2FT790M+mutant&doi=10.1016%2Fj.ejmech.2020.112199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span></div><div class="casAuthors">Zhang, Xin; Xu, Fang; Tong, Linjiang; Zhang, Tao; Xie, Hua; Lu, Xiaoyun; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112199</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of PROTAC (proteolysis targeting chimera) based selective EGFRL858R/T790M (leucine 858 to arginine 858 mutation and threonine 790 to methionine 790) mutant degraders were designed and synthesized.  One of the most potent compds. (I) effectively and selectively degraded EGFRL858R/T790M with an DC50 value of 5.9 nM, while did not show obvious effect on the wild-type protein.  Further mechanism investigation revealed that the degrdn. was mediated by ubiquitin proteasome pathway.  Compd. I could be utilized as an initial lead mol. for development of new EGFRL858R/T790M degrader based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDW2mGkQNzbVg90H21EOLACvtfcHk0lhgKszNH5uCuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D&md5=e8fdd02842f6cfd94e362f3a53a39096</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112199%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520selective%2520degraders%2520of%2520EGFRL858R%252FT790M%2520mutant%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112199%26doi%3D10.1016%2Fj.ejmech.2020.112199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.-C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth</span>. <i>Signal. Transduct. Target. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">214</span>, <span class="refDoi"> DOI: 10.1038/s41392-020-00251-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1038%2Fs41392-020-00251-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=33033232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FptFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=214&author=N.+Yaoauthor=C.-R.+Wangauthor=M.-Q.+Liuauthor=Y.-J.+Liauthor=W.-M.+Chenauthor=Z.-Q.+Liauthor=Q.+Qiauthor=J.-J.+Luauthor=C.-L.+Fanauthor=M.-F.+Chenauthor=M.+Qiauthor=X.-B.+Liauthor=J.+Hongauthor=D.-M.+Zhangauthor=W.-C.+Ye&title=Discovery+of+a+novel+EGFR+ligand+DPBA+that+degrades+EGFR+and+suppresses+EGFR-positive+NSCLC+growth&doi=10.1038%2Fs41392-020-00251-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth</span></div><div class="casAuthors">Yao Nan; Wang Chen-Ran; Liu Ming-Qun; Li Ying-Jie; Chen Wei-Min; Li Zheng-Qiu; Fan Chun-Lin; Chen Min-Feng; Qi Ming; Li Xiao-Bo; Zhang Dong-Mei; Ye Wen-Cai; Yao Nan; Wang Chen-Ran; Fan Chun-Lin; Chen Min-Feng; Qi Ming; Li Xiao-Bo; Zhang Dong-Mei; Ye Wen-Cai; Qi Qi; Hong Jian; Lu Jin-Jian</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy.  EGFR tyrosine kinase inhibitors (TKIs) have been canonically used in NSCLC treatment.  However, prevalent innate and acquired resistances and EGFR kinase-independent pro-survival properties limit the clinical efficacy of EGFR TKIs.  Therefore, the discovery of novel EGFR degraders is a promising approach towards improving therapeutic efficacy and overcoming drug resistance.  Here, we identified a 23-hydroxybetulinic acid derivative, namely DPBA, as a novel EGFR small-molecule ligand.  It exerted potent in vitro and in vivo anticancer activity in both EGFR wild type and mutant NSCLC by degrading EGFR.  Mechanistic studies disclosed that DPBA binds to the EGFR extracellular domain at sites differing from those of EGF and EGFR.  DPBA did not induce EGFR dimerization, phosphorylation, and ubiquitination, but it significantly promoted EGFR degradation and repressed downstream survival pathways.  Further analyses showed that DPBA induced clathrin-independent EGFR endocytosis mediated by flotillin-dependent lipid rafts and unaffected by EGFR TKIs.  Activation of the early and late endosome markers rab5 and rab7 but not the recycling endosome marker rab11 was involved in DPBA-induced EGFR lysosomal degradation.  The present study offers a new EGFR ligand for EGFR pharmacological degradation and proposes it as a potential treatment for EGFR-positive NSCLC, particularly NSCLC with innate or acquired EGFR TKI resistance.  DPBA can also serve as a chemical probe in the studies on EGFR trafficking and degradation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROSMCy6-iUr9-cVm4E2RlLfW6udTcc2eaP7eabA3sMjLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FptFGmsA%253D%253D&md5=5ddec18a5fd78c386b375e46c7d3b26a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41392-020-00251-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-020-00251-2%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.-R.%26aulast%3DLiu%26aufirst%3DM.-Q.%26aulast%3DLi%26aufirst%3DY.-J.%26aulast%3DChen%26aufirst%3DW.-M.%26aulast%3DLi%26aufirst%3DZ.-Q.%26aulast%3DQi%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DFan%26aufirst%3DC.-L.%26aulast%3DChen%26aufirst%3DM.-F.%26aulast%3DQi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.-B.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.-M.%26aulast%3DYe%26aufirst%3DW.-C.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520EGFR%2520ligand%2520DPBA%2520that%2520degrades%2520EGFR%2520and%2520suppresses%2520EGFR-positive%2520NSCLC%2520growth%26jtitle%3DSignal.%2520Transduct.%2520Target.%2520Ther.%26date%3D2020%26volume%3D5%26spage%3D214%26doi%3D10.1038%2Fs41392-020-00251-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non%E2%80%93small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lhgKszNH5uCuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">1163</span>, <span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0liWxB2gfaPluA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukamatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, H.</span></span> <span> </span><span class="NLM_article-title">Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer: a multicenter phase 2 trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e201250</span>– <span class="NLM_lpage">e201250</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2020.1250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1001%2Fjamaoncol.2020.1250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=32407455" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=e201250-e201250&author=S.+Miyamotoauthor=K.+Azumaauthor=H.+Ishiiauthor=A.+Besshoauthor=S.+Hosokawaauthor=N.+Fukamatsuauthor=H.+Kunitohauthor=M.+Ishiiauthor=H.+Tanakaauthor=H.+Aonoauthor=Y.+Nakaharaauthor=K.+Kusakaauthor=Y.+Hosomiauthor=N.+Kikuchiauthor=Y.+Moriauthor=H.+Itaniauthor=A.+Hamadaauthor=K.+Yamadaauthor=H.+Okamoto&title=Low-dose+erlotinib+treatment+in+elderly+or+frail+patients+with+EGFR+mutation%E2%80%93positive+non%E2%80%93small+cell+lung+cancer%3A+a+multicenter+phase+2+trial&doi=10.1001%2Fjamaoncol.2020.1250"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2020.1250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2020.1250%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DBessho%26aufirst%3DA.%26aulast%3DHosokawa%26aufirst%3DS.%26aulast%3DFukamatsu%26aufirst%3DN.%26aulast%3DKunitoh%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DAono%26aufirst%3DH.%26aulast%3DNakahara%26aufirst%3DY.%26aulast%3DKusaka%26aufirst%3DK.%26aulast%3DHosomi%26aufirst%3DY.%26aulast%3DKikuchi%26aufirst%3DN.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DItani%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DH.%26atitle%3DLow-dose%2520erlotinib%2520treatment%2520in%2520elderly%2520or%2520frail%2520patients%2520with%2520EGFR%2520mutation%25E2%2580%2593positive%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%253A%2520a%2520multicenter%2520phase%25202%2520trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2020%26volume%3D6%26spage%3De201250%26epage%3De201250%26doi%3D10.1001%2Fjamaoncol.2020.1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broderick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">20932</span>, <span class="refDoi"> DOI: 10.1073/pnas.0710370104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1073%2Fpnas.0710370104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=18093943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlyhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20932&author=J.+Beanauthor=C.+Brennanauthor=J.-Y.+Shihauthor=G.+Rielyauthor=A.+Vialeauthor=L.+Wangauthor=D.+Chitaleauthor=N.+Motoiauthor=J.+Szokeauthor=S.+Broderickauthor=M.+Balakauthor=W.-C.+Changauthor=C.-J.+Yuauthor=A.+Gazdarauthor=H.+Passauthor=V.+Ruschauthor=W.+Geraldauthor=S.-F.+Huangauthor=P.-C.+Yangauthor=V.+Millerauthor=M.+Ladanyiauthor=C.-H.+Yangauthor=W.+Pao&title=MET+amplification+occurs+with+or+without+T790M+mutations+in+EGFR+mutant+lung+tumors+with+acquired+resistance+to+gefitinib+or+erlotinib&doi=10.1073%2Fpnas.0710370104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Met amplification occurs with or without T790m mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib</span></div><div class="casAuthors">Bean, James; Brennan, Cameron; Shih, Jin-Yuan; Riely, Gregory; Viale, Agnes; Wang, Lu; Chitale, Dhananjay; Motoi, Noriko; Szoke, Janos; Broderick, Stephen; Balak, Marissa; Chang, Wen-Cheng; Yu, Chong-Jen; Gazdar, Adi; Pass, Harvey; Rusch, Valerie; Gerald, William; Huang, Shiu-Feng; Yang, Pan-Chyr; Miller, Vincent; Ladanyi, Marc; Yang, Chih-Hsin; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20932-20937</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is assocd. with approx. half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib.  To identify other potential mechanisms that contribute to disease progression, we used array-based comparative genomic hybridization (aCGH) to compare genomic profiles of EGFR mutant tumors from untreated patients with those from patients with acquired resistance.  Among three loci demonstrating recurrent copy no. alterations (CNAs) specific to the acquired resistance set, one contained the MET proto-oncogene.  Collectively, anal. of tumor samples from multiple independent patient cohorts revealed that MET was amplified in tumors from 9 of 43 (21%) patients with acquired resistance but in only two tumors from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test).  Among 10 resistant tumors from the nine patients with MET amplification, 4 also harbored the EGFRT790M mutation.  We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H820, harbors MET amplification in addn. to a drug-sensitive EGFR mutation and the T790M change.  Growth inhibition studies demonstrate that these cells are resistant to both erlotinib and an irreversible EGFR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity against MET.  Taken together, these data suggest that MET amplification occurs independently of EGFRT790M mutations and that MET may be a clin. relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVkBqKpZ-f97Vg90H21EOLACvtfcHk0liWxB2gfaPluA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlyhsg%253D%253D&md5=3c80cf95fd68733e20b469e79035e721</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710370104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710370104%26sid%3Dliteratum%253Aachs%26aulast%3DBean%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DRiely%26aufirst%3DG.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChitale%26aufirst%3DD.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DSzoke%26aufirst%3DJ.%26aulast%3DBroderick%26aufirst%3DS.%26aulast%3DBalak%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DPass%26aufirst%3DH.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DGerald%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-F.%26aulast%3DYang%26aufirst%3DP.-C.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DMET%2520amplification%2520occurs%2520with%2520or%2520without%2520T790M%2520mutations%2520in%2520EGFR%2520mutant%2520lung%2520tumors%2520with%2520acquired%2520resistance%2520to%2520gefitinib%2520or%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D20932%26doi%3D10.1073%2Fpnas.0710370104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lgBArEybuHWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugazagoitia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">i10</span>– <span class="NLM_lpage">i19</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1093%2Fannonc%2Fmdx703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=29462254" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i10-i19&author=D.+Westoverauthor=J.+Zugazagoitiaauthor=B.+C.+Choauthor=C.+M.+Lovlyauthor=L.+Paz-Ares&title=Mechanisms+of+acquired+resistance+to+first-+and+second-generation+EGFR+tyrosine+kinase+inhibitors&doi=10.1093%2Fannonc%2Fmdx703"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx703%26sid%3Dliteratum%253Aachs%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DZugazagoitia%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520first-%2520and%2520second-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Di10%26epage%3Di19%26doi%3D10.1093%2Fannonc%2Fmdx703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.-M.+Chenauthor=K.+Parkauthor=S.-W.+Kimauthor=C.+Zhouauthor=W.-C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.-H.+Tanauthor=T.-Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.-H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lgBArEybuHWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-M.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Possinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Grève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasching, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse-Hammer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttenreuther-Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span> <span> </span><span class="NLM_article-title">A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.1007/s10549-012-2126-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1007%2Fs10549-012-2126-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=22763464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=1149-1159&author=M.+Schulerauthor=A.+Awadaauthor=P.+Harterauthor=J.+L.+Canonauthor=K.+Possingerauthor=M.+Schmidtauthor=J.+De+Gr%C3%A8veauthor=P.+Nevenauthor=L.+Dirixauthor=W.+Jonatauthor=M.+W.+Beckmannauthor=J.+Sch%C3%BCtteauthor=P.+A.+Faschingauthor=N.+Gottschalkauthor=T.+Besse-Hammerauthor=F.+Fleischerauthor=S.+Windauthor=M.+Uttenreuther-Fischerauthor=M.+Piccartauthor=N.+Harbeck&title=A+phase+II+trial+to+assess+efficacy+and+safety+of+afatinib+in+extensively+pretreated+patients+with+HER2-negative+metastatic+breast+cancer&doi=10.1007%2Fs10549-012-2126-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer</span></div><div class="casAuthors">Schuler, Martin; Awada, Ahmad; Harter, Philipp; Canon, Jean Luc; Possinger, Kurt; Schmidt, Marcus; Greve, Jacques; Neven, Patrick; Dirix, Luc; Jonat, Walter; Beckmann, Matthias W.; Schuette, Jochen; Fasching, Peter A.; Gottschalk, Nina; Besse-Hammer, Tatiana; Fleischer, Frank; Wind, Sven; Uttenreuther-Fischer, Martina; Piccart, Martine; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1149-1159</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevant ErbB-family dimers.  Afatinib has demonstrated preclin. activity in human epidermal growth factor receptor HER2 (ErbB2)-pos. and triple-neg. xenograft models of breast cancer, and clin. activity in phase I studies.  This was a multicenter phase II study enrolling patients with HER2-neg. metastatic breast cancer progressing following no more than three lines of chemotherapy.  No prior epidermal growth factor receptor-targeted therapy was allowed.  Patients received 50-mg afatinib once daily until disease progression.  Tumor assessment was performed at every other 28-day treatment course.  The primary endpoint was clin. benefit (CB) for ≥4 treatment courses in triple-neg. (Cohort A) metastatic breast cancer (TNBC) and objective responses measured by Response Evaluation Criteria in Solid Tumors in patients with HER2-neg., estrogen receptor-pos., and/or progesterone receptor-pos. breast cancer (Cohort B).  Fifty patients received treatment, including 29 patients in Cohort A and 21 patients in Cohort B. No objective responses were obsd. in either cohort.  Median progression-free survival was 7.4 and 7.7 wk in Cohorts A and B, resp.  Three patients with TNBC had stable disease for ≥4 treatment courses, one of them for 12 courses (median 26.3 wk; range 18.9-47.9 wk).  The most frequently obsd. afatinib-assocd. adverse events (AEs) were gastrointestinal and skin-related side effects, which were manageable by symptomatic treatment and dose redns.  Afatinib pharmacokinetics were comparable to those obsd. in previously reported phase I trials.  In conclusion, afatinib had limited activity in HER2-neg. breast cancer.  AEs were generally manageable and mainly affected the skin and the gastrointestinal tract.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_1ZX211pphbVg90H21EOLACvtfcHk0lgBArEybuHWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrsrzO&md5=e1823963d2d19bdf92dfa59849c31d1b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs10549-012-2126-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-012-2126-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DCanon%26aufirst%3DJ.%2BL.%26aulast%3DPossinger%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DDe%2BGr%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DJonat%26aufirst%3DW.%26aulast%3DBeckmann%26aufirst%3DM.%2BW.%26aulast%3DSch%25C3%25BCtte%26aufirst%3DJ.%26aulast%3DFasching%26aufirst%3DP.%2BA.%26aulast%3DGottschalk%26aufirst%3DN.%26aulast%3DBesse-Hammer%26aufirst%3DT.%26aulast%3DFleischer%26aufirst%3DF.%26aulast%3DWind%26aufirst%3DS.%26aulast%3DUttenreuther-Fischer%26aufirst%3DM.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DHarbeck%26aufirst%3DN.%26atitle%3DA%2520phase%2520II%2520trial%2520to%2520assess%2520efficacy%2520and%2520safety%2520of%2520afatinib%2520in%2520extensively%2520pretreated%2520patients%2520with%2520HER2-negative%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D134%26spage%3D1149%26epage%3D1159%26doi%3D10.1007%2Fs10549-012-2126-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1953</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1028-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1007%2Fs40265-018-1028-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=30506139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1947-1953&author=M.+Shirley&title=Dacomitinib%3A+first+global+approval&doi=10.1007%2Fs40265-018-1028-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib: First Global Approval</span></div><div class="casAuthors">Shirley Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1947-1953</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dacomitinib (Vizimpro(®)) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours.  In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.  Registration applications for the use of dacomitinib as first-line treatment for patients with EGFR-mutation-positive metastatic NSCLC have also been submitted in the EU and Japan.  This article summarizes the milestones in the development of dacomitinib leading to this first approval for the first-line treatment of patients with EGFR-mutated metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQfSAs_PE1QvifW6udTcc2eaflmhkL5ykVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D&md5=0e035cd4b47b60f40c2af1d3c1fb5add</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1028-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1028-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DDacomitinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1947%26epage%3D1953%26doi%3D10.1007%2Fs40265-018-1028-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+non-small+cell+lung+cancer%3A+Comparative+pharmacokinetics+and+drug%E2%80%93drug+interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0ljvMWNmxroYCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520Comparative%2520pharmacokinetics%2520and%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non–small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1709</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.-C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non%E2%80%93small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eaflmhkL5ykVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laktionov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.-V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akewanlop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atasoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in resected EGFR-mutated non–small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2027071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1056%2FNEJMoa2027071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=32955177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1WltbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=1711-1723&author=Y.-L.+Wuauthor=M.+Tsuboiauthor=J.+Heauthor=T.+Johnauthor=C.+Groheauthor=M.+Majemauthor=J.+W.+Goldmanauthor=K.+Laktionovauthor=S.-W.+Kimauthor=T.+Katoauthor=H.-V.+Vuauthor=S.+Luauthor=K.-Y.+Leeauthor=C.+Akewanlopauthor=C.-J.+Yuauthor=F.+de+Marinisauthor=L.+Bonannoauthor=M.+Domineauthor=F.+A.+Shepherdauthor=L.+Zengauthor=R.+Hodgeauthor=A.+Atasoyauthor=Y.+Rukazenkovauthor=R.+S.+Herbst&title=Osimertinib+in+resected+EGFR-mutated+non%E2%80%93small-cell+lung+cancer&doi=10.1056%2FNEJMoa2027071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in resected EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Wu, Yi-Long; Tsuboi, Masahiro; He, Jie; John, Thomas; Grohe, Christian; Majem, Margarita; Goldman, Jonathan W.; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu-Vinh; Lu, Shun</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1711-1723</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Osimertinib is std.-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-pos. advanced non-small-cell lung cancer (NSCLC).  The efficacy and safety of osimertinib as adjuvant therapy are unknown. methods In this double-blind, phase 3 trial, we randomly assigned patients with completely resected EGFR mutation-pos. NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily) or placebo for 3 years.  The primary end point was disease-free survival among patients with stage II to IIIA disease (according to investigator assessment).  The secondary end points included disease-free survival in the overall population of patients with stage IB to IIIA disease, overall survival, and safety. results A total of 682 patients underwent randomization (339 to the osimertinib group and 343 to the placebo group).  At 24 mo, 90% of the patients with stage II to IIIA disease in the osimertinib group (95% confidence interval [CI], 84 to 93) and 44% of those in the placebo group (95% CI, 37 to 51) were alive and disease-free (overall hazard ratio for disease recurrence or death, 0.17; 99.06% CI, 0.11 to 0.26; P<0.001).  In the overall population, 89% of the patients in the osimertinib group (95% CI, 85 to 92) and 52% of those in the placebo group (95% CI, 46 to 58) were alive and disease-free at 24 mo (overall hazard ratio for disease recurrence or death, 0.20; 99.12% CI, 0.14 to 0.30; P<0.001).  At 24 mo, 98% of the patients in the osimertinib group (95% CI, 95 to 99) and 85% of those in the placebo group (95% CI, 80 to 89) were alive and did not have central nervous system disease (overall hazard ratio for disease recurrence or death, 0.18; 95% CI, 0.10 to 0.33).  Overall survival data were immature; 29 patients died (9 in the osimertinib group and 20 in the placebo group).  No new safety concerns were noted. conclusions In patients with stage IB to IIIA EGFR mutation-pos. NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRzcWa1nfJ2bVg90H21EOLACvtfcHk0lj-oeU_lJkiFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1WltbvJ&md5=ee10dbb28360a197acd6ebcf3b5ddd80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2027071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2027071%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DTsuboi%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DGrohe%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DLaktionov%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DVu%26aufirst%3DH.-V.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.-Y.%26aulast%3DAkewanlop%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DBonanno%26aufirst%3DL.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DAtasoy%26aufirst%3DA.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26atitle%3DOsimertinib%2520in%2520resected%2520EGFR-mutated%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26spage%3D1711%26epage%3D1723%26doi%3D10.1056%2FNEJMoa2027071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayaz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of AZD9291 selectivity for EGFR T790M</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8502</span>– <span class="NLM_lpage">8511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00891</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00891" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8502-8511&author=X.-E.+Yanauthor=P.+Ayazauthor=S.-J.+Zhuauthor=P.+Zhaoauthor=L.+Liangauthor=C.+H.+Zhangauthor=Y.-C.+Wuauthor=J.-L.+Liauthor=H.+G.+Choiauthor=X.+Huangauthor=Y.+Shanauthor=D.+E.+Shawauthor=C.-H.+Yun&title=Structural+basis+of+AZD9291+selectivity+for+EGFR+T790M&doi=10.1021%2Facs.jmedchem.0c00891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of AZD9291 Selectivity for EGFR T790M</span></div><div class="casAuthors">Yan, Xiao-E.; Ayaz, Pelin; Zhu, Su-Jie; Zhao, Peng; Liang, Ling; Zhang, Casey H.; Wu, Ya-Chuang; Li, Je-Luen; Choi, Hwan Geun; Huang, Xin; Shan, Yibing; Shaw, David E.; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8502-8511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance.  Despite the remarkable success of AZD9291, its binding pose with EGFR T790M remains unclear.  Here, we report unbiased, at.-level mol. dynamics (MD) simulations in which spontaneous assocn. of AZD9291 with EGFR kinases having WT and T790M mutant gatekeepers was obsd.  Simulation-generated structural models suggest that the binding pose of AZD9291 with T790M differs from its binding pose with the WT, and that AZD9291 interacts extensively with the gatekeeper residue (Met 790) in T790M but not with Thr 790 in the WT, which explains why AZD9291 binds T790M with higher affinity.  The MD simulation-generated models were confirmed by exptl. detd. EGFR/T790M complex crystal structures.  This work may facilitate the rational design of drugs that can overcome resistance mutations to AZD9291, and more generally it suggests the potential of using unbiased MD simulation to elucidate small-mol. binding poses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjAuoE85GWLVg90H21EOLACvtfcHk0liy4XWEZm3wOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsL7K&md5=8fd2853a9495729019f23d8d9b2595ab</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00891%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DX.-E.%26aulast%3DAyaz%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DY.-C.%26aulast%3DLi%26aufirst%3DJ.-L.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DYun%26aufirst%3DC.-H.%26atitle%3DStructural%2520basis%2520of%2520AZD9291%2520selectivity%2520for%2520EGFR%2520T790M%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8502%26epage%3D8511%26doi%3D10.1021%2Facs.jmedchem.0c00891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1093%2Fannonc%2Fmdw129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=26961148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1165-1170&author=A.+Yver&title=Osimertinib+%28AZD9291%29%E2%80%94a+science-driven%2C+collaborative+approach+to+rapid+drug+design+and+development&doi=10.1093%2Fannonc%2Fmdw129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development</span></div><div class="casAuthors">Yver A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1165-1170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTcfXYyifUoEewzGPswiWOfW6udTcc2ealpB4ZUYhOCrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D&md5=903bbb3edf2d109af352ef0354e4bca6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw129%26sid%3Dliteratum%253Aachs%26aulast%3DYver%26aufirst%3DA.%26atitle%3DOsimertinib%2520%2528AZD9291%2529%25E2%2580%2594a%2520science-driven%252C%2520collaborative%2520approach%2520to%2520rapid%2520drug%2520design%2520and%2520development%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D1165%26epage%3D1170%26doi%3D10.1093%2Fannonc%2Fmdw129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+selective+and+rigidify%3A+the+discovery+path+toward+a+next+generation+of+EGFR+tyrosine+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0liy4XWEZm3wOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520selective%2520and%2520rigidify%253A%2520the%2520discovery%2520path%2520toward%2520a%2520next%2520generation%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFRL858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&author=J.+Shenauthor=T.+Zhangauthor=S.-J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-based+design+of+5-methylpyrimidopyridone+derivatives+as+new+wild-type+sparing+inhibitors+of+the+epidermal+growth+factor+receptor+triple+mutant+%28EGFRL858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0ljmo3_G1Uapjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-based%2520design%2520of%25205-methylpyrimidopyridone%2520derivatives%2520as%2520new%2520wild-type%2520sparing%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520triple%2520mutant%2520%2528EGFRL858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengstler, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Structure-guided development of covalent and mutant-selective pyrazolopyrimidines to target T790M drug resistance in epidermal growth factor receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7725</span>– <span class="NLM_lpage">7744</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVWmsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7725-7744&author=J.+Engelauthor=S.+Smithauthor=J.+Lategahnauthor=H.+L.+Tumbrinkauthor=L.+Goebelauthor=C.+Beckerauthor=E.+Hennesauthor=M.+Keulauthor=A.+Ungerauthor=H.+M%C3%BCllerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+G%C3%BCntherauthor=J.+G.+Hengstlerauthor=D.+Rauh&title=Structure-guided+development+of+covalent+and+mutant-selective+pyrazolopyrimidines+to+target+T790M+drug+resistance+in+epidermal+growth+factor+receptor&doi=10.1021%2Facs.jmedchem.7b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Engel, Julian; Smith, Steven; Lategahn, Jonas; Tumbrink, Hannah L.; Goebel, Lisa; Becker, Christian; Hennes, Elisabeth; Keul, Marina; Unger, Anke; Mueller, Heiko; Baumann, Matthias; Schultz-Fademrecht, Carsten; Guenther, Georgia; Hengstler, Jan G.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7725-7744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a beneficial clin. response in non-small cell lung cancer patients who harbor activating mutations in EGFR.  However, resistance mutations, particularly the gatekeeper mutation T790M, limit this efficacy.  Here, we describe a structure-guided development of a series of covalent and mutant-selective EGFR inhibitors that effectively target the T790M mutant.  The pyrazolopyrimidine-based core differs structurally from that of aminopyrimidine-based third-generation EGFR inhibitors and therefore constitutes a new set of inhibitors that target this mechanism of drug resistance.  These inhibitors exhibited strong inhibitory effects toward EGFR kinase activity and excellent inhibition of cell growth in the drug-resistant cell line H1975, without significantly affecting EGFR wild-type cell lines.  Addnl., we present the in vitro ADME/DMPK parameters for a subset of the inhibitors as well as in vivo pharmacokinetics in mice for a candidate with promising activity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJrYeYCvPOGLVg90H21EOLACvtfcHk0ljmo3_G1Uapjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVWmsrjL&md5=5342017ac4e77f37516dcd8564c5a4b1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00515%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DGoebel%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DHennes%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DH.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DG%25C3%25BCnther%26aufirst%3DG.%26aulast%3DHengstler%26aufirst%3DJ.%2BG.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructure-guided%2520development%2520of%2520covalent%2520and%2520mutant-selective%2520pyrazolopyrimidines%2520to%2520target%2520T790M%2520drug%2520resistance%2520in%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7725%26epage%3D7744%26doi%3D10.1021%2Facs.jmedchem.7b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+pyridinylimidazoles+as+potent+inhibitors+of+the+clinically+resistant+L858R%2FT790M%2FC797S+EGFR+mutant%3A+targeting+of+both+hydrophobic+regions+and+the+phosphate+binding+site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0ljmo3_G1Uapjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520pyridinylimidazoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520clinically%2520resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520mutant%253A%2520targeting%2520of%2520both%2520hydrophobic%2520regions%2520and%2520the%2520phosphate%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for EGFR mutant inhibition by trisubstituted imidazole inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4293</span>– <span class="NLM_lpage">4305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4293-4305&author=D.+E.+Heppnerauthor=M.+G%C3%BCntherauthor=F.+Wittlingerauthor=S.+A.+Lauferauthor=M.+J.+Eck&title=Structural+basis+for+EGFR+mutant+inhibition+by+trisubstituted+imidazole+inhibitors&doi=10.1021%2Facs.jmedchem.0c00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors</span></div><div class="casAuthors">Heppner, David E.; Gunther, Marcel; Wittlinger, Florian; Laufer, Stefan A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4293-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy.  Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism.  To dissect the mol. basis for their activity, we detd. the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallog.  These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the "αC-helix out" inactive state.  Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant.  Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHNY-o4bNl6bVg90H21EOLACvtfcHk0lhRd9j4cikNpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D&md5=0ee498e9de51374ad9a049d7ffd9fa24</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DWittlinger%26aufirst%3DF.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520EGFR%2520mutant%2520inhibition%2520by%2520trisubstituted%2520imidazole%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4293%26epage%3D4305%26doi%3D10.1021%2Facs.jmedchem.0c00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho-Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemkens, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson-Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafontaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+C.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+M.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.-J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-Chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+potent%2C+WT+sparing%2C+irreversible+inhibitor+of+T790M-containing+EGFR+mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</span></div><div class="casAuthors">Cheng, Hengmiao; Nair, Sajiv K.; Murray, Brion W.; Almaden, Chau; Bailey, Simon; Baxi, Sangita; Behenna, Doug; Cho-Schultz, Sujin; Dalvie, Deepak; Dinh, Dac M.; Edwards, Martin P.; Feng, Jun Li; Ferre, Rose Ann; Gajiwala, Ketan S.; Hemkens, Michelle D.; Jackson-Fisher, Amy; Jalaie, Mehran; Johnson, Ted O.; Kania, Robert S.; Kephart, Susan; Lafontaine, Jennifer; Lunney, Beth; Liu, Kevin K.-C.; Liu, Zhengyu; Matthews, Jean; Nagata, Asako; Niessen, Sherry; Ornelas, Martha A.; Orr, Suvi T. M.; Pairish, Mason; Planken, Simon; Ren, Shijian; Richter, Daniel; Ryan, Kevin; Sach, Neal; Shen, Hong; Smeal, Tod; Solowiej, Jim; Sutton, Scott; Tran, Khanh; Tseng, Elaine; Vernier, William; Walls, Marlena; Wang, Shuiwang; Weinrich, Scott L.; Xin, Shuibo; Xu, Haiwei; Yin, Min-Jean; Zientek, Michael; Zhou, Ru; Kath, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2005-2024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">First generation EGFR TKIs (gefitinib, erlotinib) provide significant clin. benefit for NSCLC cancer patients with oncogenic EGFR mutations.  Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M).  Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR.  As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR.  A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort.  PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-contg. double mutant EGFRs, (ii) minimal intrinsic chem. reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfRspJvDDNKrVg90H21EOLACvtfcHk0lhRd9j4cikNpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D&md5=b8c07b22033543305964c9e8771f3db5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520potent%252C%2520WT%2520sparing%252C%2520irreversible%2520inhibitor%2520of%2520T790M-containing%2520EGFR%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lhExEp_9FLFuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhExEp_9FLFuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickup, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span> <span> </span><span class="NLM_article-title">Metabolic disposition of Osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.069203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1124%2Fdmd.115.069203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=27226351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVajtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1201-1212&author=P.+A.+Dickinsonauthor=M.+V.+Cantariniauthor=J.+Collierauthor=P.+Frewerauthor=S.+Martinauthor=K.+Pickupauthor=P.+Ballard&title=Metabolic+disposition+of+Osimertinib+in+rats%2C+dogs%2C+and+humans%3A+insights+into+a+drug+designed+to+bind+covalently+to+a+cysteine+residue+of+epidermal+growth+factor+receptor&doi=10.1124%2Fdmd.115.069203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor</span></div><div class="casAuthors">Dickinson, Paul A.; Cantarini, Mireille V.; Collier, Jo; Frewer, Paul; Martin, Scott; Pickup, Kathryn; Ballard, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1201-1212</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Preclin. and clin. studies were conducted to det. the metab. and pharmacokinetics of osimertinib and key metabolites AZ5104 and AZ7550.  Osimertinib was designed to covalently bind to epidermal growth factor receptors, allowing it to achieve nanomolar cellular potency.  Covalent binding was obsd. in incubations of radiolabeled osimertinib with human and rat hepatocytes, human and rat plasma, and human serum albumin.  Osimertinib, AZ5104, and AZ7550 were predominantly metabolized by CYP3A.  Seven metabolites were detected in human hepatocytes, also obsd. in rat or dog hepatocytes at similar or higher levels.  After oral administration of radiolabeled osimertinib to rats, drug-related material was widely distributed, with the highest radioactivity concns. measured at 6 h postdose in most tissues; radioactivity was detectable in 42% of tissues 60 days postdose.  Concns. of [14C]-radioactivity in blood were lower than in most tissues.  After the administration of a single oral dose of 20 mg of radiolabeled osimertinib to healthy male volunteers, ∼19% of the dose was recovered by 3 days postdose.  At 84 days postdose, mean total radioactivity recovery was 14.2% and 67.8% of the dose in urine and feces.  The most abundant metabolite identified in feces was AZ5104 (∼6% of dose).  Osimertinib accounted for ∼1% of total radioactivity in the plasma of non-small cell lung cancer patients after 22 days of 80-mg osimertinib once-daily treatment; the most abundant circulatory metabolites were AZ7550 and AZ5104 (<10% of total osimertinib-related material).  Osimertinib is extensively distributed and metabolized in humans and is eliminated primarily via the fecal route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqslCW8h-RI9bVg90H21EOLACvtfcHk0li8h_tntrP2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVajtb%252FO&md5=4115de7691a3b39eec091660b5e5b1d6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.069203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.069203%26sid%3Dliteratum%253Aachs%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DCantarini%26aufirst%3DM.%2BV.%26aulast%3DCollier%26aufirst%3DJ.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DPickup%26aufirst%3DK.%26aulast%3DBallard%26aufirst%3DP.%26atitle%3DMetabolic%2520disposition%2520of%2520Osimertinib%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%253A%2520insights%2520into%2520a%2520drug%2520designed%2520to%2520bind%2520covalently%2520to%2520a%2520cysteine%2520residue%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D1201%26epage%3D1212%26doi%3D10.1124%2Fdmd.115.069203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khozin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Osimertinib for the treatment of metastatic EGFR T790M mutation–positive non–small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2131</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1158%2F1078-0432.CCR-16-1773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=27923840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFegtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=2131&author=S.+Khozinauthor=C.+Weinstockauthor=G.+M.+Blumenthalauthor=J.+Chengauthor=K.+Heauthor=L.+Zhuangauthor=H.+Zhaoauthor=R.+Charlabauthor=I.+Fanauthor=P.+Keeganauthor=R.+Pazdur&title=Osimertinib+for+the+treatment+of+metastatic+EGFR+T790M+mutation%E2%80%93positive+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-16-1773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Khozin, Sean; Weinstock, Chana; Blumenthal, Gideon M.; Cheng, Joyce; He, Kun; Zhuang, Luning; Zhao, Hong; Charlab, Rosane; Fan, Ingrid; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2131-2135</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Nov. 13, 2015, the FDA granted accelerated approval to osimertinib (TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the treatment of patients with metastatic EGFR T790M mutation-pos. non-small cell lung cancer, as detected by an FDA-approved test, with progression on or after EGFR tyrosine kinase inhibitor therapy.  Approval was based on durable tumor response rates in two single-arm, multicenter trials: the dose extension cohort of a first-in-human trial (FIH; AURA extension; n = 201) and a fixed-dose, activity-estg. trial (AURA2; n = 210).  Osimertinib was administered at 80 mg orally once daily.  The objective response rates (ORR) per blinded independent committee review were 57% [95% confidence interval (CI), 50-64] in AURA extension and 61% (95% CI, 54-68) in AURA2. Median duration of response (DOR) could not be estd.  Supportive efficacy data from 63 patients in the dose-finding part of the FIH trial demonstrated an ORR of 51% (95% CI, 38-64), with a median DOR of 12.4 mo.  Common adverse events (AE) evaluated in 411 patients included diarrhea (42%), rash (41%), dry skin (31%), and nail toxicity (25%).  Grade 3 to 4 AEs occurred in 28% of patients, and 5.6% discontinued treatment due to AEs.  Clin Cancer Res; 23(9); 2131-5. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_rTdjsi7krVg90H21EOLACvtfcHk0li8h_tntrP2PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFegtb8%253D&md5=b18e69d7192c21d88c6333aade5a64fc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1773%26sid%3Dliteratum%253Aachs%26aulast%3DKhozin%26aufirst%3DS.%26aulast%3DWeinstock%26aufirst%3DC.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhuang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DI.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DOsimertinib%2520for%2520the%2520treatment%2520of%2520metastatic%2520EGFR%2520T790M%2520mutation%25E2%2580%2593positive%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D2131%26doi%3D10.1158%2F1078-0432.CCR-16-1773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using deuterium in drug discovery: leaving the label in the drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+deuterium+in+drug+discovery%3A+leaving+the+label+in+the+drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0lj5sIkMMjcInQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520deuterium%2520in%2520drug%2520discovery%253A%2520leaving%2520the%2520label%2520in%2520the%2520drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerekes, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposite, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagat, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tevar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span> <span> </span><span class="NLM_article-title">Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1021/jm1010995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1010995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=201-210&author=A.+D.+Kerekesauthor=S.+J.+Espositeauthor=R.+J.+Dollauthor=J.+R.+Tagatauthor=T.+Yuauthor=Y.+Xiaoauthor=Y.+Zhangauthor=D.+B.+Preluskyauthor=S.+Tevarauthor=K.+Grayauthor=G.+A.+Terracinaauthor=S.+Leeauthor=J.+Jonesauthor=M.+Liuauthor=A.+D.+Bassoauthor=E.+B.+Smith&title=Aurora+kinase+inhibitors+based+on+the+imidazo%5B1%2C2-a%5Dpyrazine+core%3A+fluorine+and+deuterium+incorporation+improve+oral+absorption+and+exposure&doi=10.1021%2Fjm1010995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure</span></div><div class="casAuthors">Kerekes, Angela D.; Esposite, Sara J.; Doll, Ronald J.; Tagat, Jayaram R.; Yu, Tao; Xiao, Yushi; Zhang, Yonglian; Prelusky, Dan B.; Tevar, Seema; Gray, Kimberly; Terracina, Gaby A.; Lee, Suining; Jones, Jennifer; Liu, Ming; Basso, Andrea D.; Smith, Elizabeth B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-210</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aurora kinases are cell cycle regulated serine/threonine kinases that have been linked to cancer.  Compd. 1 was identified as a potent Aurora inhibitor but lacked oral bioavailability.  Optimization of 1 led to the discovery of a series of fluoroamine and deuterated analogs, exemplified by compd. 25 (I), with an improved pharmacokinetic profile.  We found that blocking oxidative metab. at the benzylic position and decreasing the basicity of the amine are important to obtaining compds. with good biol. profiles and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3YIdBKno7NLVg90H21EOLACvtfcHk0lj5sIkMMjcInQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbzP&md5=af7c338866058e7d63116c8c8aa2d3fd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm1010995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1010995%26sid%3Dliteratum%253Aachs%26aulast%3DKerekes%26aufirst%3DA.%2BD.%26aulast%3DEsposite%26aufirst%3DS.%2BJ.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPrelusky%26aufirst%3DD.%2BB.%26aulast%3DTevar%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DTerracina%26aufirst%3DG.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DBasso%26aufirst%3DA.%2BD.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26atitle%3DAurora%2520kinase%2520inhibitors%2520based%2520on%2520the%2520imidazo%255B1%252C2-a%255Dpyrazine%2520core%253A%2520fluorine%2520and%2520deuterium%2520incorporation%2520improve%2520oral%2520absorption%2520and%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D201%26epage%3D210%26doi%3D10.1021%2Fjm1010995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maltais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanoury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perni, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawgo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazhanisamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybuck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennani, Y. L.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7993</span>– <span class="NLM_lpage">8001</span>, <span class="refDoi"> DOI: 10.1021/jm901023f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901023f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOksrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7993-8001&author=F.+Maltaisauthor=Y.+C.+Jungauthor=M.+Chenauthor=J.+Tanouryauthor=R.+B.+Perniauthor=N.+Maniauthor=L.+Laitinenauthor=H.+Huangauthor=S.+Liaoauthor=H.+Gaoauthor=H.+Tsaoauthor=E.+Blockauthor=C.+Maauthor=R.+S.+Shawgoauthor=C.+Townauthor=C.+L.+Brummelauthor=D.+Howeauthor=S.+Pazhanisamyauthor=S.+Raybuckauthor=M.+Namchukauthor=Y.+L.+Bennani&title=In+vitro+and+in+vivo+isotope+effects+with+hepatitis+C+protease+inhibitors%3A+enhanced+plasma+exposure+of+deuterated+telaprevir+versus+telaprevir+in+rats&doi=10.1021%2Fjm901023f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Vivo Isotope Effects with Hepatitis C Protease Inhibitors: Enhanced Plasma Exposure of Deuterated Telaprevir versus Telaprevir in Rats</span></div><div class="casAuthors">Maltais, Francois; Jung, Young Chun; Chen, Minzhang; Tanoury, Jerry; Perni, Robert B.; Mani, Nagraj; Laitinen, Leena; Huang, Hui; Liao, Shengkai; Gao, Hongying; Tsao, Hong; Block, Eric; Ma, Chien; Shawgo, Rebecca S.; Town, Christopher; Brummel, Christopher L.; Howe, David; Pazhanisamy, S.; Raybuck, Scott; Namchuk, Mark; Bennani, Youssef L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7993-8001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Telaprevir (I) (VX-950), an inhibitor of the hepatitis C virus (HCVa) NS3-4A protease, is in phase 3 clin. trials.  One of the major metabolites of I is its P1-(R)-diastereoisomer (VRT-394), contg. an inversion at the chiral center next to the α-ketoamide on exchange of a proton with solvent.  Compd. VRT-394 is approx. 30-fold less active against HCV protease.  In an attempt to suppress the epimerization of I without losing activity against the HCV protease, the proton at that chiral site was replaced with deuterium (d).  The compd. II (d-telaprevir) is as efficacious as I in in vitro inhibition of protease activity and viral replication (replicon) assays.  The kinetics of in vitro stability of I and II in buffered pH solns. and plasma samples, including human plasma, suggest that II is significantly more stable than I.  Oral administration (10 mg/kg) in rats resulted in a ∼13% increase of AUC for II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkqwA80elhh7Vg90H21EOLACvtfcHk0lj5sIkMMjcInQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOksrbI&md5=244f41b401086e8541efc9203d22b503</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901023f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901023f%26sid%3Dliteratum%253Aachs%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DJung%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTanoury%26aufirst%3DJ.%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DMani%26aufirst%3DN.%26aulast%3DLaitinen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DTsao%26aufirst%3DH.%26aulast%3DBlock%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DShawgo%26aufirst%3DR.%2BS.%26aulast%3DTown%26aufirst%3DC.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DHowe%26aufirst%3DD.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DRaybuck%26aufirst%3DS.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520isotope%2520effects%2520with%2520hepatitis%2520C%2520protease%2520inhibitors%253A%2520enhanced%2520plasma%2520exposure%2520of%2520deuterated%2520telaprevir%2520versus%2520telaprevir%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7993%26epage%3D8001%26doi%3D10.1021%2Fjm901023f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uskokovic, M. R.</span></span> <span> </span><span class="NLM_article-title">Diastereotopic and deuterium effects in gemini</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3878</span>– <span class="NLM_lpage">3888</span>, <span class="refDoi"> DOI: 10.1021/jm400032t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400032t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3878-3888&author=H.+Maehrauthor=N.+Rochelauthor=H.+J.+Leeauthor=N.+Suhauthor=M.+R.+Uskokovic&title=Diastereotopic+and+deuterium+effects+in+gemini&doi=10.1021%2Fjm400032t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereotopic and Deuterium Effects in Gemini</span></div><div class="casAuthors">Maehr, Hubert; Rochel, Natacha; Lee, Hong Jin; Suh, Nanjoo; Uskokovic, Milan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3878-3888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Changing the geminal Me groups on 1α,25-dihydroxyvitamin D3 and its analogs to the deuterio versions generally improves the bioactivity.  Derivs. of 1α,25-dihydroxyvitamin D3 with two chains emanating at C20, commonly referred to as gemini, are subject to the same phenomenon.  Addnl., gemini with different side chains are susceptible to bioactivity differentials where the C17-C20 threo configuration usually imparts higher activity than the corresponding erythro arrangement.  In an effort to analyze the deuterium effect on gemini with minimal diastereotopic distortion, we synthesized gemini with equal side chains but introduced deuterium diastereospecifically on either chain.  We solved the crystal structures of these compds. in the zebra fish zVDR ligand binding domain as complexes with NCoA-2 coactivator peptide and correlated the findings with growth inhibition in a breast cancer cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp8s9r_J8o2rVg90H21EOLACvtfcHk0ljUW8rcd9EYsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsbo%253D&md5=5d6784fd9736bdc323cf7d6a64c824fa</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm400032t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400032t%26sid%3Dliteratum%253Aachs%26aulast%3DMaehr%26aufirst%3DH.%26aulast%3DRochel%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSuh%26aufirst%3DN.%26aulast%3DUskokovic%26aufirst%3DM.%2BR.%26atitle%3DDiastereotopic%2520and%2520deuterium%2520effects%2520in%2520gemini%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3878%26epage%3D3888%26doi%3D10.1021%2Fjm400032t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span>; <span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">2-(2,4,5-Substituted Phenylamino) Pyrimidine Derivatives, Preparation Method and Application in Preparation of Antitumor Drugs</span>. CN Patent <span class="NLM_patent">ZL201711282598.8</span>, Aug 27, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+Chang&author=J.+Du&title=2-%282%2C4%2C5-Substituted+Phenylamino%29+Pyrimidine+Derivatives%2C+Preparation+Method+and+Application+in+Preparation+of+Antitumor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26atitle%3D2-%25282%252C4%252C5-Substituted%2520Phenylamino%2529%2520Pyrimidine%2520Derivatives%252C%2520Preparation%2520Method%2520and%2520Application%2520in%2520Preparation%2520of%2520Antitumor%2520Drugs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span>; <span class="NLM_string-name">Wen, S.</span>; <span class="NLM_string-name">Li, H. J.</span></span> <span> </span><span class="NLM_article-title">Fluorine and/or Deuterium-Containing Compounds for The Treatment of Non-Small Cell Lung Cancer and Related Diseases</span>. U.S. Patent <span class="NLM_patent">US20190169171</span>, April 28, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Cheng&author=S.+Wen&author=H.+J.+Li&title=Fluorine+and%2For+Deuterium-Containing+Compounds+for+The+Treatment+of+Non-Small+Cell+Lung+Cancer+and+Related+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%26atitle%3DFluorine%2520and%252For%2520Deuterium-Containing%2520Compounds%2520for%2520The%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520and%2520Related%2520Diseases%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5609</span>– <span class="NLM_lpage">5622</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5609-5622&author=Y.+Haoauthor=J.+Lyuauthor=R.+Quauthor=Y.+Tongauthor=D.+Sunauthor=F.+Fengauthor=L.+Tongauthor=T.+Yangauthor=Z.+Zhaoauthor=L.+Zhuauthor=J.+Dingauthor=Y.+Xuauthor=H.+Xieauthor=H.+Li&title=Design%2C+synthesis%2C+and+biological+evaluation+of+pyrimido%5B4%2C5-d%5Dpyrimidine-2%2C4%281H%2C3H%29-diones+as+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+L858R%2FT790M+resistance+mutation&doi=10.1021%2Facs.jmedchem.8b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation</span></div><div class="casAuthors">Hao, Yongjia; Lyu, Jiankun; Qu, Rong; Tong, Yi; Sun, Deheng; Feng, Fang; Tong, Linjiang; Yang, Tingyuan; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Xu, Yufang; Xie, Hua; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5609-5622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clin. efficacy for nonsmall cell lung cancer (NSCLC) patients with EGFR activating mutations.  However, their clin. benefit was limited by the emergence of acquired resistance mutations.  In most cases (approx. 60%), the resistance was caused by the secondary EGFR T790M gatekeeper mutation.  Thus, it is still desirable to develop novel third-generation EGFR inhibitors to overcome T790M mutation while sparing wild-type (WT) EGFR.  Herein, a series of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivs. were designed and synthesized, among which the most potent compd. I not only demonstrated significant inhibitory activity and selectivity for EGFRL858R/T790M and H1975 cells in vitro but also displayed outstanding antitumor efficiency in H1975 xenograft mouse model.  The encouraging mutant-selective results at both in vitro and in vivo levels suggested that I might be used as a promising lead compd. for further structural optimization as potent and selective EGFRL858R/T790M inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTI-rgEr_o17Vg90H21EOLACvtfcHk0ljUW8rcd9EYsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrrJ&md5=02f8cb7542273f2ae972d54b86f88fb3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00346%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520pyrimido%255B4%252C5-d%255Dpyrimidine-2%252C4%25281H%252C3H%2529-diones%2520as%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520L858R%252FT790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5609%26epage%3D5622%26doi%3D10.1021%2Facs.jmedchem.8b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. N.</span></span> <span> </span><span class="NLM_article-title">Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1177/1087057112463732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1177%2F1087057112463732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=23071008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OktrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=199-210&author=R.+D.+Pelletierauthor=W.+G.+Laiauthor=Y.+N.+Wong&title=Application+of+a+substrate+cocktail+approach+in+the+assessment+of+cytochrome+P450+induction+using+cultured+human+hepatocytes&doi=10.1177%2F1087057112463732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes</span></div><div class="casAuthors">Pelletier, Robert D.; Lai, W. George; Wong, Y. Nancy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-210, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Induction of the cytochrome P 450 (CYP) family of enzymes by coadministered compds. can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.  Identification of potential drug-drug interactions due to CYP induction during drug discovery is crit.  We present a substrate cocktail method that was applied to assess the induction of CYP1A, CYP2B6, CYP2C9, and CYP3A using a 96-well high-throughput format.  Viable cell counts were detd. using a high-content screening system to normalize activities.  Substrate cocktail incubations demonstrated a similar fold induction for known inducers as compared with discrete probe incubations.  The system was further validated by detg. the induction potency of rifampicin.  The Emax and EC50 values in two sep. lots of hepatocytes for CYP3A induction by rifampicin in a 96-well format were similar when discrete probe was compared with the probe cocktail.  This system has been demonstrated to be suitable for high-throughput assessments of CYP induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr116eNO0uPC7Vg90H21EOLACvtfcHk0lhSIhQobITuXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OktrfJ&md5=6783e972d6d0c86a0509ae872b7449a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1177%2F1087057112463732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057112463732%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DR.%2BD.%26aulast%3DLai%26aufirst%3DW.%2BG.%26aulast%3DWong%26aufirst%3DY.%2BN.%26atitle%3DApplication%2520of%2520a%2520substrate%2520cocktail%2520approach%2520in%2520the%2520assessment%2520of%2520cytochrome%2520P450%2520induction%2520using%2520cultured%2520human%2520hepatocytes%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2013%26volume%3D18%26spage%3D199%26epage%3D210%26doi%3D10.1177%2F1087057112463732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Marta Serafini, Sarah Cargnin, Alberto Massarotti, Gian Cesare Tron, Tracey Pirali, <span class="NLM_string-name hlFld-ContribAuthor">Armando A. Genazzani</span>. </span><span class="cited-content_cbyCitation_article-title">What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (8)
                                     , 4410-4429. <a href="https://doi.org/10.1021/acs.jmedchem.1c00181" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00181%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DWhat%2525E2%252580%252599s%252Bin%252Ba%252BName%25253F%252BDrug%252BNomenclature%252Band%252BMedicinal%252BChemistry%252BTrends%252Busing%252BINN%252BPublications%26aulast%3DSerafini%26aufirst%3DMarta%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01022021%26date%3D13042021%26volume%3D64%26issue%3D8%26spage%3D4410%26epage%3D4429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Hailan  Huang</span>, <span class="hlFld-ContribAuthor ">Ziheng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiangkun  Yan</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Wenbo  Yin</span>, <span class="hlFld-ContribAuthor ">Yixiang  Sun</span>, <span class="hlFld-ContribAuthor ">Xinran  Wang</span>, <span class="hlFld-ContribAuthor ">Yanting  Gu</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113501. <a href="https://doi.org/10.1016/j.ejmech.2021.113501" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113501</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113501%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bbenzofuran%252Bderivatives%252Bas%252Bpotent%252BLSD1%252Binhibitors%26aulast%3DZhang%26aufirst%3DXiangyu%26date%3D2021%26volume%3D220%26spage%3D113501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dong-Jun  Fu</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Bin  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Annual review of LSD1/KDM1A inhibitors in 2020. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113254. <a href="https://doi.org/10.1016/j.ejmech.2021.113254" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113254%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAnnual%252Breview%252Bof%252BLSD1%25252FKDM1A%252Binhibitors%252Bin%252B2020%26aulast%3DFu%26aufirst%3DDong-Jun%26date%3D2021%26volume%3D214%26spage%3D113254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prince Kumar  Gupta</span>, <span class="hlFld-ContribAuthor ">Arvind Kumar  Yadav</span>, <span class="hlFld-ContribAuthor ">Anup Kumar  Sharma</span>, <span class="hlFld-ContribAuthor ">Krishna Nand  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Iodine-catalyzed thioallylation of indoles using Bunte salts prepared from Baylis–Hillman bromides. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>106 </em><a href="https://doi.org/10.1039/D1OB00377A" title="DOI URL">https://doi.org/10.1039/D1OB00377A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00377A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00377A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DIodine-catalyzed%252Bthioallylation%252Bof%252Bindoles%252Busing%252BBunte%252Bsalts%252Bprepared%252Bfrom%252BBaylis%2525E2%252580%252593Hillman%252Bbromides%26aulast%3DGupta%26aufirst%3DPrince%2BKumar%26date%3D2021%26date%3D2021%26volume%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative EGFR inhibitors in the clinic, the key metabolites AZ5104 and AZ7550 of osimertinib, and dosimertinib reported in this work.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>2a</b>–<b>2g</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) isobutyryl chloride, NaOH, THF/H<sub>2</sub>O (4:1); (b) crotonic acid, HBTU, DIPEA, DMF, rt; (c) 2-trifluoromethyl acrylic acid, T3P, TEA, DCM, rt; (d) 2-fluoroacrylic acid, HBTU, DIPEA, DMF, rt; (e) 2-chloroacrylic acid, HBTU, DIPEA, DMF, rt; (f) 2-broroacrylic acid, HBTU, DIPEA, DMF, rt; (g) diethylphosphonoacetic acid, HATU, DIPEA, DMF, rt; (h) (CD<sub>2</sub>O)<sub><i>n</i></sub>, LiOH, KOH, THF/H<sub>2</sub>O (4/1), rt.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Dosimertinib<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) diethylphosphonoacetic acid, HATU, DIPEA, THF, rt; (b) (CD<sub>2</sub>O)<i><sub>n</sub></i>, LiOH, KOH, THF/H<sub>2</sub>O (4/1), rt; (c) MeSO<sub>3</sub>H, acetone/H<sub>2</sub>O (10:1), 50 °C.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibitory effects of osimertinib and <b>2h</b> on EGFR and downstream signaling transduction in H1975 cells (A) and A431 cells (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Target duration <i>in vitro</i>. H1975 cells were treated with <b>2h</b> (A) or osimertinib (B) for 2 h, then washed with PBS three times. Target inhibition at different time points was detected by Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> antitumor effects of dosimertinib or osimertinib on H1975 (A) and BaF3 (C) tumor xenografts for 18–24 days. The body weight was measured twice a week in H1975 (B) and BaF3 (D) tumor xenograft mice. All values represent mean ± SEM. **<i>p</i> < 0.01 and ***<i>p</i> < 0.001 compared to the vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Metabolic profiling of dosimertinib in liver microsomes of five different species (mouse, rat, dog, monkey, and human).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/medium/jm0c02005_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Reaction phenotyping of dosimertinib. (A) Inhibition in the formation of M1, M6, and M11 in HLMs in the presence of selective P450 inhibitors, respectively. (B) Relative contribution of various recombinant P450 isoforms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-2/acs.jmedchem.0c02005/20210121/images/large/jm0c02005_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02005&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i40">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50113" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50113" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lgsfzbPBSxjHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rude
Voldborg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damstrup, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spang-Thomsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skovgaard Poulsen, H.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1197</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1023/A:1008209720526</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1023%2FA%3A1008209720526" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=9496384" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1997&pages=1197-1206&author=B.+Rude%0AVoldborgauthor=L.+Damstrupauthor=M.+Spang-Thomsenauthor=H.+Skovgaard+Poulsen&title=Epidermal+growth+factor+receptor+%28EGFR%29+and+EGFR+mutations%2C+function+and+possible+role+in+clinical+trials&doi=10.1023%2FA%3A1008209720526"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1023%2FA%3A1008209720526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1008209720526%26sid%3Dliteratum%253Aachs%26aulast%3DRude%2BVoldborg%26aufirst%3DB.%26aulast%3DDamstrup%26aufirst%3DL.%26aulast%3DSpang-Thomsen%26aufirst%3DM.%26aulast%3DSkovgaard%2BPoulsen%26aufirst%3DH.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520EGFR%2520mutations%252C%2520function%2520and%2520possible%2520role%2520in%2520clinical%2520trials%26jtitle%3DAnn.%2520Oncol.%26date%3D1997%26volume%3D8%26spage%3D1197%26epage%3D1206%26doi%3D10.1023%2FA%3A1008209720526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wieduwilt, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moasser, M. M.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor family: Biology driving targeted therapeutics</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1584</span>, <span class="refDoi"> DOI: 10.1007/s00018-008-7440-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1007%2Fs00018-008-7440-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=18259690" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt12qu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=1566-1584&author=M.+J.+Wieduwiltauthor=M.+M.+Moasser&title=The+epidermal+growth+factor+receptor+family%3A+Biology+driving+targeted+therapeutics&doi=10.1007%2Fs00018-008-7440-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The epidermal growth factor receptor family: Biology driving targeted therapeutics</span></div><div class="casAuthors">Wieduwilt, M. J.; Moasser, M. M.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1566-1584</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review of the biol. of ErbB receptors, including their structure, signaling, regulation, and roles in development and disease, and their increasing roles as targets for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcSSPMwgxaFLVg90H21EOLACvtfcHk0lgsfzbPBSxjHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt12qu7o%253D&md5=d0e8b0634b2b401b1c94838fe389ca91</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs00018-008-7440-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-008-7440-8%26sid%3Dliteratum%253Aachs%26aulast%3DWieduwilt%26aufirst%3DM.%2BJ.%26aulast%3DMoasser%26aufirst%3DM.%2BM.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520family%253A%2520Biology%2520driving%2520targeted%2520therapeutics%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2008%26volume%3D65%26spage%3D1566%26epage%3D1584%26doi%3D10.1007%2Fs00018-008-7440-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scaltriti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">The epidermal growth factor receptor pathway: a model for targeted therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5268</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-1554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1158%2F1078-0432.CCR-05-1554" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=17000658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD28XpvFShs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=5268&author=M.+Scaltritiauthor=J.+Baselga&title=The+epidermal+growth+factor+receptor+pathway%3A+a+model+for+targeted+therapy&doi=10.1158%2F1078-0432.CCR-05-1554"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The Epidermal Growth Factor Receptor Pathway: a Model for Targeted Therapy</span></div><div class="casAuthors">Scaltriti, Maurizio; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5268-5272</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase receptor that is frequently expressed in epithelial tumors.  The EGFR was the first receptor to be proposed as a target for cancer therapy, and after 2 decades of intensive research, there are several anti-EGFR agents available in the clinic.  Recent advances in our understanding in the mechanisms of receptor activation and function, discovery of primary and secondary EGFR somatic mutations, as well as a new generation of anti-EGFR agents provide new leads on the clin. targeting of this receptor and may serve as a model for strategies aimed at targeting other receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPXuFE-mrma7Vg90H21EOLACvtfcHk0lgsfzbPBSxjHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpvFShs74%253D&md5=1dce384cc003760669ffd798bdcca768</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-1554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-1554%26sid%3Dliteratum%253Aachs%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DThe%2520epidermal%2520growth%2520factor%2520receptor%2520pathway%253A%2520a%2520model%2520for%2520targeted%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D5268%26doi%3D10.1158%2F1078-0432.CCR-05-1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1193</span>– <span class="NLM_lpage">1203</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2019.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2Fj.apsb.2019.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=31867165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BB3MbjtV2rtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1193-1203&author=P.+Heauthor=S.+Niuauthor=S.+Wangauthor=X.+Shiauthor=S.+Fengauthor=L.+Duauthor=X.+Zhangauthor=Z.+Maauthor=B.+Yuauthor=H.+Liu&title=Discovery+of+WS-157+as+a+highly+potent%2C+selective+and+orally+active+EGFR+inhibitor&doi=10.1016%2Fj.apsb.2019.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of WS-157 as a highly potent, selective and orally active EGFR inhibitor</span></div><div class="casAuthors">He Pengxing; Niu Shenghui; Wang Shuai; Shi Xiaojing; Feng Siqi; Du Linna; Zhang Xuyang; Ma Zhilu; Yu Bin; Liu Hongmin; Yu Bin</div><div class="citationInfo"><span class="NLM_cas:title">Acta pharmaceutica Sinica. B</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1193-1203</span>
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    </div><div class="casAbstract">EGFR tyrosine kinase inhibitor (EGFR-TKI) has been used successfully in clinic for the treatment of solid tumors.  In the present study, we reported the discovery of WS-157 from our in-house diverse compound library, which was validated to be a potent and selective EGFR-TKI.  WS-157 showed excellent inhibitory activities against EGFR (IC50 = 0.81 nmol/L), EGFR([d746-750]) (IC50 = 1.2 nmol/L) and EGFR([L858R]) (IC50 = 1.1 nmol/L), but was less effective or even inactive against other nine kinases.  WS-157 also displayed excellent antiproliferative activities against a panel of human cancer cell lines, and exhibited the ability to reduce colony formation and wound healing the same as gefitinib.  We found that WS-157 upon oral administration showed better anti-tumor activity in A431 bearing xenograft mouse models compared to gefitinib.  In addition, WS-157 showed better intestinal absorption than gefitinib and had favorable pharmacokinetic properties and microsomal metabolic stability in different species.  These studies indicate that WS-157 has strong antitumor activity in vitro and in vivo, and could be used for the development of anti-lung cancer agent targeting EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTlv_RDCglknUewzGPswiWOfW6udTcc2eaGYJkG5B44Frntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbjtV2rtg%253D%253D&md5=028496f2984bc9d3a62f4b1812b45fb5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2019.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2019.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DFeng%26aufirst%3DS.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DMa%26aufirst%3DZ.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520WS-157%2520as%2520a%2520highly%2520potent%252C%2520selective%2520and%2520orally%2520active%2520EGFR%2520inhibitor%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2019%26volume%3D9%26spage%3D1193%26epage%3D1203%26doi%3D10.1016%2Fj.apsb.2019.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span> <span> </span><span class="NLM_article-title">Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4290</span>– <span class="NLM_lpage">4300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01310</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01310" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4290-4300&author=L.+Chenauthor=W.+Fuauthor=L.+Zhengauthor=Z.+Liuauthor=G.+Liang&title=Recent+progress+of+small-molecule+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+C797S+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.7b01310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Chen, Lingfeng; Fu, Weitao; Zheng, Lulu; Liu, Zhiguo; Liang, Guang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4290-4300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) has been a particular interest for drug development for treatment of non-small-cell lung cancer (NSCLC).  The current third-generation EGFR small-mol. inhibitors, esp. osimertinib, are at the forefront clin. for treatment of patients with NSCLC.  However, a high percentage of these treated patients developed a tertiary cysteine-797 to serine-790 (C797S) mutation in the EGFR kinase domain.  This C797S mutation is thought to induce resistance to all current irreversible EGFR TKIs.  In this Miniperspective, the authors present key mechanisms of resistance in response to third-generation EGFR TKIs, and emerging reports on novel EGFR TKIs to combat the resistance.  Specifically, the authors analyze the allosteric and ATP-competitive inhibitors in terms of drug discovery, binding mechanism, and their potency and selectivity against EGFR harboring C797S mutations.  Lastly, the authors provide some perspectives on new challenges and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIcPvOmj29UbVg90H21EOLACvtfcHk0lifH44pkmRFHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvVWntrvK&md5=6d3bc978d3896a4e1027cbacd2dad9e9</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01310%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DLiang%26aufirst%3DG.%26atitle%3DRecent%2520progress%2520of%2520small-molecule%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520C797S%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4290%26epage%3D4300%26doi%3D10.1021%2Facs.jmedchem.7b01310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span> <span> </span><span class="NLM_article-title">Challenges and perspectives on the development of small-molecule EGFR inhibitors against T790M-mediated resistance in non-small-cell lung cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6580</span>– <span class="NLM_lpage">6594</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00840</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00840" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6580-6594&author=Z.+Songauthor=Y.+Geauthor=C.+Wangauthor=S.+Huangauthor=X.+Shuauthor=K.+Liuauthor=Y.+Zhouauthor=X.+Ma&title=Challenges+and+perspectives+on+the+development+of+small-molecule+EGFR+inhibitors+against+T790M-mediated+resistance+in+non-small-cell+lung+cancer&doi=10.1021%2Facs.jmedchem.5b00840"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Song, Zhendong; Ge, Yang; Wang, Changyuan; Huang, Shanshan; Shu, Xiaohong; Liu, Kexin; Zhou, Youwen; Ma, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6580-6594</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the development of drug-resistance mutations, particularly the "gatekeeper" threonine790-to-methionine790 (T790M) mutation in the ATP-binding pocket of the epidermal growth factor receptor (EGFR), the current generation of EGFR tyrosine kinase inhibitors lost their clin. efficacy.  Recently, a large no. of small-mol. inhibitors with striking inhibitory potency against EGFR mutants with the T790M change have been identified.  In particular, the inhibitors rociletinib and osimertinib, which can selectively target both sensitizing mutations and the T790M resistance while sparing the wild-type (WT) form of the receptor, have been designated as breakthrough therapies in the treatment of mutant non-small-cell lung cancer (NSCLC) by the U.S.  FDA in 2014.  We hope that this review on the small-mol. EGFR T790M inhibitors, along with their discovery strategies, will assist in the design of future T790M-contg. EGFR inhibitors with high levels of selectivity over WT EGFR, broad kinase selectivity, and desirable physicochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEcAydAIVpNbVg90H21EOLACvtfcHk0lifH44pkmRFHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisFGntbo%253D&md5=2112d52e116494f61b1c8bd3f8f383d9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DShu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26atitle%3DChallenges%2520and%2520perspectives%2520on%2520the%2520development%2520of%2520small-molecule%2520EGFR%2520inhibitors%2520against%2520T790M-mediated%2520resistance%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6580%26epage%3D6594%26doi%3D10.1021%2Facs.jmedchem.5b00840" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, D. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponthier, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mushajiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Mutant-selective allosteric EGFR degraders are effective against a broad range of drug-resistant mutations</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">14481</span>– <span class="NLM_lpage">14489</span>, <span class="refDoi"> DOI: 10.1002/anie.202003500</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1002%2Fanie.202003500" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2020&pages=14481-14489&author=J.+Jangauthor=C.+Toauthor=D.+J.+H.+De+Clercqauthor=E.+Parkauthor=C.+M.+Ponthierauthor=B.+H.+Shinauthor=M.+Mushajiangauthor=R.+P.+Nowakauthor=E.+S.+Fischerauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Mutant-selective+allosteric+EGFR+degraders+are+effective+against+a+broad+range+of+drug-resistant+mutations&doi=10.1002%2Fanie.202003500"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations</span></div><div class="casAuthors">Jang, Jaebong; To, Ciric; De Clercq, Dries J. H.; Park, Eunyoung; Ponthier, Charles M.; Shin, Bo Hee; Mushajiang, Mierzhati; Nowak, Radoslaw P.; Fischer, Eric S.; Eck, Michael J.; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">14481-14489</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Targeting epidermal growth factor receptor (EGFR) through an allosteric mechanism provides a potential therapeutic strategy to overcome drug-resistant EGFR mutations that emerge within the ATP binding site.  Here, we develop an allosteric EGFR degrader, DDC-01-163, which can selectively inhibit the proliferation of L858R/T790M (L/T) mutant Ba/F3 cells while leaving wildtype EGFR Ba/F3 cells unaffected.  DDC-01-163 is also effective against osimertinib-resistant cells with L/T/C797S and L/T/L718Q EGFR mutations.  When combined with an ATP-site EGFR inhibitor, osimertinib, the anti-proliferative activity of DDC-01-163 against L858R/T790M EGFR-Ba/F3 cells is enhanced.  Collectively, DDC-01-163 is a promising allosteric EGFR degrader with selective activity against various clin. relevant EGFR mutants as a single agent and when combined with an ATP-site inhibitor.  Our data suggests that targeted protein degrdn. is a promising drug development approach for mutant EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpo-uPhJ2k9kLVg90H21EOLACvtfcHk0ljlxbYBPhKMPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlKnsL7I&md5=4e24a6a1a746e446a052f27e404f8adf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.202003500&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.202003500%26sid%3Dliteratum%253Aachs%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DD.%2BJ.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DPonthier%26aufirst%3DC.%2BM.%26aulast%3DShin%26aufirst%3DB.%2BH.%26aulast%3DMushajiang%26aufirst%3DM.%26aulast%3DNowak%26aufirst%3DR.%2BP.%26aulast%3DFischer%26aufirst%3DE.%2BS.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DMutant-selective%2520allosteric%2520EGFR%2520degraders%2520are%2520effective%2520against%2520a%2520broad%2520range%2520of%2520drug-resistant%2520mutations%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2020%26volume%3D59%26spage%3D14481%26epage%3D14489%26doi%3D10.1002%2Fanie.202003500" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent and selective epidermal growth factor receptor (EGFR) bifunctional small-molecule degraders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1216</span>– <span class="NLM_lpage">1232</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01566</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01566" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1216-1232&author=M.+Chengauthor=X.+Yuauthor=K.+Luauthor=L.+Xieauthor=L.+Wangauthor=F.+Mengauthor=X.+Hanauthor=X.+Chenauthor=J.+Liuauthor=Y.+Xiongauthor=J.+Jin&title=Discovery+of+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+bifunctional+small-molecule+degraders&doi=10.1021%2Facs.jmedchem.9b01566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders</span></div><div class="casAuthors">Cheng, Meng; Yu, Xufen; Lu, Kaylene; Xie, Ling; Wang, Li; Meng, Fanye; Han, Xiaoran; Chen, Xian; Liu, Jing; Xiong, Yue; Jin, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1216-1232</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors have been developed and approved by Food and Drug Administration for the treatment of non-small-cell lung cancers, but their efficacy can be compromised by acquired drug resistance conferred by EGFR-mutant variants.  Here, we described the discovery of a novel E3 ligase von Hippel-Lindau-recruiting EGFR degrader, MS39 (compd. 6), and a first-in-class E3 ligase cereblon-recruiting EGFR degrader, MS154 (compd. 10), using the proteolysis targeting chimera technol.  These compds. potently induced the degrdn. of mutant but not wild-type EGFR in an E3 ligase-dependent manner in cancer cell lines and effectively suppressed the growth of lung cancer cells compared with the corresponding neg. controls.  The global proteomic analyses revealed that the compds. were highly selective for EGFR.  Furthermore, both compds. were bioavailable in mouse pharmacokinetic studies, and compd. 6 is the first EGFR degrader suitable for in vivo efficacy studies.  Overall, we provide a set of well-characterized chem. tools to the research community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraFLSjUGE-6rVg90H21EOLACvtfcHk0ljlxbYBPhKMPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFWksA%253D%253D&md5=ec831897a4258f1968e254aa433426c3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01566%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DF.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520bifunctional%2520small-molecule%2520degraders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1216%26epage%3D1232%26doi%3D10.1021%2Facs.jmedchem.9b01566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112199</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2Fj.ejmech.2020.112199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=32171162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112199&author=X.+Zhangauthor=F.+Xuauthor=L.+Tongauthor=T.+Zhangauthor=H.+Xieauthor=X.+Luauthor=X.+Renauthor=K.+Ding&title=Design+and+synthesis+of+selective+degraders+of+EGFRL858R%2FT790M+mutant&doi=10.1016%2Fj.ejmech.2020.112199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of selective degraders of EGFRL858R/T790M mutant</span></div><div class="casAuthors">Zhang, Xin; Xu, Fang; Tong, Linjiang; Zhang, Tao; Xie, Hua; Lu, Xiaoyun; Ren, Xiaomei; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112199</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of PROTAC (proteolysis targeting chimera) based selective EGFRL858R/T790M (leucine 858 to arginine 858 mutation and threonine 790 to methionine 790) mutant degraders were designed and synthesized.  One of the most potent compds. (I) effectively and selectively degraded EGFRL858R/T790M with an DC50 value of 5.9 nM, while did not show obvious effect on the wild-type protein.  Further mechanism investigation revealed that the degrdn. was mediated by ubiquitin proteasome pathway.  Compd. I could be utilized as an initial lead mol. for development of new EGFRL858R/T790M degrader based therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoDW2mGkQNzbVg90H21EOLACvtfcHk0ljlxbYBPhKMPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFyltbk%253D&md5=e8fdd02842f6cfd94e362f3a53a39096</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112199%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520selective%2520degraders%2520of%2520EGFRL858R%252FT790M%2520mutant%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112199%26doi%3D10.1016%2Fj.ejmech.2020.112199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, W.-C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth</span>. <i>Signal. Transduct. Target. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">214</span>, <span class="refDoi"> DOI: 10.1038/s41392-020-00251-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1038%2Fs41392-020-00251-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=33033232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BB3s%252FptFGmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=214&author=N.+Yaoauthor=C.-R.+Wangauthor=M.-Q.+Liuauthor=Y.-J.+Liauthor=W.-M.+Chenauthor=Z.-Q.+Liauthor=Q.+Qiauthor=J.-J.+Luauthor=C.-L.+Fanauthor=M.-F.+Chenauthor=M.+Qiauthor=X.-B.+Liauthor=J.+Hongauthor=D.-M.+Zhangauthor=W.-C.+Ye&title=Discovery+of+a+novel+EGFR+ligand+DPBA+that+degrades+EGFR+and+suppresses+EGFR-positive+NSCLC+growth&doi=10.1038%2Fs41392-020-00251-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth</span></div><div class="casAuthors">Yao Nan; Wang Chen-Ran; Liu Ming-Qun; Li Ying-Jie; Chen Wei-Min; Li Zheng-Qiu; Fan Chun-Lin; Chen Min-Feng; Qi Ming; Li Xiao-Bo; Zhang Dong-Mei; Ye Wen-Cai; Yao Nan; Wang Chen-Ran; Fan Chun-Lin; Chen Min-Feng; Qi Ming; Li Xiao-Bo; Zhang Dong-Mei; Ye Wen-Cai; Qi Qi; Hong Jian; Lu Jin-Jian</div><div class="citationInfo"><span class="NLM_cas:title">Signal transduction and targeted therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">214</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) activation plays a pivotal role in EGFR-driven non-small cell lung cancer (NSCLC) and is considered as a key target of molecular targeted therapy.  EGFR tyrosine kinase inhibitors (TKIs) have been canonically used in NSCLC treatment.  However, prevalent innate and acquired resistances and EGFR kinase-independent pro-survival properties limit the clinical efficacy of EGFR TKIs.  Therefore, the discovery of novel EGFR degraders is a promising approach towards improving therapeutic efficacy and overcoming drug resistance.  Here, we identified a 23-hydroxybetulinic acid derivative, namely DPBA, as a novel EGFR small-molecule ligand.  It exerted potent in vitro and in vivo anticancer activity in both EGFR wild type and mutant NSCLC by degrading EGFR.  Mechanistic studies disclosed that DPBA binds to the EGFR extracellular domain at sites differing from those of EGF and EGFR.  DPBA did not induce EGFR dimerization, phosphorylation, and ubiquitination, but it significantly promoted EGFR degradation and repressed downstream survival pathways.  Further analyses showed that DPBA induced clathrin-independent EGFR endocytosis mediated by flotillin-dependent lipid rafts and unaffected by EGFR TKIs.  Activation of the early and late endosome markers rab5 and rab7 but not the recycling endosome marker rab11 was involved in DPBA-induced EGFR lysosomal degradation.  The present study offers a new EGFR ligand for EGFR pharmacological degradation and proposes it as a potential treatment for EGFR-positive NSCLC, particularly NSCLC with innate or acquired EGFR TKI resistance.  DPBA can also serve as a chemical probe in the studies on EGFR trafficking and degradation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcROSMCy6-iUr9-cVm4E2RlLfW6udTcc2ebAyCEFirGJsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s%252FptFGmsA%253D%253D&md5=5ddec18a5fd78c386b375e46c7d3b26a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41392-020-00251-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41392-020-00251-2%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DC.-R.%26aulast%3DLiu%26aufirst%3DM.-Q.%26aulast%3DLi%26aufirst%3DY.-J.%26aulast%3DChen%26aufirst%3DW.-M.%26aulast%3DLi%26aufirst%3DZ.-Q.%26aulast%3DQi%26aufirst%3DQ.%26aulast%3DLu%26aufirst%3DJ.-J.%26aulast%3DFan%26aufirst%3DC.-L.%26aulast%3DChen%26aufirst%3DM.-F.%26aulast%3DQi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.-B.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DD.-M.%26aulast%3DYe%26aufirst%3DW.-C.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520EGFR%2520ligand%2520DPBA%2520that%2520degrades%2520EGFR%2520and%2520suppresses%2520EGFR-positive%2520NSCLC%2520growth%26jtitle%3DSignal.%2520Transduct.%2520Target.%2520Ther.%26date%3D2020%26volume%3D5%26spage%3D214%26doi%3D10.1038%2Fs41392-020-00251-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurubhagavatula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okimoto, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannigan, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haserlat, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supko, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haluska, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christiani, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>350</i></span>,  <span class="NLM_fpage">2129</span>– <span class="NLM_lpage">2139</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa040938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1056%2FNEJMoa040938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=15118073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2129-2139&author=T.+J.+Lynchauthor=D.+W.+Bellauthor=R.+Sordellaauthor=S.+Gurubhagavatulaauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=S.+M.+Haserlatauthor=J.+G.+Supkoauthor=F.+G.+Haluskaauthor=D.+N.+Louisauthor=D.+C.+Christianiauthor=J.+Settlemanauthor=D.+A.+Haber&title=Activating+mutations+in+the+epidermal+growth+factor+receptor+underlying+responsiveness+of+non%E2%80%93small-cell+lung+cancer+to+gefitinib&doi=10.1056%2FNEJMoa040938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella; Gurubhagavatula, Sarada; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Haserlat, Sara M.; Supko, Jeffrey G.; Haluska, Frank G.; Louis, David N.; Christiani, David C.; Settleman, Jeff; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">2129-2139</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR).  However, about 10% of patients have a rapid and often dramatic clin. response.  The mol. mechanisms underlying sensitivity to gefitinib are unknown.  We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib.  The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.  Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P < 0.001).  Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain.  Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8%).  All mutations were heterozygous, and identical mutations were obsd. in multiple patients, suggesting an additive specific gain of function.  In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib.  A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clin. responsiveness to the tyrosine kinase inhibitor gefitinib.  These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.  Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwWGeAQrNTLVg90H21EOLACvtfcHk0lifp5gpJ76Yig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktF2js7c%253D&md5=fad70aa0f32ad4105ad6f3db98135bf9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa040938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa040938%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DGurubhagavatula%26aufirst%3DS.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DHaserlat%26aufirst%3DS.%2BM.%26aulast%3DSupko%26aufirst%3DJ.%2BG.%26aulast%3DHaluska%26aufirst%3DF.%2BG.%26aulast%3DLouis%26aufirst%3DD.%2BN.%26aulast%3DChristiani%26aufirst%3DD.%2BC.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DActivating%2520mutations%2520in%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520underlying%2520responsiveness%2520of%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2129%26epage%3D2139%26doi%3D10.1056%2FNEJMoa040938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">1163</span>, <span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0lifp5gpJ76Yig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bessho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosokawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukamatsu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunitoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aono, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakahara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusaka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hosomi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, H.</span></span> <span> </span><span class="NLM_article-title">Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer: a multicenter phase 2 trial</span>. <i>JAMA Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e201250</span>– <span class="NLM_lpage">e201250</span>, <span class="refDoi"> DOI: 10.1001/jamaoncol.2020.1250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1001%2Fjamaoncol.2020.1250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=32407455" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=e201250-e201250&author=S.+Miyamotoauthor=K.+Azumaauthor=H.+Ishiiauthor=A.+Besshoauthor=S.+Hosokawaauthor=N.+Fukamatsuauthor=H.+Kunitohauthor=M.+Ishiiauthor=H.+Tanakaauthor=H.+Aonoauthor=Y.+Nakaharaauthor=K.+Kusakaauthor=Y.+Hosomiauthor=N.+Kikuchiauthor=Y.+Moriauthor=H.+Itaniauthor=A.+Hamadaauthor=K.+Yamadaauthor=H.+Okamoto&title=Low-dose+erlotinib+treatment+in+elderly+or+frail+patients+with+EGFR+mutation%E2%80%93positive+non%E2%80%93small+cell+lung+cancer%3A+a+multicenter+phase+2+trial&doi=10.1001%2Fjamaoncol.2020.1250"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1001%2Fjamaoncol.2020.1250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjamaoncol.2020.1250%26sid%3Dliteratum%253Aachs%26aulast%3DMiyamoto%26aufirst%3DS.%26aulast%3DAzuma%26aufirst%3DK.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DBessho%26aufirst%3DA.%26aulast%3DHosokawa%26aufirst%3DS.%26aulast%3DFukamatsu%26aufirst%3DN.%26aulast%3DKunitoh%26aufirst%3DH.%26aulast%3DIshii%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DAono%26aufirst%3DH.%26aulast%3DNakahara%26aufirst%3DY.%26aulast%3DKusaka%26aufirst%3DK.%26aulast%3DHosomi%26aufirst%3DY.%26aulast%3DKikuchi%26aufirst%3DN.%26aulast%3DMori%26aufirst%3DY.%26aulast%3DItani%26aufirst%3DH.%26aulast%3DHamada%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DH.%26atitle%3DLow-dose%2520erlotinib%2520treatment%2520in%2520elderly%2520or%2520frail%2520patients%2520with%2520EGFR%2520mutation%25E2%2580%2593positive%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%253A%2520a%2520multicenter%2520phase%25202%2520trial%26jtitle%3DJAMA%2520Oncol.%26date%3D2020%26volume%3D6%26spage%3De201250%26epage%3De201250%26doi%3D10.1001%2Fjamaoncol.2020.1250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bean, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brennan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chitale, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motoi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broderick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerald, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">20932</span>, <span class="refDoi"> DOI: 10.1073/pnas.0710370104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1073%2Fpnas.0710370104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=18093943" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlyhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=20932&author=J.+Beanauthor=C.+Brennanauthor=J.-Y.+Shihauthor=G.+Rielyauthor=A.+Vialeauthor=L.+Wangauthor=D.+Chitaleauthor=N.+Motoiauthor=J.+Szokeauthor=S.+Broderickauthor=M.+Balakauthor=W.-C.+Changauthor=C.-J.+Yuauthor=A.+Gazdarauthor=H.+Passauthor=V.+Ruschauthor=W.+Geraldauthor=S.-F.+Huangauthor=P.-C.+Yangauthor=V.+Millerauthor=M.+Ladanyiauthor=C.-H.+Yangauthor=W.+Pao&title=MET+amplification+occurs+with+or+without+T790M+mutations+in+EGFR+mutant+lung+tumors+with+acquired+resistance+to+gefitinib+or+erlotinib&doi=10.1073%2Fpnas.0710370104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Met amplification occurs with or without T790m mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib</span></div><div class="casAuthors">Bean, James; Brennan, Cameron; Shih, Jin-Yuan; Riely, Gregory; Viale, Agnes; Wang, Lu; Chitale, Dhananjay; Motoi, Noriko; Szoke, Janos; Broderick, Stephen; Balak, Marissa; Chang, Wen-Cheng; Yu, Chong-Jen; Gazdar, Adi; Pass, Harvey; Rusch, Valerie; Gerald, William; Huang, Shiu-Feng; Yang, Pan-Chyr; Miller, Vincent; Ladanyi, Marc; Yang, Chih-Hsin; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">20932-20937</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is assocd. with approx. half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib.  To identify other potential mechanisms that contribute to disease progression, we used array-based comparative genomic hybridization (aCGH) to compare genomic profiles of EGFR mutant tumors from untreated patients with those from patients with acquired resistance.  Among three loci demonstrating recurrent copy no. alterations (CNAs) specific to the acquired resistance set, one contained the MET proto-oncogene.  Collectively, anal. of tumor samples from multiple independent patient cohorts revealed that MET was amplified in tumors from 9 of 43 (21%) patients with acquired resistance but in only two tumors from 62 untreated patients (3%) (P = 0.007, Fisher's Exact test).  Among 10 resistant tumors from the nine patients with MET amplification, 4 also harbored the EGFRT790M mutation.  We also found that an existing EGFR mutant lung adenocarcinoma cell line, NCI-H820, harbors MET amplification in addn. to a drug-sensitive EGFR mutation and the T790M change.  Growth inhibition studies demonstrate that these cells are resistant to both erlotinib and an irreversible EGFR inhibitor (CL-387,785) but sensitive to a multikinase inhibitor (XL880) with potent activity against MET.  Taken together, these data suggest that MET amplification occurs independently of EGFRT790M mutations and that MET may be a clin. relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVkBqKpZ-f97Vg90H21EOLACvtfcHk0lg6ZbDvTvqpgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlyhsg%253D%253D&md5=3c80cf95fd68733e20b469e79035e721</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710370104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710370104%26sid%3Dliteratum%253Aachs%26aulast%3DBean%26aufirst%3DJ.%26aulast%3DBrennan%26aufirst%3DC.%26aulast%3DShih%26aufirst%3DJ.-Y.%26aulast%3DRiely%26aufirst%3DG.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DChitale%26aufirst%3DD.%26aulast%3DMotoi%26aufirst%3DN.%26aulast%3DSzoke%26aufirst%3DJ.%26aulast%3DBroderick%26aufirst%3DS.%26aulast%3DBalak%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DW.-C.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3DGazdar%26aufirst%3DA.%26aulast%3DPass%26aufirst%3DH.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DGerald%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-F.%26aulast%3DYang%26aufirst%3DP.-C.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DC.-H.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DMET%2520amplification%2520occurs%2520with%2520or%2520without%2520T790M%2520mutations%2520in%2520EGFR%2520mutant%2520lung%2520tumors%2520with%2520acquired%2520resistance%2520to%2520gefitinib%2520or%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D20932%26doi%3D10.1073%2Fpnas.0710370104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070&author=C.-H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.-K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lg6ZbDvTvqpgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zugazagoitia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">i10</span>– <span class="NLM_lpage">i19</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx703</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1093%2Fannonc%2Fmdx703" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=29462254" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=i10-i19&author=D.+Westoverauthor=J.+Zugazagoitiaauthor=B.+C.+Choauthor=C.+M.+Lovlyauthor=L.+Paz-Ares&title=Mechanisms+of+acquired+resistance+to+first-+and+second-generation+EGFR+tyrosine+kinase+inhibitors&doi=10.1093%2Fannonc%2Fmdx703"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx703&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx703%26sid%3Dliteratum%253Aachs%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DZugazagoitia%26aufirst%3DJ.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520first-%2520and%2520second-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3Di10%26epage%3Di19%26doi%3D10.1093%2Fannonc%2Fmdx703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.-M.+Chenauthor=K.+Parkauthor=S.-W.+Kimauthor=C.+Zhouauthor=W.-C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.-H.+Tanauthor=T.-Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.-H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0liM5hdsimQBVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-M.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canon, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Possinger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Grève, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neven, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dirix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonat, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schütte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fasching, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottschalk, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse-Hammer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uttenreuther-Fischer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span> <span> </span><span class="NLM_article-title">A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer</span>. <i>Breast Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1159</span>, <span class="refDoi"> DOI: 10.1007/s10549-012-2126-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1007%2Fs10549-012-2126-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=22763464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrsrzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2012&pages=1149-1159&author=M.+Schulerauthor=A.+Awadaauthor=P.+Harterauthor=J.+L.+Canonauthor=K.+Possingerauthor=M.+Schmidtauthor=J.+De+Gr%C3%A8veauthor=P.+Nevenauthor=L.+Dirixauthor=W.+Jonatauthor=M.+W.+Beckmannauthor=J.+Sch%C3%BCtteauthor=P.+A.+Faschingauthor=N.+Gottschalkauthor=T.+Besse-Hammerauthor=F.+Fleischerauthor=S.+Windauthor=M.+Uttenreuther-Fischerauthor=M.+Piccartauthor=N.+Harbeck&title=A+phase+II+trial+to+assess+efficacy+and+safety+of+afatinib+in+extensively+pretreated+patients+with+HER2-negative+metastatic+breast+cancer&doi=10.1007%2Fs10549-012-2126-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer</span></div><div class="casAuthors">Schuler, Martin; Awada, Ahmad; Harter, Philipp; Canon, Jean Luc; Possinger, Kurt; Schmidt, Marcus; Greve, Jacques; Neven, Patrick; Dirix, Luc; Jonat, Walter; Beckmann, Matthias W.; Schuette, Jochen; Fasching, Peter A.; Gottschalk, Nina; Besse-Hammer, Tatiana; Fleischer, Frank; Wind, Sven; Uttenreuther-Fischer, Martina; Piccart, Martine; Harbeck, Nadia</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1149-1159</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Afatinib (BIBW 2992) is an ErbB-family blocker that irreversibly inhibits signaling from all relevant ErbB-family dimers.  Afatinib has demonstrated preclin. activity in human epidermal growth factor receptor HER2 (ErbB2)-pos. and triple-neg. xenograft models of breast cancer, and clin. activity in phase I studies.  This was a multicenter phase II study enrolling patients with HER2-neg. metastatic breast cancer progressing following no more than three lines of chemotherapy.  No prior epidermal growth factor receptor-targeted therapy was allowed.  Patients received 50-mg afatinib once daily until disease progression.  Tumor assessment was performed at every other 28-day treatment course.  The primary endpoint was clin. benefit (CB) for ≥4 treatment courses in triple-neg. (Cohort A) metastatic breast cancer (TNBC) and objective responses measured by Response Evaluation Criteria in Solid Tumors in patients with HER2-neg., estrogen receptor-pos., and/or progesterone receptor-pos. breast cancer (Cohort B).  Fifty patients received treatment, including 29 patients in Cohort A and 21 patients in Cohort B. No objective responses were obsd. in either cohort.  Median progression-free survival was 7.4 and 7.7 wk in Cohorts A and B, resp.  Three patients with TNBC had stable disease for ≥4 treatment courses, one of them for 12 courses (median 26.3 wk; range 18.9-47.9 wk).  The most frequently obsd. afatinib-assocd. adverse events (AEs) were gastrointestinal and skin-related side effects, which were manageable by symptomatic treatment and dose redns.  Afatinib pharmacokinetics were comparable to those obsd. in previously reported phase I trials.  In conclusion, afatinib had limited activity in HER2-neg. breast cancer.  AEs were generally manageable and mainly affected the skin and the gastrointestinal tract.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_1ZX211pphbVg90H21EOLACvtfcHk0liM5hdsimQBVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrsrzO&md5=e1823963d2d19bdf92dfa59849c31d1b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs10549-012-2126-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-012-2126-1%26sid%3Dliteratum%253Aachs%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DAwada%26aufirst%3DA.%26aulast%3DHarter%26aufirst%3DP.%26aulast%3DCanon%26aufirst%3DJ.%2BL.%26aulast%3DPossinger%26aufirst%3DK.%26aulast%3DSchmidt%26aufirst%3DM.%26aulast%3DDe%2BGr%25C3%25A8ve%26aufirst%3DJ.%26aulast%3DNeven%26aufirst%3DP.%26aulast%3DDirix%26aufirst%3DL.%26aulast%3DJonat%26aufirst%3DW.%26aulast%3DBeckmann%26aufirst%3DM.%2BW.%26aulast%3DSch%25C3%25BCtte%26aufirst%3DJ.%26aulast%3DFasching%26aufirst%3DP.%2BA.%26aulast%3DGottschalk%26aufirst%3DN.%26aulast%3DBesse-Hammer%26aufirst%3DT.%26aulast%3DFleischer%26aufirst%3DF.%26aulast%3DWind%26aufirst%3DS.%26aulast%3DUttenreuther-Fischer%26aufirst%3DM.%26aulast%3DPiccart%26aufirst%3DM.%26aulast%3DHarbeck%26aufirst%3DN.%26atitle%3DA%2520phase%2520II%2520trial%2520to%2520assess%2520efficacy%2520and%2520safety%2520of%2520afatinib%2520in%2520extensively%2520pretreated%2520patients%2520with%2520HER2-negative%2520metastatic%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2012%26volume%3D134%26spage%3D1149%26epage%3D1159%26doi%3D10.1007%2Fs10549-012-2126-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shirley, M.</span></span> <span> </span><span class="NLM_article-title">Dacomitinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1947</span>– <span class="NLM_lpage">1953</span>, <span class="refDoi"> DOI: 10.1007/s40265-018-1028-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1007%2Fs40265-018-1028-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=30506139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=1947-1953&author=M.+Shirley&title=Dacomitinib%3A+first+global+approval&doi=10.1007%2Fs40265-018-1028-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib: First Global Approval</span></div><div class="casAuthors">Shirley Matt</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1947-1953</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Dacomitinib (Vizimpro(®)) is an orally administered, small-molecule irreversible inhibitor of HER1 (EGFR), HER2 and HER4 that was developed by Pfizer Inc. for the treatment of solid tumours.  In September 2018, dacomitinib received its first global approval, in the USA, for use in the first-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.  Registration applications for the use of dacomitinib as first-line treatment for patients with EGFR-mutation-positive metastatic NSCLC have also been submitted in the EU and Japan.  This article summarizes the milestones in the development of dacomitinib leading to this first approval for the first-line treatment of patients with EGFR-mutated metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA4VT-ypttQfSAs_PE1QvifW6udTcc2eawNdEA4koNnrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crnslGgsw%253D%253D&md5=0e035cd4b47b60f40c2af1d3c1fb5add</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1007%2Fs40265-018-1028-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-018-1028-x%26sid%3Dliteratum%253Aachs%26aulast%3DShirley%26aufirst%3DM.%26atitle%3DDacomitinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2018%26volume%3D78%26spage%3D1947%26epage%3D1953%26doi%3D10.1007%2Fs40265-018-1028-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+non-small+cell+lung+cancer%3A+Comparative+pharmacokinetics+and+drug%E2%80%93drug+interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0lhAYsqT2XKa-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520Comparative%2520pharmacokinetics%2520and%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakelee, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadgeel, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varga, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dziadziuszko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garon, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heist, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendenhall, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piotrowska, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlovich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isaacson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Despain, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheny, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span> <span> </span><span class="NLM_article-title">Rociletinib in EGFR-mutated non–small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1700</span>– <span class="NLM_lpage">1709</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1413654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1056%2FNEJMoa1413654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=25923550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1700-1709&author=L.+V.+Sequistauthor=J.-C.+Soriaauthor=J.+W.+Goldmanauthor=H.+A.+Wakeleeauthor=S.+M.+Gadgeelauthor=A.+Vargaauthor=V.+Papadimitrakopoulouauthor=B.+J.+Solomonauthor=G.+R.+Oxnardauthor=R.+Dziadziuszkoauthor=D.+L.+Aisnerauthor=R.+C.+Doebeleauthor=C.+Galassoauthor=E.+B.+Garonauthor=R.+S.+Heistauthor=J.+Loganauthor=J.+W.+Nealauthor=M.+A.+Mendenhallauthor=S.+Nicholsauthor=Z.+Piotrowskaauthor=A.+J.+Wozniakauthor=M.+Raponiauthor=C.+A.+Karlovichauthor=S.+Jaw-Tsaiauthor=J.+Isaacsonauthor=D.+Despainauthor=S.+L.+Mathenyauthor=L.+Rolfeauthor=A.+R.+Allenauthor=D.+R.+Camidge&title=Rociletinib+in+EGFR-mutated+non%E2%80%93small-cell+lung+cancer&doi=10.1056%2FNEJMoa1413654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Rociletinib in EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Sequist Lecia V; Soria Jean-Charles; Goldman Jonathan W; Wakelee Heather A; Gadgeel Shirish M; Varga Andrea; Papadimitrakopoulou Vassiliki; Solomon Benjamin J; Oxnard Geoffrey R; Dziadziuszko Rafal; Aisner Dara L; Doebele Robert C; Galasso Cathy; Garon Edward B; Heist Rebecca S; Logan Jennifer; Neal Joel W; Mendenhall Melody A; Nichols Suzanne; Piotrowska Zofia; Wozniak Antoinette J; Raponi Mitch; Karlovich Chris A; Jaw-Tsai Sarah; Isaacson Jeffrey; Despain Darrin; Matheny Shannon L; Rolfe Lindsey; Allen Andrew R; Camidge D Ross</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1700-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Non-small-cell lung cancer (NSCLC) with a mutation in the gene encoding epidermal growth factor receptor (EGFR) is sensitive to approved EGFR inhibitors, but resistance develops, mediated by the T790M EGFR mutation in most cases.  Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.  METHODS:  In this phase 1-2 study, we administered rociletinib to patients with EGFR-mutated NSCLC who had disease progression during previous treatment with an existing EGFR inhibitor.  In the expansion (phase 2) part of the study, patients with T790M-positive disease received rociletinib at a dose of 500 mg twice daily, 625 mg twice daily, or 750 mg twice daily.  Key objectives were assessment of safety, side-effect profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.  Tumor biopsies to identify T790M were performed during screening.  Treatment was administered in continuous 21-day cycles.  RESULTS:  A total of 130 patients were enrolled.  The first 57 patients to be enrolled received the free-base form of rociletinib (150 mg once daily to 900 mg twice daily).  The remaining patients received the hydrogen bromide salt (HBr) form (500 mg twice daily to 1000 mg twice daily).  A maximum tolerated dose (the highest dose associated with a rate of dose-limiting toxic effects of less than 33%) was not identified.  The only common dose-limiting adverse event was hyperglycemia.  In an efficacy analysis that included patients who received free-base rociletinib at a dose of 900 mg twice daily or the HBr form at any dose, the objective response rate among the 46 patients with T790M-positive disease who could be evaluated was 59% (95% confidence interval [CI], 45 to 73), and the rate among the 17 patients with T790M-negative disease who could be evaluated was 29% (95% CI, 8 to 51).  CONCLUSIONS:  Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation. (Funded by Clovis Oncology; ClinicalTrials.gov number, NCT01526928.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQME11ovAjH3ZPq5LRczm8ffW6udTcc2eZcJwMt_nf-f7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mjpt1yltQ%253D%253D&md5=5a5d21d36c081a5ef0f9e650d5cc84b9</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1413654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1413654%26sid%3Dliteratum%253Aachs%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DSoria%26aufirst%3DJ.-C.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DWakelee%26aufirst%3DH.%2BA.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DVarga%26aufirst%3DA.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DDziadziuszko%26aufirst%3DR.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DGalasso%26aufirst%3DC.%26aulast%3DGaron%26aufirst%3DE.%2BB.%26aulast%3DHeist%26aufirst%3DR.%2BS.%26aulast%3DLogan%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DJ.%2BW.%26aulast%3DMendenhall%26aufirst%3DM.%2BA.%26aulast%3DNichols%26aufirst%3DS.%26aulast%3DPiotrowska%26aufirst%3DZ.%26aulast%3DWozniak%26aufirst%3DA.%2BJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DKarlovich%26aufirst%3DC.%2BA.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DIsaacson%26aufirst%3DJ.%26aulast%3DDespain%26aufirst%3DD.%26aulast%3DMatheny%26aufirst%3DS.%2BL.%26aulast%3DRolfe%26aufirst%3DL.%26aulast%3DAllen%26aufirst%3DA.%2BR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DRociletinib%2520in%2520EGFR-mutated%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1700%26epage%3D1709%26doi%3D10.1056%2FNEJMoa1413654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grohe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majem, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laktionov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, H.-V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akewanlop, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonanno, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodge, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atasoy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rukazenkov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, R. S.</span></span> <span> </span><span class="NLM_article-title">Osimertinib in resected EGFR-mutated non–small-cell lung cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>383</i></span>,  <span class="NLM_fpage">1711</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa2027071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1056%2FNEJMoa2027071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=32955177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1WltbvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=383&publication_year=2020&pages=1711-1723&author=Y.-L.+Wuauthor=M.+Tsuboiauthor=J.+Heauthor=T.+Johnauthor=C.+Groheauthor=M.+Majemauthor=J.+W.+Goldmanauthor=K.+Laktionovauthor=S.-W.+Kimauthor=T.+Katoauthor=H.-V.+Vuauthor=S.+Luauthor=K.-Y.+Leeauthor=C.+Akewanlopauthor=C.-J.+Yuauthor=F.+de+Marinisauthor=L.+Bonannoauthor=M.+Domineauthor=F.+A.+Shepherdauthor=L.+Zengauthor=R.+Hodgeauthor=A.+Atasoyauthor=Y.+Rukazenkovauthor=R.+S.+Herbst&title=Osimertinib+in+resected+EGFR-mutated+non%E2%80%93small-cell+lung+cancer&doi=10.1056%2FNEJMoa2027071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib in resected EGFR-mutated non-small-cell lung cancer</span></div><div class="casAuthors">Wu, Yi-Long; Tsuboi, Masahiro; He, Jie; John, Thomas; Grohe, Christian; Majem, Margarita; Goldman, Jonathan W.; Laktionov, Konstantin; Kim, Sang-We; Kato, Terufumi; Vu, Huu-Vinh; Lu, Shun</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">383</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1711-1723</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Osimertinib is std.-of-care therapy for previously untreated epidermal growth factor receptor (EGFR) mutation-pos. advanced non-small-cell lung cancer (NSCLC).  The efficacy and safety of osimertinib as adjuvant therapy are unknown. methods In this double-blind, phase 3 trial, we randomly assigned patients with completely resected EGFR mutation-pos. NSCLC in a 1:1 ratio to receive either osimertinib (80 mg once daily) or placebo for 3 years.  The primary end point was disease-free survival among patients with stage II to IIIA disease (according to investigator assessment).  The secondary end points included disease-free survival in the overall population of patients with stage IB to IIIA disease, overall survival, and safety. results A total of 682 patients underwent randomization (339 to the osimertinib group and 343 to the placebo group).  At 24 mo, 90% of the patients with stage II to IIIA disease in the osimertinib group (95% confidence interval [CI], 84 to 93) and 44% of those in the placebo group (95% CI, 37 to 51) were alive and disease-free (overall hazard ratio for disease recurrence or death, 0.17; 99.06% CI, 0.11 to 0.26; P<0.001).  In the overall population, 89% of the patients in the osimertinib group (95% CI, 85 to 92) and 52% of those in the placebo group (95% CI, 46 to 58) were alive and disease-free at 24 mo (overall hazard ratio for disease recurrence or death, 0.20; 99.12% CI, 0.14 to 0.30; P<0.001).  At 24 mo, 98% of the patients in the osimertinib group (95% CI, 95 to 99) and 85% of those in the placebo group (95% CI, 80 to 89) were alive and did not have central nervous system disease (overall hazard ratio for disease recurrence or death, 0.18; 95% CI, 0.10 to 0.33).  Overall survival data were immature; 29 patients died (9 in the osimertinib group and 20 in the placebo group).  No new safety concerns were noted. conclusions In patients with stage IB to IIIA EGFR mutation-pos. NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRzcWa1nfJ2bVg90H21EOLACvtfcHk0ljQVRjeEucDqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1WltbvJ&md5=ee10dbb28360a197acd6ebcf3b5ddd80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2027071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2027071%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DY.-L.%26aulast%3DTsuboi%26aufirst%3DM.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DJohn%26aufirst%3DT.%26aulast%3DGrohe%26aufirst%3DC.%26aulast%3DMajem%26aufirst%3DM.%26aulast%3DGoldman%26aufirst%3DJ.%2BW.%26aulast%3DLaktionov%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DKato%26aufirst%3DT.%26aulast%3DVu%26aufirst%3DH.-V.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DK.-Y.%26aulast%3DAkewanlop%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.-J.%26aulast%3Dde%2BMarinis%26aufirst%3DF.%26aulast%3DBonanno%26aufirst%3DL.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DZeng%26aufirst%3DL.%26aulast%3DHodge%26aufirst%3DR.%26aulast%3DAtasoy%26aufirst%3DA.%26aulast%3DRukazenkov%26aufirst%3DY.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26atitle%3DOsimertinib%2520in%2520resected%2520EGFR-mutated%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D383%26spage%3D1711%26epage%3D1723%26doi%3D10.1056%2FNEJMoa2027071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayaz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span> <span> </span><span class="NLM_article-title">Structural basis of AZD9291 selectivity for EGFR T790M</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8502</span>– <span class="NLM_lpage">8511</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00891</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00891" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8502-8511&author=X.-E.+Yanauthor=P.+Ayazauthor=S.-J.+Zhuauthor=P.+Zhaoauthor=L.+Liangauthor=C.+H.+Zhangauthor=Y.-C.+Wuauthor=J.-L.+Liauthor=H.+G.+Choiauthor=X.+Huangauthor=Y.+Shanauthor=D.+E.+Shawauthor=C.-H.+Yun&title=Structural+basis+of+AZD9291+selectivity+for+EGFR+T790M&doi=10.1021%2Facs.jmedchem.0c00891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of AZD9291 Selectivity for EGFR T790M</span></div><div class="casAuthors">Yan, Xiao-E.; Ayaz, Pelin; Zhu, Su-Jie; Zhao, Peng; Liang, Ling; Zhang, Casey H.; Wu, Ya-Chuang; Li, Je-Luen; Choi, Hwan Geun; Huang, Xin; Shan, Yibing; Shaw, David E.; Yun, Cai-Hong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8502-8511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">AZD9291 (Osimertinib) is highly effective in treating EGFR-mutated non-small-cell lung cancers (NSCLCs) with T790M-mediated drug resistance.  Despite the remarkable success of AZD9291, its binding pose with EGFR T790M remains unclear.  Here, we report unbiased, at.-level mol. dynamics (MD) simulations in which spontaneous assocn. of AZD9291 with EGFR kinases having WT and T790M mutant gatekeepers was obsd.  Simulation-generated structural models suggest that the binding pose of AZD9291 with T790M differs from its binding pose with the WT, and that AZD9291 interacts extensively with the gatekeeper residue (Met 790) in T790M but not with Thr 790 in the WT, which explains why AZD9291 binds T790M with higher affinity.  The MD simulation-generated models were confirmed by exptl. detd. EGFR/T790M complex crystal structures.  This work may facilitate the rational design of drugs that can overcome resistance mutations to AZD9291, and more generally it suggests the potential of using unbiased MD simulation to elucidate small-mol. binding poses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcjAuoE85GWLVg90H21EOLACvtfcHk0ljQVRjeEucDqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsL7K&md5=8fd2853a9495729019f23d8d9b2595ab</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00891%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DX.-E.%26aulast%3DAyaz%26aufirst%3DP.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DLiang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DWu%26aufirst%3DY.-C.%26aulast%3DLi%26aufirst%3DJ.-L.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DShan%26aufirst%3DY.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DYun%26aufirst%3DC.-H.%26atitle%3DStructural%2520basis%2520of%2520AZD9291%2520selectivity%2520for%2520EGFR%2520T790M%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8502%26epage%3D8511%26doi%3D10.1021%2Facs.jmedchem.0c00891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yver, A.</span></span> <span> </span><span class="NLM_article-title">Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1170</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdw129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1093%2Fannonc%2Fmdw129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=26961148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=1165-1170&author=A.+Yver&title=Osimertinib+%28AZD9291%29%E2%80%94a+science-driven%2C+collaborative+approach+to+rapid+drug+design+and+development&doi=10.1093%2Fannonc%2Fmdw129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development</span></div><div class="casAuthors">Yver A</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1165-1170</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTcfXYyifUoEewzGPswiWOfW6udTcc2eZRxUHb284CK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28joslCgsA%253D%253D&md5=903bbb3edf2d109af352ef0354e4bca6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdw129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdw129%26sid%3Dliteratum%253Aachs%26aulast%3DYver%26aufirst%3DA.%26atitle%3DOsimertinib%2520%2528AZD9291%2529%25E2%2580%2594a%2520science-driven%252C%2520collaborative%2520approach%2520to%2520rapid%2520drug%2520design%2520and%2520development%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D1165%26epage%3D1170%26doi%3D10.1093%2Fannonc%2Fmdw129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Böse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petronczki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bader, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döbel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engelhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonnella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondal, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haddad, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopfgartner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kousek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krawiec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simov, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnitzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrenk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharps, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoephel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McConnell, D. B.</span></span> <span> </span><span class="NLM_article-title">Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">10272</span>– <span class="NLM_lpage">10293</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=10272-10293&author=H.+Engelhardtauthor=D.+B%C3%B6seauthor=M.+Petronczkiauthor=D.+Scharnauthor=G.+Baderauthor=A.+Baumauthor=A.+Bergnerauthor=E.+Chongauthor=S.+D%C3%B6belauthor=G.+Eggerauthor=C.+Engelhardtauthor=P.+Ettmayerauthor=J.+E.+Fuchsauthor=T.+Gerstbergerauthor=N.+Gonnellaauthor=A.+Grimmauthor=E.+Grondalauthor=N.+Haddadauthor=B.+Hopfgartnerauthor=R.+Kousekauthor=M.+Krawiecauthor=M.+Krizauthor=L.+Lamarreauthor=J.+Leungauthor=M.+Mayerauthor=N.+D.+Patelauthor=B.+P.+Simovauthor=J.+T.+Reevesauthor=R.+Schnitzerauthor=A.+Schrenkauthor=B.+Sharpsauthor=F.+Solcaauthor=H.+Stadtm%C3%BCllerauthor=Z.+Tanauthor=T.+Wunbergauthor=A.+Zoephelauthor=D.+B.+McConnell&title=Start+selective+and+rigidify%3A+the+discovery+path+toward+a+next+generation+of+EGFR+tyrosine+kinase+inhibitors&doi=10.1021%2Facs.jmedchem.9b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Engelhardt, Harald; Boese, Dietrich; Petronczki, Mark; Scharn, Dirk; Bader, Gerd; Baum, Anke; Bergner, Andreas; Chong, Eugene; Doebel, Sandra; Egger, Georg; Engelhardt, Christian; Ettmayer, Peter; Fuchs, Julian E.; Gerstberger, Thomas; Gonnella, Nina; Grimm, Andreas; Grondal, Elisabeth; Haddad, Nizar; Hopfgartner, Barbara; Kousek, Roland; Krawiec, Mariusz; Kriz, Monika; Lamarre, Lyne; Leung, Joyce; Mayer, Moriz; Patel, Nitinchandra D.; Simov, Biljana Peric; Reeves, Jonathan T.; Schnitzer, Renate; Schrenk, Andreas; Sharps, Bernadette; Solca, Flavio; Stadtmueller, Heinz; Tan, Zhulin; Wunberg, Tobias; Zoephel, Andreas; McConnell, Darryl B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10272-10293</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors.  While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable.  Most patients relapse within two years of therapy often due to acquisition of an addnl. mutation in EGFR kinase domain that confers resistance to TKIs.  Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs.  Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI.  BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model.  Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the mol. through macrocyclization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmZRwjkT9vdLVg90H21EOLACvtfcHk0lhe5zeqdsilxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFSqtLvK&md5=0f8d0eed6ae93bfbb8f7a6337bb1ecd3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01169%26sid%3Dliteratum%253Aachs%26aulast%3DEngelhardt%26aufirst%3DH.%26aulast%3DB%25C3%25B6se%26aufirst%3DD.%26aulast%3DPetronczki%26aufirst%3DM.%26aulast%3DScharn%26aufirst%3DD.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DBergner%26aufirst%3DA.%26aulast%3DChong%26aufirst%3DE.%26aulast%3DD%25C3%25B6bel%26aufirst%3DS.%26aulast%3DEgger%26aufirst%3DG.%26aulast%3DEngelhardt%26aufirst%3DC.%26aulast%3DEttmayer%26aufirst%3DP.%26aulast%3DFuchs%26aufirst%3DJ.%2BE.%26aulast%3DGerstberger%26aufirst%3DT.%26aulast%3DGonnella%26aufirst%3DN.%26aulast%3DGrimm%26aufirst%3DA.%26aulast%3DGrondal%26aufirst%3DE.%26aulast%3DHaddad%26aufirst%3DN.%26aulast%3DHopfgartner%26aufirst%3DB.%26aulast%3DKousek%26aufirst%3DR.%26aulast%3DKrawiec%26aufirst%3DM.%26aulast%3DKriz%26aufirst%3DM.%26aulast%3DLamarre%26aufirst%3DL.%26aulast%3DLeung%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DN.%2BD.%26aulast%3DSimov%26aufirst%3DB.%2BP.%26aulast%3DReeves%26aufirst%3DJ.%2BT.%26aulast%3DSchnitzer%26aufirst%3DR.%26aulast%3DSchrenk%26aufirst%3DA.%26aulast%3DSharps%26aufirst%3DB.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DWunberg%26aufirst%3DT.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DMcConnell%26aufirst%3DD.%2BB.%26atitle%3DStart%2520selective%2520and%2520rigidify%253A%2520the%2520discovery%2520path%2520toward%2520a%2520next%2520generation%2520of%2520EGFR%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D10272%26epage%3D10293%26doi%3D10.1021%2Facs.jmedchem.9b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of 5-methylpyrimidopyridone derivatives as new wild-type sparing inhibitors of the epidermal growth factor receptor triple mutant (EGFRL858R/T790M/C797S)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7302</span>– <span class="NLM_lpage">7308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00576</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00576" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7302-7308&author=J.+Shenauthor=T.+Zhangauthor=S.-J.+Zhuauthor=M.+Sunauthor=L.+Tongauthor=M.+Laiauthor=R.+Zhangauthor=W.+Xuauthor=R.+Wuauthor=J.+Dingauthor=C.-H.+Yunauthor=H.+Xieauthor=X.+Luauthor=K.+Ding&title=Structure-based+design+of+5-methylpyrimidopyridone+derivatives+as+new+wild-type+sparing+inhibitors+of+the+epidermal+growth+factor+receptor+triple+mutant+%28EGFRL858R%2FT790M%2FC797S%29&doi=10.1021%2Facs.jmedchem.9b00576"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S)</span></div><div class="casAuthors">Shen, Jiayi; Zhang, Tao; Zhu, Su-Jie; Sun, Min; Tong, Linjiang; Lai, Mengzhen; Zhang, Rong; Xu, Wei; Wu, Ruibo; Ding, Jian; Yun, Cai-Hong; Xie, Hua; Lu, Xiaoyun; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7302-7308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Azaheterocyclyl-substituted pyridopyrimidinones such as I were prepd. as selective inhibitors of the mutant epidermal growth factor receptor (EGFR) EGFRL858R/T790M/C797S with selectivity over the wild-type EGFR for potential use in treating osimertinib-resistant non-small-cell lung cancer.  I exhibited an IC50 of 27.5 nM against the EGFRL858R/T790M/C797S mutant, while being significantly less potent against the wild-type EGFR with an IC50 value of > 1.0 μM.  Cocrystallog. structure detn. and computational investigation were conducted to elucidate its target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQFRlnoJItB7Vg90H21EOLACvtfcHk0lhe5zeqdsilxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhurnI&md5=70ca1144f3b73d0ccd412406b1072a1f</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DS.-J.%26aulast%3DSun%26aufirst%3DM.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DR.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DStructure-based%2520design%2520of%25205-methylpyrimidopyridone%2520derivatives%2520as%2520new%2520wild-type%2520sparing%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520triple%2520mutant%2520%2528EGFRL858R%252FT790M%252FC797S%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7302%26epage%3D7308%26doi%3D10.1021%2Facs.jmedchem.9b00576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz-Fademrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengstler, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Structure-guided development of covalent and mutant-selective pyrazolopyrimidines to target T790M drug resistance in epidermal growth factor receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7725</span>– <span class="NLM_lpage">7744</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00515</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00515" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVWmsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7725-7744&author=J.+Engelauthor=S.+Smithauthor=J.+Lategahnauthor=H.+L.+Tumbrinkauthor=L.+Goebelauthor=C.+Beckerauthor=E.+Hennesauthor=M.+Keulauthor=A.+Ungerauthor=H.+M%C3%BCllerauthor=M.+Baumannauthor=C.+Schultz-Fademrechtauthor=G.+G%C3%BCntherauthor=J.+G.+Hengstlerauthor=D.+Rauh&title=Structure-guided+development+of+covalent+and+mutant-selective+pyrazolopyrimidines+to+target+T790M+drug+resistance+in+epidermal+growth+factor+receptor&doi=10.1021%2Facs.jmedchem.7b00515"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor</span></div><div class="casAuthors">Engel, Julian; Smith, Steven; Lategahn, Jonas; Tumbrink, Hannah L.; Goebel, Lisa; Becker, Christian; Hennes, Elisabeth; Keul, Marina; Unger, Anke; Mueller, Heiko; Baumann, Matthias; Schultz-Fademrecht, Carsten; Guenther, Georgia; Hengstler, Jan G.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7725-7744</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors prompt a beneficial clin. response in non-small cell lung cancer patients who harbor activating mutations in EGFR.  However, resistance mutations, particularly the gatekeeper mutation T790M, limit this efficacy.  Here, we describe a structure-guided development of a series of covalent and mutant-selective EGFR inhibitors that effectively target the T790M mutant.  The pyrazolopyrimidine-based core differs structurally from that of aminopyrimidine-based third-generation EGFR inhibitors and therefore constitutes a new set of inhibitors that target this mechanism of drug resistance.  These inhibitors exhibited strong inhibitory effects toward EGFR kinase activity and excellent inhibition of cell growth in the drug-resistant cell line H1975, without significantly affecting EGFR wild-type cell lines.  Addnl., we present the in vitro ADME/DMPK parameters for a subset of the inhibitors as well as in vivo pharmacokinetics in mice for a candidate with promising activity profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJrYeYCvPOGLVg90H21EOLACvtfcHk0lhe5zeqdsilxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVWmsrjL&md5=5342017ac4e77f37516dcd8564c5a4b1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00515%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DGoebel%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DHennes%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DH.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DG%25C3%25BCnther%26aufirst%3DG.%26aulast%3DHengstler%26aufirst%3DJ.%2BG.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructure-guided%2520development%2520of%2520covalent%2520and%2520mutant-selective%2520pyrazolopyrimidines%2520to%2520target%2520T790M%2520drug%2520resistance%2520in%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7725%26epage%3D7744%26doi%3D10.1021%2Facs.jmedchem.7b00515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juchum, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Döring, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S.</span></span> <span> </span><span class="NLM_article-title">Trisubstituted pyridinylimidazoles as potent inhibitors of the clinically resistant L858R/T790M/C797S EGFR mutant: targeting of both hydrophobic regions and the phosphate binding site</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5613</span>– <span class="NLM_lpage">5637</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00316</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00316" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5613-5637&author=M.+G%C3%BCntherauthor=J.+Lategahnauthor=M.+Juchumauthor=E.+D%C3%B6ringauthor=M.+Keulauthor=J.+Engelauthor=H.+L.+Tumbrinkauthor=D.+Rauhauthor=S.+Laufer&title=Trisubstituted+pyridinylimidazoles+as+potent+inhibitors+of+the+clinically+resistant+L858R%2FT790M%2FC797S+EGFR+mutant%3A+targeting+of+both+hydrophobic+regions+and+the+phosphate+binding+site&doi=10.1021%2Facs.jmedchem.7b00316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site</span></div><div class="casAuthors">Guenther, Marcel; Lategahn, Jonas; Juchum, Michael; Doering, Eva; Keul, Marina; Engel, Julian; Tumbrink, Hannah L.; Rauh, Daniel; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5613-5637</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the epidermal growth factor receptor represents one of the most promising strategies in the treatment of lung cancer.  Acquired resistance compromises the clin. efficacy of EGFR inhibitors during long-term treatment.  The recently discovered EGFR-C797S mutation causes resistance against third-generation EGFR inhibitors.  Here we present a rational approach based on extending the inhibition profile of a p38 MAP kinase inhibitor toward mutant EGFR inhibition.  We used a privileged scaffold with proven cellular potency as well as in vivo efficacy and low toxicity.  Guided by mol. modeling, we synthesized and studied the structure-activity relationship of 40 compds. against clin. relevant EGFR mutants.  We successfully improved the cellular EGFR inhibition down to the low nanomolar range with covalently binding inhibitors against a gefitinib resistant T790M mutant cell line.  We identified addnl. noncovalent interactions, which allowed us to develop metabolically stable inhibitors with high activities against the osimertinib resistant L858R/T790M/C797S mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrikF9dZWUv2bVg90H21EOLACvtfcHk0lhSuyeB5reoCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpslSrsL0%253D&md5=b258bbd393c9738cb68062c53dcc093f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00316%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DJuchum%26aufirst%3DM.%26aulast%3DD%25C3%25B6ring%26aufirst%3DE.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DTrisubstituted%2520pyridinylimidazoles%2520as%2520potent%2520inhibitors%2520of%2520the%2520clinically%2520resistant%2520L858R%252FT790M%252FC797S%2520EGFR%2520mutant%253A%2520targeting%2520of%2520both%2520hydrophobic%2520regions%2520and%2520the%2520phosphate%2520binding%2520site%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5613%26epage%3D5637%26doi%3D10.1021%2Facs.jmedchem.7b00316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heppner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Günther, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittlinger, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laufer, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structural basis for EGFR mutant inhibition by trisubstituted imidazole inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4293</span>– <span class="NLM_lpage">4305</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4293-4305&author=D.+E.+Heppnerauthor=M.+G%C3%BCntherauthor=F.+Wittlingerauthor=S.+A.+Lauferauthor=M.+J.+Eck&title=Structural+basis+for+EGFR+mutant+inhibition+by+trisubstituted+imidazole+inhibitors&doi=10.1021%2Facs.jmedchem.0c00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors</span></div><div class="casAuthors">Heppner, David E.; Gunther, Marcel; Wittlinger, Florian; Laufer, Stefan A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4293-4305</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Acquired drug resistance in epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer is a persistent challenge in cancer therapy.  Previous studies of trisubstituted imidazole inhibitors led to the serendipitous discovery of inhibitors that target the drug resistant EGFR(L858R/T790M/C797S) mutant with nanomolar potencies in a reversible binding mechanism.  To dissect the mol. basis for their activity, we detd. the binding modes of several trisubstituted imidazole inhibitors in complex with the EGFR kinase domain with X-ray crystallog.  These structures reveal that the imidazole core acts as an H-bond acceptor for the catalytic lysine (K745) in the "αC-helix out" inactive state.  Selective N-methylation of the H-bond accepting nitrogen ablates inhibitor potency, confirming the role of the K745 H-bond in potent, noncovalent inhibition of the C797S variant.  Insights from these studies offer new strategies for developing next generation inhibitors targeting EGFR in non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHNY-o4bNl6bVg90H21EOLACvtfcHk0lhSuyeB5reoCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtl2mtbc%253D&md5=0ee498e9de51374ad9a049d7ffd9fa24</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00200%26sid%3Dliteratum%253Aachs%26aulast%3DHeppner%26aufirst%3DD.%2BE.%26aulast%3DG%25C3%25BCnther%26aufirst%3DM.%26aulast%3DWittlinger%26aufirst%3DF.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructural%2520basis%2520for%2520EGFR%2520mutant%2520inhibition%2520by%2520trisubstituted%2520imidazole%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4293%26epage%3D4305%26doi%3D10.1021%2Facs.jmedchem.0c00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almaden, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behenna, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho-Schultz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalvie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinh, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hemkens, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson-Fisher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalaie, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafontaine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, K. K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ornelas, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orr, S. T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sach, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vernier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walls, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zientek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span> <span> </span><span class="NLM_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a potent, WT sparing, irreversible inhibitor of T790M-containing EGFR mutants</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2005</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01633</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01633" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2005-2024&author=H.+Chengauthor=S.+K.+Nairauthor=B.+W.+Murrayauthor=C.+Almadenauthor=S.+Baileyauthor=S.+Baxiauthor=D.+Behennaauthor=S.+Cho-Schultzauthor=D.+Dalvieauthor=D.+M.+Dinhauthor=M.+P.+Edwardsauthor=J.+L.+Fengauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+D.+Hemkensauthor=A.+Jackson-Fisherauthor=M.+Jalaieauthor=T.+O.+Johnsonauthor=R.+S.+Kaniaauthor=S.+Kephartauthor=J.+Lafontaineauthor=B.+Lunneyauthor=K.+K.+C.+Liuauthor=Z.+Liuauthor=J.+Matthewsauthor=A.+Nagataauthor=S.+Niessenauthor=M.+A.+Ornelasauthor=S.+T.+M.+Orrauthor=M.+Pairishauthor=S.+Plankenauthor=S.+Renauthor=D.+Richterauthor=K.+Ryanauthor=N.+Sachauthor=H.+Shenauthor=T.+Smealauthor=J.+Solowiejauthor=S.+Suttonauthor=K.+Tranauthor=E.+Tsengauthor=W.+Vernierauthor=M.+Wallsauthor=S.+Wangauthor=S.+L.+Weinrichauthor=S.+Xinauthor=H.+Xuauthor=M.-J.+Yinauthor=M.+Zientekauthor=R.+Zhouauthor=J.+C.+Kath&title=Discovery+of+1-%7B%283R%2C4R%29-3-%5B%28%7B5-Chloro-2-%5B%281-methyl-1H-pyrazol-4-yl%29amino%5D-7H-pyrrolo%5B2%2C3-d%5Dpyrimidin-4-yl%7Doxy%29methyl%5D-4-methoxypyrrolidin-1-yl%7Dprop-2-en-1-one+%28PF-06459988%29%2C+a+potent%2C+WT+sparing%2C+irreversible+inhibitor+of+T790M-containing+EGFR+mutants&doi=10.1021%2Facs.jmedchem.5b01633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</span></div><div class="casAuthors">Cheng, Hengmiao; Nair, Sajiv K.; Murray, Brion W.; Almaden, Chau; Bailey, Simon; Baxi, Sangita; Behenna, Doug; Cho-Schultz, Sujin; Dalvie, Deepak; Dinh, Dac M.; Edwards, Martin P.; Feng, Jun Li; Ferre, Rose Ann; Gajiwala, Ketan S.; Hemkens, Michelle D.; Jackson-Fisher, Amy; Jalaie, Mehran; Johnson, Ted O.; Kania, Robert S.; Kephart, Susan; Lafontaine, Jennifer; Lunney, Beth; Liu, Kevin K.-C.; Liu, Zhengyu; Matthews, Jean; Nagata, Asako; Niessen, Sherry; Ornelas, Martha A.; Orr, Suvi T. M.; Pairish, Mason; Planken, Simon; Ren, Shijian; Richter, Daniel; Ryan, Kevin; Sach, Neal; Shen, Hong; Smeal, Tod; Solowiej, Jim; Sutton, Scott; Tran, Khanh; Tseng, Elaine; Vernier, William; Walls, Marlena; Wang, Shuiwang; Weinrich, Scott L.; Xin, Shuibo; Xu, Haiwei; Yin, Min-Jean; Zientek, Michael; Zhou, Ru; Kath, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2005-2024</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">First generation EGFR TKIs (gefitinib, erlotinib) provide significant clin. benefit for NSCLC cancer patients with oncogenic EGFR mutations.  Ultimately, these patients' disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M).  Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR.  As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR.  A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort.  PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-contg. double mutant EGFRs, (ii) minimal intrinsic chem. reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfRspJvDDNKrVg90H21EOLACvtfcHk0lj8VpO1nquykw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslChtQ%253D%253D&md5=b8c07b22033543305964c9e8771f3db5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DNair%26aufirst%3DS.%2BK.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DBaxi%26aufirst%3DS.%26aulast%3DBehenna%26aufirst%3DD.%26aulast%3DCho-Schultz%26aufirst%3DS.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DDinh%26aufirst%3DD.%2BM.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BL.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHemkens%26aufirst%3DM.%2BD.%26aulast%3DJackson-Fisher%26aufirst%3DA.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DKephart%26aufirst%3DS.%26aulast%3DLafontaine%26aufirst%3DJ.%26aulast%3DLunney%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DK.%2BK.%2BC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMatthews%26aufirst%3DJ.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DOrnelas%26aufirst%3DM.%2BA.%26aulast%3DOrr%26aufirst%3DS.%2BT.%2BM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DPlanken%26aufirst%3DS.%26aulast%3DRen%26aufirst%3DS.%26aulast%3DRichter%26aufirst%3DD.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSach%26aufirst%3DN.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DSmeal%26aufirst%3DT.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DSutton%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DK.%26aulast%3DTseng%26aufirst%3DE.%26aulast%3DVernier%26aufirst%3DW.%26aulast%3DWalls%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWeinrich%26aufirst%3DS.%2BL.%26aulast%3DXin%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DYin%26aufirst%3DM.-J.%26aulast%3DZientek%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520of%25201-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2520%2528PF-06459988%2529%252C%2520a%2520potent%252C%2520WT%2520sparing%252C%2520irreversible%2520inhibitor%2520of%2520T790M-containing%2520EGFR%2520mutants%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2005%26epage%3D2024%26doi%3D10.1021%2Facs.jmedchem.5b01633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lj8VpO1nquykw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhWjomxDSRRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dickinson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frewer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickup, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span> <span> </span><span class="NLM_article-title">Metabolic disposition of Osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">1201</span>– <span class="NLM_lpage">1212</span>, <span class="refDoi"> DOI: 10.1124/dmd.115.069203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1124%2Fdmd.115.069203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=27226351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVajtb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2016&pages=1201-1212&author=P.+A.+Dickinsonauthor=M.+V.+Cantariniauthor=J.+Collierauthor=P.+Frewerauthor=S.+Martinauthor=K.+Pickupauthor=P.+Ballard&title=Metabolic+disposition+of+Osimertinib+in+rats%2C+dogs%2C+and+humans%3A+insights+into+a+drug+designed+to+bind+covalently+to+a+cysteine+residue+of+epidermal+growth+factor+receptor&doi=10.1124%2Fdmd.115.069203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor</span></div><div class="casAuthors">Dickinson, Paul A.; Cantarini, Mireille V.; Collier, Jo; Frewer, Paul; Martin, Scott; Pickup, Kathryn; Ballard, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism & Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1201-1212</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">1521-009X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Preclin. and clin. studies were conducted to det. the metab. and pharmacokinetics of osimertinib and key metabolites AZ5104 and AZ7550.  Osimertinib was designed to covalently bind to epidermal growth factor receptors, allowing it to achieve nanomolar cellular potency.  Covalent binding was obsd. in incubations of radiolabeled osimertinib with human and rat hepatocytes, human and rat plasma, and human serum albumin.  Osimertinib, AZ5104, and AZ7550 were predominantly metabolized by CYP3A.  Seven metabolites were detected in human hepatocytes, also obsd. in rat or dog hepatocytes at similar or higher levels.  After oral administration of radiolabeled osimertinib to rats, drug-related material was widely distributed, with the highest radioactivity concns. measured at 6 h postdose in most tissues; radioactivity was detectable in 42% of tissues 60 days postdose.  Concns. of [14C]-radioactivity in blood were lower than in most tissues.  After the administration of a single oral dose of 20 mg of radiolabeled osimertinib to healthy male volunteers, ∼19% of the dose was recovered by 3 days postdose.  At 84 days postdose, mean total radioactivity recovery was 14.2% and 67.8% of the dose in urine and feces.  The most abundant metabolite identified in feces was AZ5104 (∼6% of dose).  Osimertinib accounted for ∼1% of total radioactivity in the plasma of non-small cell lung cancer patients after 22 days of 80-mg osimertinib once-daily treatment; the most abundant circulatory metabolites were AZ7550 and AZ5104 (<10% of total osimertinib-related material).  Osimertinib is extensively distributed and metabolized in humans and is eliminated primarily via the fecal route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqslCW8h-RI9bVg90H21EOLACvtfcHk0lhWjomxDSRRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVajtb%252FO&md5=4115de7691a3b39eec091660b5e5b1d6</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fdmd.115.069203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.115.069203%26sid%3Dliteratum%253Aachs%26aulast%3DDickinson%26aufirst%3DP.%2BA.%26aulast%3DCantarini%26aufirst%3DM.%2BV.%26aulast%3DCollier%26aufirst%3DJ.%26aulast%3DFrewer%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DPickup%26aufirst%3DK.%26aulast%3DBallard%26aufirst%3DP.%26atitle%3DMetabolic%2520disposition%2520of%2520Osimertinib%2520in%2520rats%252C%2520dogs%252C%2520and%2520humans%253A%2520insights%2520into%2520a%2520drug%2520designed%2520to%2520bind%2520covalently%2520to%2520a%2520cysteine%2520residue%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2016%26volume%3D44%26spage%3D1201%26epage%3D1212%26doi%3D10.1124%2Fdmd.115.069203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khozin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinstock, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenthal, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charlab, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">Osimertinib for the treatment of metastatic EGFR T790M mutation–positive non–small cell lung cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2131</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-16-1773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1158%2F1078-0432.CCR-16-1773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=27923840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFegtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=2131&author=S.+Khozinauthor=C.+Weinstockauthor=G.+M.+Blumenthalauthor=J.+Chengauthor=K.+Heauthor=L.+Zhuangauthor=H.+Zhaoauthor=R.+Charlabauthor=I.+Fanauthor=P.+Keeganauthor=R.+Pazdur&title=Osimertinib+for+the+treatment+of+metastatic+EGFR+T790M+mutation%E2%80%93positive+non%E2%80%93small+cell+lung+cancer&doi=10.1158%2F1078-0432.CCR-16-1773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Khozin, Sean; Weinstock, Chana; Blumenthal, Gideon M.; Cheng, Joyce; He, Kun; Zhuang, Luning; Zhao, Hong; Charlab, Rosane; Fan, Ingrid; Keegan, Patricia; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2131-2135</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On Nov. 13, 2015, the FDA granted accelerated approval to osimertinib (TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the treatment of patients with metastatic EGFR T790M mutation-pos. non-small cell lung cancer, as detected by an FDA-approved test, with progression on or after EGFR tyrosine kinase inhibitor therapy.  Approval was based on durable tumor response rates in two single-arm, multicenter trials: the dose extension cohort of a first-in-human trial (FIH; AURA extension; n = 201) and a fixed-dose, activity-estg. trial (AURA2; n = 210).  Osimertinib was administered at 80 mg orally once daily.  The objective response rates (ORR) per blinded independent committee review were 57% [95% confidence interval (CI), 50-64] in AURA extension and 61% (95% CI, 54-68) in AURA2. Median duration of response (DOR) could not be estd.  Supportive efficacy data from 63 patients in the dose-finding part of the FIH trial demonstrated an ORR of 51% (95% CI, 38-64), with a median DOR of 12.4 mo.  Common adverse events (AE) evaluated in 411 patients included diarrhea (42%), rash (41%), dry skin (31%), and nail toxicity (25%).  Grade 3 to 4 AEs occurred in 28% of patients, and 5.6% discontinued treatment due to AEs.  Clin Cancer Res; 23(9); 2131-5. ©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd_rTdjsi7krVg90H21EOLACvtfcHk0lhWjomxDSRRBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFegtb8%253D&md5=b18e69d7192c21d88c6333aade5a64fc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-16-1773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-16-1773%26sid%3Dliteratum%253Aachs%26aulast%3DKhozin%26aufirst%3DS.%26aulast%3DWeinstock%26aufirst%3DC.%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DK.%26aulast%3DZhuang%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DCharlab%26aufirst%3DR.%26aulast%3DFan%26aufirst%3DI.%26aulast%3DKeegan%26aufirst%3DP.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DOsimertinib%2520for%2520the%2520treatment%2520of%2520metastatic%2520EGFR%2520T790M%2520mutation%25E2%2580%2593positive%2520non%25E2%2580%2593small%2520cell%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D2131%26doi%3D10.1158%2F1078-0432.CCR-16-1773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gant, T. G.</span></span> <span> </span><span class="NLM_article-title">Using deuterium in drug discovery: leaving the label in the drug</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">3595</span>– <span class="NLM_lpage">3611</span>, <span class="refDoi"> DOI: 10.1021/jm4007998</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4007998" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3595-3611&author=T.+G.+Gant&title=Using+deuterium+in+drug+discovery%3A+leaving+the+label+in+the+drug&doi=10.1021%2Fjm4007998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Using Deuterium in Drug Discovery: Leaving the Label in the Drug</span></div><div class="casAuthors">Gant, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3595-3611</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Deuterium, the stable isotope of hydrogen, is known to medicinal chemists for its utility in mechanistic, spectroscopic, and tracer studies.  In fact, well-known applications utilizing deuterium exist within every subdiscipline in pharmaceutical discovery and development.  Recent emphasis on incorporation of deuterium into the active pharmaceutical ingredient has come about as a result of inquiries into the potential for substantial benefits of the deuterium kinetic isotope effect on the safety and disposition of the drug substance.  This Perspective traces the author's experience in reviving and expanding this potential utility, first suggested many decades prior by the discoverer of this, the simplest of all isotopes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4z14tbfBfBbVg90H21EOLACvtfcHk0lh7wf0oyuO6Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsrvJ&md5=3818a1dba9be431098ad9dd941dababc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm4007998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4007998%26sid%3Dliteratum%253Aachs%26aulast%3DGant%26aufirst%3DT.%2BG.%26atitle%3DUsing%2520deuterium%2520in%2520drug%2520discovery%253A%2520leaving%2520the%2520label%2520in%2520the%2520drug%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3595%26epage%3D3611%26doi%3D10.1021%2Fjm4007998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kerekes, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esposite, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doll, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tagat, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tevar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracina, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basso, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. B.</span></span> <span> </span><span class="NLM_article-title">Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1021/jm1010995</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1010995" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=201-210&author=A.+D.+Kerekesauthor=S.+J.+Espositeauthor=R.+J.+Dollauthor=J.+R.+Tagatauthor=T.+Yuauthor=Y.+Xiaoauthor=Y.+Zhangauthor=D.+B.+Preluskyauthor=S.+Tevarauthor=K.+Grayauthor=G.+A.+Terracinaauthor=S.+Leeauthor=J.+Jonesauthor=M.+Liuauthor=A.+D.+Bassoauthor=E.+B.+Smith&title=Aurora+kinase+inhibitors+based+on+the+imidazo%5B1%2C2-a%5Dpyrazine+core%3A+fluorine+and+deuterium+incorporation+improve+oral+absorption+and+exposure&doi=10.1021%2Fjm1010995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Aurora Kinase Inhibitors Based on the Imidazo[1,2-a]pyrazine Core: Fluorine and Deuterium Incorporation Improve Oral Absorption and Exposure</span></div><div class="casAuthors">Kerekes, Angela D.; Esposite, Sara J.; Doll, Ronald J.; Tagat, Jayaram R.; Yu, Tao; Xiao, Yushi; Zhang, Yonglian; Prelusky, Dan B.; Tevar, Seema; Gray, Kimberly; Terracina, Gaby A.; Lee, Suining; Jones, Jennifer; Liu, Ming; Basso, Andrea D.; Smith, Elizabeth B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-210</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aurora kinases are cell cycle regulated serine/threonine kinases that have been linked to cancer.  Compd. 1 was identified as a potent Aurora inhibitor but lacked oral bioavailability.  Optimization of 1 led to the discovery of a series of fluoroamine and deuterated analogs, exemplified by compd. 25 (I), with an improved pharmacokinetic profile.  We found that blocking oxidative metab. at the benzylic position and decreasing the basicity of the amine are important to obtaining compds. with good biol. profiles and oral bioavailability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3YIdBKno7NLVg90H21EOLACvtfcHk0lh7wf0oyuO6Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbzP&md5=af7c338866058e7d63116c8c8aa2d3fd</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm1010995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1010995%26sid%3Dliteratum%253Aachs%26aulast%3DKerekes%26aufirst%3DA.%2BD.%26aulast%3DEsposite%26aufirst%3DS.%2BJ.%26aulast%3DDoll%26aufirst%3DR.%2BJ.%26aulast%3DTagat%26aufirst%3DJ.%2BR.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DPrelusky%26aufirst%3DD.%2BB.%26aulast%3DTevar%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DTerracina%26aufirst%3DG.%2BA.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DBasso%26aufirst%3DA.%2BD.%26aulast%3DSmith%26aufirst%3DE.%2BB.%26atitle%3DAurora%2520kinase%2520inhibitors%2520based%2520on%2520the%2520imidazo%255B1%252C2-a%255Dpyrazine%2520core%253A%2520fluorine%2520and%2520deuterium%2520incorporation%2520improve%2520oral%2520absorption%2520and%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D201%26epage%3D210%26doi%3D10.1021%2Fjm1010995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maltais, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanoury, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perni, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Block, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shawgo, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazhanisamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raybuck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namchuk, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennani, Y. L.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7993</span>– <span class="NLM_lpage">8001</span>, <span class="refDoi"> DOI: 10.1021/jm901023f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901023f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOksrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7993-8001&author=F.+Maltaisauthor=Y.+C.+Jungauthor=M.+Chenauthor=J.+Tanouryauthor=R.+B.+Perniauthor=N.+Maniauthor=L.+Laitinenauthor=H.+Huangauthor=S.+Liaoauthor=H.+Gaoauthor=H.+Tsaoauthor=E.+Blockauthor=C.+Maauthor=R.+S.+Shawgoauthor=C.+Townauthor=C.+L.+Brummelauthor=D.+Howeauthor=S.+Pazhanisamyauthor=S.+Raybuckauthor=M.+Namchukauthor=Y.+L.+Bennani&title=In+vitro+and+in+vivo+isotope+effects+with+hepatitis+C+protease+inhibitors%3A+enhanced+plasma+exposure+of+deuterated+telaprevir+versus+telaprevir+in+rats&doi=10.1021%2Fjm901023f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Vivo Isotope Effects with Hepatitis C Protease Inhibitors: Enhanced Plasma Exposure of Deuterated Telaprevir versus Telaprevir in Rats</span></div><div class="casAuthors">Maltais, Francois; Jung, Young Chun; Chen, Minzhang; Tanoury, Jerry; Perni, Robert B.; Mani, Nagraj; Laitinen, Leena; Huang, Hui; Liao, Shengkai; Gao, Hongying; Tsao, Hong; Block, Eric; Ma, Chien; Shawgo, Rebecca S.; Town, Christopher; Brummel, Christopher L.; Howe, David; Pazhanisamy, S.; Raybuck, Scott; Namchuk, Mark; Bennani, Youssef L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7993-8001</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Telaprevir (I) (VX-950), an inhibitor of the hepatitis C virus (HCVa) NS3-4A protease, is in phase 3 clin. trials.  One of the major metabolites of I is its P1-(R)-diastereoisomer (VRT-394), contg. an inversion at the chiral center next to the α-ketoamide on exchange of a proton with solvent.  Compd. VRT-394 is approx. 30-fold less active against HCV protease.  In an attempt to suppress the epimerization of I without losing activity against the HCV protease, the proton at that chiral site was replaced with deuterium (d).  The compd. II (d-telaprevir) is as efficacious as I in in vitro inhibition of protease activity and viral replication (replicon) assays.  The kinetics of in vitro stability of I and II in buffered pH solns. and plasma samples, including human plasma, suggest that II is significantly more stable than I.  Oral administration (10 mg/kg) in rats resulted in a ∼13% increase of AUC for II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkqwA80elhh7Vg90H21EOLACvtfcHk0lh7wf0oyuO6Yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOksrbI&md5=244f41b401086e8541efc9203d22b503</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm901023f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901023f%26sid%3Dliteratum%253Aachs%26aulast%3DMaltais%26aufirst%3DF.%26aulast%3DJung%26aufirst%3DY.%2BC.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTanoury%26aufirst%3DJ.%26aulast%3DPerni%26aufirst%3DR.%2BB.%26aulast%3DMani%26aufirst%3DN.%26aulast%3DLaitinen%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DLiao%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DTsao%26aufirst%3DH.%26aulast%3DBlock%26aufirst%3DE.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DShawgo%26aufirst%3DR.%2BS.%26aulast%3DTown%26aufirst%3DC.%26aulast%3DBrummel%26aufirst%3DC.%2BL.%26aulast%3DHowe%26aufirst%3DD.%26aulast%3DPazhanisamy%26aufirst%3DS.%26aulast%3DRaybuck%26aufirst%3DS.%26aulast%3DNamchuk%26aufirst%3DM.%26aulast%3DBennani%26aufirst%3DY.%2BL.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520isotope%2520effects%2520with%2520hepatitis%2520C%2520protease%2520inhibitors%253A%2520enhanced%2520plasma%2520exposure%2520of%2520deuterated%2520telaprevir%2520versus%2520telaprevir%2520in%2520rats%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7993%26epage%3D8001%26doi%3D10.1021%2Fjm901023f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maehr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uskokovic, M. R.</span></span> <span> </span><span class="NLM_article-title">Diastereotopic and deuterium effects in gemini</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3878</span>– <span class="NLM_lpage">3888</span>, <span class="refDoi"> DOI: 10.1021/jm400032t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400032t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3878-3888&author=H.+Maehrauthor=N.+Rochelauthor=H.+J.+Leeauthor=N.+Suhauthor=M.+R.+Uskokovic&title=Diastereotopic+and+deuterium+effects+in+gemini&doi=10.1021%2Fjm400032t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereotopic and Deuterium Effects in Gemini</span></div><div class="casAuthors">Maehr, Hubert; Rochel, Natacha; Lee, Hong Jin; Suh, Nanjoo; Uskokovic, Milan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3878-3888</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Changing the geminal Me groups on 1α,25-dihydroxyvitamin D3 and its analogs to the deuterio versions generally improves the bioactivity.  Derivs. of 1α,25-dihydroxyvitamin D3 with two chains emanating at C20, commonly referred to as gemini, are subject to the same phenomenon.  Addnl., gemini with different side chains are susceptible to bioactivity differentials where the C17-C20 threo configuration usually imparts higher activity than the corresponding erythro arrangement.  In an effort to analyze the deuterium effect on gemini with minimal diastereotopic distortion, we synthesized gemini with equal side chains but introduced deuterium diastereospecifically on either chain.  We solved the crystal structures of these compds. in the zebra fish zVDR ligand binding domain as complexes with NCoA-2 coactivator peptide and correlated the findings with growth inhibition in a breast cancer cell line.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp8s9r_J8o2rVg90H21EOLACvtfcHk0lhMlQoeeLpa_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlsV2gsbo%253D&md5=5d6784fd9736bdc323cf7d6a64c824fa</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm400032t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400032t%26sid%3Dliteratum%253Aachs%26aulast%3DMaehr%26aufirst%3DH.%26aulast%3DRochel%26aufirst%3DN.%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSuh%26aufirst%3DN.%26aulast%3DUskokovic%26aufirst%3DM.%2BR.%26atitle%3DDiastereotopic%2520and%2520deuterium%2520effects%2520in%2520gemini%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3878%26epage%3D3888%26doi%3D10.1021%2Fjm400032t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J.</span>; <span class="NLM_string-name">Du, J.</span></span> <span> </span><span class="NLM_article-title">2-(2,4,5-Substituted Phenylamino) Pyrimidine Derivatives, Preparation Method and Application in Preparation of Antitumor Drugs</span>. CN Patent <span class="NLM_patent">ZL201711282598.8</span>, Aug 27, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+Chang&author=J.+Du&title=2-%282%2C4%2C5-Substituted+Phenylamino%29+Pyrimidine+Derivatives%2C+Preparation+Method+and+Application+in+Preparation+of+Antitumor+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DJ.%26atitle%3D2-%25282%252C4%252C5-Substituted%2520Phenylamino%2529%2520Pyrimidine%2520Derivatives%252C%2520Preparation%2520Method%2520and%2520Application%2520in%2520Preparation%2520of%2520Antitumor%2520Drugs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span>; <span class="NLM_string-name">Wen, S.</span>; <span class="NLM_string-name">Li, H. J.</span></span> <span> </span><span class="NLM_article-title">Fluorine and/or Deuterium-Containing Compounds for The Treatment of Non-Small Cell Lung Cancer and Related Diseases</span>. U.S. Patent <span class="NLM_patent">US20190169171</span>, April 28, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Cheng&author=S.+Wen&author=H.+J.+Li&title=Fluorine+and%2For+Deuterium-Containing+Compounds+for+The+Treatment+of+Non-Small+Cell+Lung+Cancer+and+Related+Diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%26atitle%3DFluorine%2520and%252For%2520Deuterium-Containing%2520Compounds%2520for%2520The%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520and%2520Related%2520Diseases%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5609</span>– <span class="NLM_lpage">5622</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5609-5622&author=Y.+Haoauthor=J.+Lyuauthor=R.+Quauthor=Y.+Tongauthor=D.+Sunauthor=F.+Fengauthor=L.+Tongauthor=T.+Yangauthor=Z.+Zhaoauthor=L.+Zhuauthor=J.+Dingauthor=Y.+Xuauthor=H.+Xieauthor=H.+Li&title=Design%2C+synthesis%2C+and+biological+evaluation+of+pyrimido%5B4%2C5-d%5Dpyrimidine-2%2C4%281H%2C3H%29-diones+as+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+L858R%2FT790M+resistance+mutation&doi=10.1021%2Facs.jmedchem.8b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation</span></div><div class="casAuthors">Hao, Yongjia; Lyu, Jiankun; Qu, Rong; Tong, Yi; Sun, Deheng; Feng, Fang; Tong, Linjiang; Yang, Tingyuan; Zhao, Zhenjiang; Zhu, Lili; Ding, Jian; Xu, Yufang; Xie, Hua; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5609-5622</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clin. efficacy for nonsmall cell lung cancer (NSCLC) patients with EGFR activating mutations.  However, their clin. benefit was limited by the emergence of acquired resistance mutations.  In most cases (approx. 60%), the resistance was caused by the secondary EGFR T790M gatekeeper mutation.  Thus, it is still desirable to develop novel third-generation EGFR inhibitors to overcome T790M mutation while sparing wild-type (WT) EGFR.  Herein, a series of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivs. were designed and synthesized, among which the most potent compd. I not only demonstrated significant inhibitory activity and selectivity for EGFRL858R/T790M and H1975 cells in vitro but also displayed outstanding antitumor efficiency in H1975 xenograft mouse model.  The encouraging mutant-selective results at both in vitro and in vivo levels suggested that I might be used as a promising lead compd. for further structural optimization as potent and selective EGFRL858R/T790M inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTI-rgEr_o17Vg90H21EOLACvtfcHk0lhMlQoeeLpa_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFCmsrrJ&md5=02f8cb7542273f2ae972d54b86f88fb3</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00346%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DR.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520pyrimido%255B4%252C5-d%255Dpyrimidine-2%252C4%25281H%252C3H%2529-diones%2520as%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520L858R%252FT790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5609%26epage%3D5622%26doi%3D10.1021%2Facs.jmedchem.8b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, Y. N.</span></span> <span> </span><span class="NLM_article-title">Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1177/1087057112463732</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=10.1177%2F1087057112463732" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=23071008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OktrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=199-210&author=R.+D.+Pelletierauthor=W.+G.+Laiauthor=Y.+N.+Wong&title=Application+of+a+substrate+cocktail+approach+in+the+assessment+of+cytochrome+P450+induction+using+cultured+human+hepatocytes&doi=10.1177%2F1087057112463732"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes</span></div><div class="casAuthors">Pelletier, Robert D.; Lai, W. George; Wong, Y. Nancy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-210, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Induction of the cytochrome P 450 (CYP) family of enzymes by coadministered compds. can result in drug-drug interactions, as in the case of the coadministration of rifampicin with many CYP3A substrates, including midazolam.  Identification of potential drug-drug interactions due to CYP induction during drug discovery is crit.  We present a substrate cocktail method that was applied to assess the induction of CYP1A, CYP2B6, CYP2C9, and CYP3A using a 96-well high-throughput format.  Viable cell counts were detd. using a high-content screening system to normalize activities.  Substrate cocktail incubations demonstrated a similar fold induction for known inducers as compared with discrete probe incubations.  The system was further validated by detg. the induction potency of rifampicin.  The Emax and EC50 values in two sep. lots of hepatocytes for CYP3A induction by rifampicin in a 96-well format were similar when discrete probe was compared with the probe cocktail.  This system has been demonstrated to be suitable for high-throughput assessments of CYP induction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr116eNO0uPC7Vg90H21EOLACvtfcHk0ljPz91VKMJaIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OktrfJ&md5=6783e972d6d0c86a0509ae872b7449a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1177%2F1087057112463732&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057112463732%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DR.%2BD.%26aulast%3DLai%26aufirst%3DW.%2BG.%26aulast%3DWong%26aufirst%3DY.%2BN.%26atitle%3DApplication%2520of%2520a%2520substrate%2520cocktail%2520approach%2520in%2520the%2520assessment%2520of%2520cytochrome%2520P450%2520induction%2520using%2520cultured%2520human%2520hepatocytes%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2013%26volume%3D18%26spage%3D199%26epage%3D210%26doi%3D10.1177%2F1087057112463732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i36"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02005">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07771"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02005?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02005</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental details, NMR spectra, and HPLC traces of representative compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_001.pdf">jm0c02005_si_001.pdf (1.42 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c02005/suppl_file/jm0c02005_si_002.csv">jm0c02005_si_002.csv (1.51 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02005&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-2%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02005%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02005" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5d7a3a7b3c46","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
